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ABSTRACT 
Drosophila nucleosome remodelling factor (NURF) is one of the founding members of the 
ISWI family of ATP-dependent chromatin remodelling enzymes and mediates energy-
dependent nucleosome sliding leading to transcription regulation. In previous work (Wysocka 
et al., 2006), NURF was shown to be recruited to gene targets by binding specific histone 
modifications. The largest subunit of NURF, NURF301, contains a bromodomain and three 
PHD finger domains that have the ability to recognize specific histone modifications. Here we 
determine the histone binding-specificities of these domains, and how NURF histone binding 
is influenced by histone modification "cross-talk" - the influence of combinations of flanking 
histone modifications. This has been analyzed by histone peptide library array assays and our 
study shows that the PHD2 domain specifically recognizes the histone H3K4me3 mark. This 
binding can be inhibited by phosphorylation of H3 Thr 3 (H3T3p), while enhanced by 
acetylation of H3 Lys 9 (H3K9ac) and phosphorylation of Ser 10 (H3S10p). The 
bromodomain binds to histone H4 multiply acetylated at the K5, K8, K12 and K16 positions. 
The PHD1 domain binds to the H3K23me3 while the N-terminal PHD domain does not show 
specific histone modifications but binds generally to the H3 and H4 N-termini. This binding 
specificity was confirmed by peptide pull-down, Biacore and immunofluorescence 
microscopy assays. Moreover, two different NURF301-A/B and NURF301-C isoforms were 
CTAP-tagged by recombineering, and we used chromatin immunoprecipitation coupled 
sequencing (ChIP-Seq) to profile the genome-wide distribution of NURF. These data have 
allowed us to confirm the influence of these modifications on NURF recruitment to chromatin 
in vivo. Therefore, our results identify regulatory mechanisms of histone modifications 
directing recruitment of ATP-dependent chromatin remodelling enzymes.  
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CHAPTER 1. INTRODUCTION 
1.1 The basic structure of chromatin 
DNA in the nucleus of eukaryotic cells does not exist in a free state but is found in repeated 
functional units called nucleosomes that form chromatin. Nucleosomes are the basic unit of 
chromatin and consist of a segment of DNA wrapped around the histone octamer (Marino-
Ramirez et al., 2005, see Fig 1-1). The histone octamer is composed of two copies each of the 
four histone proteins H2A, H2B, H3 and H4 around which 147 bp of DNA are wound in 1.65 
superhelical turns with five to ten fold compaction of DNA (Luger et al., 1997). In addition, 
 
 
Figure 1-1. The model of chromatin structure. In eukaryotes, nucleosomes are composed 
of a core particle of eight histones around which147 bp of DNA are wrapped. This basic unit 
of chromatin forms 10 nm fibres the "beads on a sting". This is then compacted into the 30 nm 
fibres and condensed further to produce 300 nm and 700 nm fibres. Figure from Annunziato 
(2008). 
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histone H1 (or H5 in avian species), as linker histone, plays an important role providing 
increased protection of approximately 168 bp of DNA and is responsible for changing 
nucleosomal structure to make the more highly packaged chromatosome (Widom, 1998; 
Woodcock et al., 2006). These repeating nucleosomes called "beads on a string" are proposed 
to be arranged into 30 nm fibres, which result in 50 fold compaction (Felsenfeld G. and 
Groudine M., 2003). The 30 nm fibres are then proposed to be progressively condensed into 
300 nm and 700 nm fibres ultimately to form chromosomes. However, the existence of the 30 
nm fibres and the hierarchy of folding is still controversial (Staynov, 2008; Grigoryev and 
Woodcock, 2012; Luger et al., 2012). By modifying nucleosome dynamics and the 
interactions between DNA and histone proteins, these higher order structures can be disrupted 
to locally or globally decondense chromatin structure and allow access of the enzymes that 
process genetic information. 
 
1.2 Chromatin and gene regulation 
Chromatin has been categorised in two different functional forms which are euchromatin and 
heterochromain. These were originally defined by Heitz (1928) who distinguished them 
cytologically by the level of staining during interphase. Euchromatin stains lightly and 
appears less condensed, whereas heterochromatin stains darkly and appears highly condensed. 
Euchromatin is thought to be transcriptionally active chromatin, while heterochromatin as 
transcriptionally inactive chromatin. It was later revealed that heterochromatin could be 
divided into two further categories - facultative heterochromain, which is interchangeable 
between open or compact conformations, and constitutive heterochromain such as 
centromeres and near telomeres (Trojer and Reinberg, 2007).  
 
3 
The highly integrated nature of DNA in nucleosomes in chromatin means that DNA is not 
freely exposed to RNA polymerase or transcription factors. In this way, compaction of DNA 
in chromatin has the ability to block transcriptional regulatory elements and promoters 
leaving them inaccessible for transcription. Moreover, it had been assumed that nucleosomes 
on the body of genes would pose a barrier to processive RNA polymerases. Surprisingly, 
recent data has shown that nucleosome structure is maintained during the active transcription 
(Jiang and Pugh, 2009). Therefore, mechanisms must exist that allow RNA polymerase to 
overcome the barriers imposed by nucleosomes and higher-order chromatin structure. Many 
studies have shown that the nucleosome is not a simple static unit but has dynamic properties 
which are tightly regulated by various protein complexes (Li and Widom, 2004; White and 
Luger, 2004). Moreover, the dynamic properties of nucleosomes are regulated by a number of 
mechanisms including histone variant incorporation, histone eviction, histone post-
translational modification and chromatin remodelling which affect all steps of transcription 
(Li et al., 2007). 
 
1.3 Changes in chromatin structure 
1.3.1 Histone variants 
The initial concepts of nucleosome formation and composition were that nucleosomes are 
composed of core histone proteins (canonical histones) that are synthesized during S phase 
when DNA is replicated and chromatin structure would be duplicated (Kornberg et al., 1999). 
However, non-allelic variants of the major histone proteins have been found in diverse species. 
These include the histone H2A variants MacroH2A, H2A.Z, H2ABbd and H2A.X and the 
histone H3 variants H3.3 and centromere-specific histone CENP-A (Redon et al., 2002). 
These variants have diverse roles in epigenetic silencing, architectural changes in 
4 
chromosomes, gene expression and centromere function (Kamakaka and Biggins, 2005; 
Malik and Henikoff, 2003). Generally, canonical histones are expressed during S phase from 
clustered histone gene cassettes and deposited during DNA replication. In contrast, most 
histone variants are produced outside of S phase and incorporated in a process that is 
independent of DNA replication (Jin et al., 2005). They can be displaced in a transcription 
dependent manner and by protein complexes involved in transcription, replication and ATP-
dependent nucleosome remodelling. For example, this histone exchange was firstly 
recognized by monitoring the exchange of fluorescently labelled histones after 
photobleaching of a small area of the nucleus. These experiments showed higher exchange 
levels of canonical histone H2A and H2B than histone H3 and H4 (Kimura and Cook, 2001). 
Later, Bruno et al. (2003) observed that several chromatin remodelling complexes, including 
the SWI/SNF, RSF and ISWIb complexes (Peterson et al., 1994; Peterson et al., 1995), can 
catalyze the exchange of H2A-H2B dimers between chromatin fragments in an ATP-
dependent reaction.  
 
It has been suggested that histone exchange reactions perform two functions in vivo (Sarma 
and Reinberg, 2005). Firstly, it allows the removal of all histone epigenetic marks and 
promotes reprogramming of genes. Secondly, the incorporated histone variants may have 
distinct biochemical properties that allow them to carry out alternative functions in cells. 
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Figure 1-2. Domain structure of the canonical histones (H3, H2A, H4 and H2B) and 
their variants. The histone-fold domain (HFD) is highly conserved in both canonical 
histones and variants. The length and major histone modification positions of N- and C-
terminal tails are slightly different. Well-established histone modifications, methylated lysines 
and phosphorylated serines are indicated by red flags and green flags respectively. Figure 
adapted from Sarma and Reinberg (2005). 
 
Histone variants generally have substantial overall sequence identity within their canonical 
core histone-fold domain (HFD) and most post-translational modification sites are conserved 
between canonical histones and variant histones. As shown in figure 1-2, four histone H3, 
variants have been found: H3.1, H3.2, H3.3 (which are highly conserved and exhibit only a 
few amino acids differences) and CENPA, which is a centromeric histone H3 that has a 
divergent N-terminal region but similar C-terminal HFD with histone H3 (Marzluff et al., 
2002; Hake et al., 2006). Histone H3.3 is found at transcriptionally active loci (Ahmad and 
Henikoff, 2002) and is incorporated during all stages of cell cycle (McKittrick et al., 2004). In 
contrast, cetromeric histone CENPA also called CenH3, is localized specifically at 
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centromeres but also spreads over the chromosome arms when overexpressed (Sullivan et al., 
1994). 
 
Histone H2A variants are also well studied. Four variants have been reported: H2A.Z, H2A.X, 
Macro H2A and H2A-bar-body-difficient (H2A.Bbd). The H2A.Z variant is highly conserved 
(Jackson et al., 1996), while Macro H2A and H2A.Bbd are found exclusively in vertebrates or 
mammals (Pehrson and Fuji, 1998; Chadwik and Willard, 2001). The H2A variants are 
distinguished from the canonical H2A histones by their C-terminal tails that vary in both 
length and sequence (Figure 1-2). The histone variant H2A.Z is the best studied H2A variant. 
Previous ChIP-chip data from yeast showed that H2A.Z is incorporated into specific 
promoter-bound nucleosomes and might confer changes in the chromatin structure that would 
allow transcriptional activation (Guillemette et al., 2005). Work in our laboratory has shown 
that the mutation of H2A.Z increases the hemocyte tumour incidence in concert with the 
nucleosome remodelling enzyme NURF in Drosophila (Badenhorst, unpublished data) 
suggesting that H2A.Z might be also involved in nucleosome positioning. 
 
Little is known about H2B and H4 variants. Two testis specific H2B variants were identified 
in human (Zalensky et al., 2002; Churikov et al., 2004), but no H4 variant has been found so 
far. 
 
1.3.2 Post-translational histone modifications 
Another mechanism by which chromatin structure can be altered is through the incorporation 
of post-translational modifications on the histone proteins. Histone post translational 
modification (HPTM) targets both the histone tails and globular domains. It has been known 
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that post-translationally modified nucleosomes are distributed in distinct localized patterns 
within the upstream region of the transcription start site (TSS), enhancer, the core promoter, 
the 5’ end of the open reading frame (ORF) and the 3’ end of the ORF (Li et al., 2007; Wang, 
2011; Zentner et al., 2011). These modifications can be divided into 4 different types: 
acetylation, methylation, phosphorylation and ubiquitylation/sumoylation. Either individually 
or in combination, these modifications can have a great effect on genome regulation and 
function (Figure 1-3). 
 
 
Figure 1-3. The main post translational modification sites on all canonical histones. In 
particular, histone N-terminal tails are subject to the modifications but some histone core 
residues are also modified. Modifications include: acetylation (blue), methylation (red), 
phosphorylation (yellow), ubiquitination (green) and ADP ribosylation (purple). Figure 
modified from Portela and Esteller (2010). 
 
For each modification, enzyme pairs exist that either can put in place the modification or 
remove the modification. For example, histone acetyltransferases (HATs)/deacetylases 
(HDACs) for acetylation and methyltransferases/demethylases for methylation exist. 
 
Acetylation was the first histone modification found in 1963 (Phillips, 1963). It has been 
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known that high level of acetylation and HAT activity is closely related to active transcription 
and also known as a major determinant of the euchromatin (Alfrey et al., 1964; Pogo et al., 
1966; Hendzel et al., 1998). This function of acetylation can partly be explained by the 
neutralizing of the positive charge of lysine residues, which decreases the charge-interaction 
of the histone with the nucleosomal DNA, linker DNA or adjacent histones (Norton et al., 
1989; Norton et al., 1990; Zentner and Henikoff, 2013). Therefore, accessibility of DNA to 
transcription factors can be increased. For example, tetra-acetylation of the histone H4 tail 
markedly reduces its binding to DNA in vitro (Hong et al., 1993). In addition, the acetylation 
modification can be also directly recognized by many proteins, so called "readers", which 
include transcription factors, activators and chromatin remodelers containing conserved 
chromatin binding domain like bromodomain (Struhl, 1998; Josling et al., 2012). In contrast, 
HDACs are more likely to work on transcriptionally silenced regions, which contain a low 
level of acetylation such as heterochromatin (Li et al., 2007). This means that sites of 
reversible acetylation can play an important role in gene regulation by turning on/off 
transcription (Shogren-Knaak et al., 2006). 
 
Methylation of histones occurs at lysine residues in histone H3 (K4, 9, 27, 36, 79) and H4 
(K20). Methylation plays a key role in both gene activation and repression. What determines 
the functional consequences of methylation is the identity of the residue that is methylated or 
demethylated. Methylated histone residues provide marks for the recruitment of effector 
complexes that can either activate or repress transcription. For example, methylation of 
histone H3 lysine 4 (H3K4) is associated with transcription activation and exerts its effect by 
recruiting the NURF complex that can mobilize nucleosomes at active genes in Drosophila 
and human (Li et al., 2006; Wysocka et al., 2006; Kwon et al., 2009). In contrast, methylation 
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of H3K9 has repressive effect by recruiting heterochromatin protein 1 (HP1) (Stewart et al., 
2005), while methylation of H3K27 also represses transcription by mediating the recruitment 
of the Polycomb repressive complex (Martin and Zhang, 2005).  
 
Phosphorylation is one of the most well studied HPTMs and the roles of kinases have been 
understood for a long time. For chromatin, kinases target phosphorylation sites in the H3 
amino terminal tail, which have important functions in transcription activation and the control 
of the cell cycle. The main sites of phosphorylation include H3 Thr 3 (H3T3), H3 Ser 10 
(H3S10) and H3 Ser 28 (H3S28). For example, phosphorylation of H3T3 by the kinase 
Haspin is able to affect mitotic chromosome regulation by maintaining cohesion (Dai et al., 
2006). H3S10 phosphorylation is highly conserved and is known as an important 
phosphorylation site in humans, Tetrahymena and Drosophila (Nowak and Corces, 2004), 
while H3S28 phosphorylation is relatively less well studied but recently found to be involved 
in Polycomb silencing (Lau and Cheung, 2011). One of the consequences of histone 
phosphorylation is to make the site negatively charged so reduce the affinity of histones for 
DNA. In this manner, chromatin compaction which is closely related to transcription can be 
altered. 
 
Ubiquitylation and sumoylation are distinct from acetylation, methylation and 
phosphorylation in that these modifications are large polypeptides which increase histone size 
by approximately 2-3 times. They also share similar sequences and three dimensional 
structures but are dissimilar in surface charge. Ubiquitylation acts on histone H2A and H2B 
and is associated with repression and activation of transcription respectively. For example, 
mono-ubiquitylation of H2B activates transcription by Rad6/Bre1 and leads to H3K4 
10 
methylation which is mark of active transcription as described above (Wood et al. 2003; Kim 
et al., 2005; Henry et al., 2003). In contrast, mono-ubiquitylation of H2A is repressive to 
transcription on Hox genes in mammals (Wei et al., 2006). Sumoylation was first found as a 
repressive histone modification in the yeast Saccharomyces cerevisiae (Nathan et al., 2006). 
Moreover, it interacts with other positive modifications like acetylation or ubiquitylation as it 
acts as a potential block to these modifications. 
 
Recently ADP ribosylation and glycosylation were also identified as important histone 
modifications. The core histones and the linker histone H1 can potentially be ADP ribosylated. 
This modification has been shown to be involved in DNA repair, cell cycle, replication and 
transcription (Alvarez et al., 2011; Hassa et al., 2006; Messner and Hottiger, 2011). 
Glycosylation is present on several threonine and serine residues of the histones H2A, H2B 
and H4, but its function remains to be determined (Sakabe et al., 2010; Zhang et al., 2011). 
 
To conclude, PTM could have three consensus functions. Firstly, with the exception of 
methylation, PTM results in a change in the net charge of the nucleosome and can modify 
nucleosomal interactions with DNA. Secondly, histone modifications can act as marks that are 
recognized by other effector proteins. Finally, some modifications directly influence higher-
order chromatin structure. 
 
1.3.3 ATP-dependent chromatin remodelling factors 
To make transcription elements accessible in packaged DNA in a regulated manner, cells have 
evolved specialized famillies of chromatin remodelling complexes. These chromatin 
remodelling enzymes utilize ATP hydrolysis as an energy source, to move, destabilize, eject, 
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or restructure nucleosomes (Becker and Horz, 2002). There are four families of chromatin 
remodelling complexes: ISWI, INO80, Mi-2 and SWI/SNF families, based on the sequence 
homology of the associated catalytic ATPase subunit. They are conserved from yeast to 
human and all share some properties including binding affinity for the nucleosome, domains 
that can recognize histone modifications, ATPase domains and domains that can interact with 
chromatin or other transcription factors (Clapier and Cairns, 2009, Figure 1-4). However, they 
also have distinctive flanking domains making each family specific in its particular task 
(Flaus et al., 2006).  
 
The ISWI (imitation switch) family of chromatin remodelling enzymes were initially 
identified in Drosophila (Elfring et al., 1994) and consist of the related NURF, CHRAC and 
ACF complexes. These complexes share the core ISWI catalytic subunit that contains a 
ATPase domain but also SANT and SLIDE domains that bind to unmodified histone tails and 
DNA (Boyer et al., 2004). The ISWI family complexes are composed of other subunits in 
addition to the ISWI subunit, and these impart many different domains including PHD 
domains, bromodomains and DNA-binding histone fold motifs. Most ISWI family complexes 
like ACF and CHRAC, promote chromatin assembly with regular spacing of nucleosomes and 
transcription repression (Längst and Becker, 2001), but they can have other functions 
depending on the attendant proteins (Corona and Tamkun, 2004b). 
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Figure 1-4. ATP dependent chromatin remodelling factor families : ISWI, INO80, Mi-2 
and SWI2/SNF2 families. Figure adapted Badenhorst (2013). 
 
The INO80/SWR1 (inositol requiring 80) complexes were initially purified from S.cerevisiae 
and have more than 10 subunits (Shen et al., 2000). The distinctive feature of these chromatin 
remodelling enzymes is that they have DNA strand displacement activity and, therefore, are 
ATP-dependent helicases different from other chromatin remodelling factors. This activity 
depends on the ATPase function of the INO80 protein (Bao and Shen, 2007). It is also 
involved in the facilitation of DNA repair (Jonsson et al., 2001). The SWR1 complex 
containing Swr1p subunit, a Swi2/Snf2-paralogue, specifically replaces histone H2A in 
nucleosomes for the H2AZ variant that could lead to structural or functional changes in the 
chromatin as described in chapter 1.3.1 (Kobor et al., 2004; Mizuguchi et al., 2004). 
 
The Mi-2 family, also called CHD (chromodomain, helicase, DNA binding) family, of 
remodelers contain two tandemly arranged chromodomains (chromatin organization modifier) 
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and interact with subunits that contain DNA-binding domains and PHD, BRK, CR1-3 and 
SANT domains (Figure 1-4). Some members of the CHD family of chromatin remodelling 
enzymes are positive regulators of transcription that slide or eject nucleosomes (Bouazoune et 
al., 2002; Clapier and Cairns, 2009), but others are repressors of transcription, for example the 
Mi-2/NuRD complex represses transcription via its chromatin remodelling and histone 
deacetylase activities (Denslow and Wade, 2007) Moreover recently, Drosophila Mi-2 was 
found as a regulator of chromosome condensation and cohesin binding in vivo (Fasulo et al., 
2012)  
 
SWI/SNF (switching defective/sucrose nonfermenting) complex was originally found in S. 
cerevisiae as a transcription activator (Winston and Carlson, 1992) and is a large complex 
containing 8 to 14 subunits. Among these subunits, SWI2/SNF2 has a major role to remodel 
nucleosome arrays as an ATPase. The SWI/SNF complex is evolutionally conserved and in 
Drosophila, the closest relative of SWI2/SNF2 is Brahma (Tamkun et al., 1992). Brahma is at 
the core of the Brahma or BAP-associated complexes which both have ATPase activity and 
contain six subunits closely related to yeast SWI2/SNF2 (Dingwall et al., 1995; Kal et al., 
2000). Mammalian SWI/SNF on the other hand, has two ATPases, Brg1 and Brm, and is 
known to be sufficient to remodel nucleosome arrays in vitro (Phelan et al., 1999; Euskirchen 
et al., 2011). The role of other subunits of these complexes has not been well characterized, 
but BAF155 and BAF170 were found to support that remodelling activity and function as 
scaffolds of other SWI/SNF subunits (Sohn et al., 2007). SWI/SNF complexes can disrupt 
nucleosomes either by repositioning or by dissociation, thus can have a major impact on 
transcriptional control, DNA repair, recombination and chromosome segregation (Clapier and 
Cairns, 2009; Liu et al., 2011). SWI/SNF chromatin remodelling is linked to tumorigenesis 
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with mutations in SWI/SNF subunits having been identified in a number of cancers (Wilson 
and Roberts, 2011) 
. 
1.4 The nucleosome remodelling factor (NURF) 
1.4.1 Identification 
The ATP-dependent nucleosome remodelling factor (NURF) is one of the ISWI family of 
chromatin remodelling enzymes. It was firstly identified and purified from Drosophila 
embryo extracts by assaying Drosophila embryo extracts (S150) for GAGA factor and ATP -
dependent nucleosome disruption of in vitro chromatinized plasmids containing the hsp70 
promoter (Tsukiyama and Wu, 1995a; Tsukiyama et al., 1995b; Clapier et al., 2009). In these 
studies, two components were found to be critical for nucleosome disruption at the hsp70 
promoter: the GAGA factor and a sarkosyl-sensitive nucleosome remodelling factor in the 
S150 extract which utilizes ATP and was named NURF (Tsukiyama and Wu, 1995a). NURF 
was purified by fractionation of S150 Drosophila embryo extracts and ultimately revealed to 
be a four subunit protein complex consisting of the catalytic ISWI ATPase subunit and three 
additional subunits (Tsukiyama et al., 1995). As shown in figure 1-5, the NURF complex is 
composed of four subunits, NURF140 (or ISWI): ATPase (Tsukiyama et al., 1995b) which 
also exists in other ISWI members (ACF and CHRAC), NURF55: a WD-40 repeat protein 
which is found in many chromatin regulatory complexes (Martinez-Balbas et al., 1998; 
Hennig et al., 2005), NURF38: inorganic pyrophosphatase (Gdula et al., 1998), and the largest 
subunit of NURF named NURF301 (Xiao et al., 2001). 
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Figure 1-5. Structure of the NURF complex. NURF is composed of four subunits including 
ISWI, NURF55 (p55), NURF38 (p38) and the largest and unique subunit, NURF301. Figure 
adapted Badenhorst (2013). 
 
Detailed biochemical experimentation has defined similarities but also important differences 
between the NURF and SWI/SNF chromatin remodelling complexes. NURF is similar to the 
yeast SWI/SNF complex as both hydrolyze ATP, contain catalytic ATPase domains with high 
sequence similarity, and structurally alter nucleosome particles (Hamiche et al., 1999). 
However NURF, as the founding member of the ISWI subfamily of chromatin remodelling 
enzymes, has a distinct size as it is composed of four polypeptides, whereas SWI/SNF is 
composed of more than 10 subunits. Moreover, the level of NURF expression is also higher 
(~ 0.08% of nuclear extract protein) than SWI/SNF protein which is only detected at ~100 
molecules in a yeast cell (Cote et al., 1994). The ATPase activity of the NURF and SWI/SNF 
complexes is also stimulated in different ways, in that NURF ATPase activity is only 
stimulated by nucleosomes, while SWI/SNF ATPase activity is stimulated by free DNA 
(Georgel et al., 1997; Corona et al., 1999). Finally, although the yeast and human SWI/SNF 
complexes alter the DNaseI digestion patterns of reconstituted mononucleosome (Imbalzano 
et al., 1994; Kwon et al., 1994), NURF shows specific induction of DNaseI protection and 
hypersensitivity at discrete sites on nucleosomal DNA (Hamiche et al., 1999). 
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1.4.2 Homologues – human and yeast NURF like complexes 
Since Drosophila NURF was purified, other complexes similar to NURF had been identified 
including the yeast ISW1 and ISW2 complexes (Tsukiyama et al., 1999) and the human 
NURF complex. Human NURF is almost identical to Drosophila NURF consisting of a large 
subunit BPTF (bromodomain and PHD domain transcription factor), a catalytic ISWI-like 
subunit SNF2L and CAF-1, a NURF55-like subunit (Barak et al., 2003). Importantly, there is 
high protein sequence identity (~35%) and sequence similarity (~50%) over the entire coding 
region between Drosophila NURF301 and human BPTF (Xiao et al., 2001, Figure 1-6). This 
allows Drosophila NURF and NURF301 to be used as good models to understand the 
function of human NURF. 
 
1.4.3 In vitro biochemistry 
The initial discovery of NURF was achieved using in vitro assays base on in vitro 
chromatinization of hsp70 promoter sequences using a cell free Drosophila embryo extract 
(Tsukiyama and Wu, 1995a). Early characterizations of NURF functions were largely 
performed using the hsp70 promoter although subsequently chromatin was reconstituted on 
this fragment using recombinant core histones and nucleosomes assembled by salt dialysis 
(Hamiche et al., 1999). Using this system, the nucleosome sliding ability, sliding position 
preference and comparison of remodelling efficiencies of ISWI alone or in complex with 
NURF were elucidated (Hamiche et al., 1999). Analysis of in vitro sliding have shown that 
only two subunits are absolutely required for nucleosome sliding, ISWI and NURF301 the 
largest subunit of NURF (Xiao et al., 2001). NURF301 is required for efficient nucleosome 
sliding and interacts with some sequence specific transcription factors, which allows it to 
target NURF recruitment to specific genes (Xiao et al., 2001). NURF301 is the only NURF-
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specific subunit of NURF as other subunits are present in other chromatin remodelling 
complexes. In particular the ISWI subunit is present in three other complexes ACF (Ito et al., 
1997a; Ito et al., 1997b), CHRAC (Varga-Weisz et al., 1997), and NORC (Strohner et al., 
2001). 
 
1.4.4 Biology and in vivo functions 
Though the basic features of NURF were revealed by in vitro assays, it was essential to 
understand the physiological roles of NURF, in other words how NURF acts in vivo. Initial 
studies focused on mutants in the ISWI subunit of the NURF complex. These studies showed 
NURF potentially was involved in homeotic gene activation and chromatin condensation 
(Deuring et al., 2000). However, the weakness of these studies was that ISWI is also present 
in other chromatin remodelling complexes preventing these phenotypes being uniquely 
ascribed to NURF function. However, by analysing mutants in the NURF-specific NURF301 
subunit it has been possible to show that NURF is required for homeotic gene expression and 
chromosome condensation (Badenhorst et al., 2002). Nurf301 mutants also develop melanotic 
tumours in the third instar larvae suggesting that NURF is required for hematopoietic 
development (Badenhorst et al., 2002). By comparing whole genome expression profiles of 
Nurf301 mutants with wild type larvae, target genes of NURF were also revealed to show 
functional involvement of NURF in ecdysteroid signalling and metamorphosis (Badenhorst et 
al., 2005). In addition these types of experiment also revealed that NURF is an important 
regulator of the JAK/STAT pathway, a signalling pathway that is closely involved in 
Drosophila innate immunity and spermatogenesis (Kwon et al., 2008; Kwon et al., 2009). 
Recent studies have shown that NURF function could be co-regulated by Putzig (Pzg) which 
is an integral component of the TRF2/DREF complex involved in regulation of replication 
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related gene activation such as Notch target genes (Kugler and Nagel, 2007; Kugler and Nagel, 
2010; Kugler et al., 2011). 
 
In contrast, the function of human NURF has not been well characterized, but the majority of 
functional studies indicate that BPTF is involved in neuronal development and 
neurodegenerative diseases such as Alzheimer's disease because of its altered expression and 
subcellular localization (Mu et al., 1997; Jordan-Sciutto et al., 2000; Strachan et al., 2004). As 
in Drosophila, it is also likely to have important role in adult germ line stem cell 
differentiation (Lazzaro et al., 2006).  
 
1.4.5 Links between NURF chromatin remodelling and histone modifications  
As described in the previous sections, Drosophila NURF interacts with transcription factors 
like GAGA, HSF (Heat Shock Factor), Ken, EcR (Ecdysone Receptor) and Pzg (Putzig). In 
addition, functional domains in the largest subunit NURF301 have the potential to bind to 
specific histone post-translational modifications. The interaction of NURF with histones 
during chromatin remodelling was primarily examined by determining the binding and sliding 
of NURF using reconstituted nucleosomes (Hamiche et al., 1999; Xiao et al., 2001). These 
nucleosomes are synthesized using bacterial over-expression systems and are devoid of 
histone post-translational modifications. However, recent studies have shown that NURF 
activity and recruitment can be regulated by histone post-translational modifications. In 
particular NURF ATPase (ISWI) activity and nucleosome binding are reduced by poly-ADP-
ribosylation (Sala et al., 2008). Acetylation of ISWI by the acetyltransferase Gcn5 has also 
been observed, but the function of this modification has not been characterized (Ferreira et al., 
2007). Other studies have shown that the NURF301 C-terminal PHD domain and 
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bromodomain can recognize specific histone protein modifications in vitro which allows 
targeted recruitment of NURF to sites containing the H3K4me3 and H4K16ac modifications 
(Wysoka et al., 2006; Kwon et al., 2009).  
 
1.5 NURF isoforms and functional domains in NURF301 
Three isoforms of Drosophila NURF301 have been identified: NURF301-A, NURF301-B 
and NURF301-C isoforms. NURF301-A and NURF301-B are full-length isoforms (~300 kDa) 
and contain several functional domains conserved in transcription factors and chromatin 
proteins. This includes a N-terminal HMG-A (High Mobility Group) domain, WAC/WACZ 
motifs, three PHD (Plant Homeo Domain) domains and a bromodomain as shown in figure 1-
6. The HMG-A domain containing two AT hooks, which are short peptide motifs binding to 
the minor groove of AT-rich regions, as well as an acidic region (Reeves and Nissen, 1990; 
Reeves and Beckerbauer, 2001; Xiao et al., 2001). The function of NURF301 WAC/WACZ 
motifs has not been determined, but it was found important for the DNA-binding activity of 
ACF1 (Fyodorov and Kadonaga, 2002). PHD finger domains and bromodomain have been 
characterized in many chromatin remodelling proteins and potentially bind to specific histone 
modifications (which will be discussed in detail in the next chapter). Unlike the NURF301-A 
and NURF301-B isoforms, the NURF301-C is a C-terminally truncated isoform (~250 kDa) 
which terminates after the 7th exon of Nurf301. This isoform lacks the two C-terminal PHD 
domains and bromodomain. Our previous study showed that loss of those domains does not 
affect viability but does affect primary spermatocyte differentiation in Drosophila (Kwon et 
al., 2009). Further specific functions of NURF301-C isoform remain to be investigated. 
Therefore, it is important to understand the modified histone-binding specificity of these 
domains to determine precisely how NURF interacts with histone proteins and is recruited to 
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gene targets, and also to discriminate the functional differences between full-length 
NURF301-A/B and NURF301-C isoforms. 
 
 
Figure 1-6. Domain structure and sequence comparison of Drosophila NURF301 with 
human BPTF. There are three NURF301 isoforms including full-length NURF301-A, NURF 
301-B and C-terminal truncated NURF301-C isoforms. NURF301 contains a number of 
functional domains which are important for its chromatin binding (HMG-A, WAC/WACZ, 
three PHD domains and bromodomain). The PHD domains of NURF301 are numbered from 
the N-terminus to C-terminus PHD, PHD1 and PHD2 respectively. Figure adapted from 
Kwon et al. (2009). 
 
1.5.1 PHD domain 
Generally, PHD domains are divided into two major classes, one that is able to recognize 
methylated histone residues, and a second which binds to unmodified histone tails. Some 
PHD finger domains have a preference for H3K9me3 or H3K36me3, whereas other PHD 
fingers prefer to bind to H3K9ac or H3K14ac (Musselman and Kutateladze, 2009). These 
binding differences are structurally well characterized as described in figure 1-7. First, the 
PHD domain in complex with H3K4me3 has a highly conserved binding mechanism. For 
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example, structural analysis of the PHD domains of BPTF and ING2 (inhibitor of growth 2), 
which were the first identified H3K4me3 readers, in complex with histone H3K4me3 peptide 
revealed conserved features of their binding pockets (Figure 1-7 (a)). Both of BPTF and ING2 
PHD domains contain a well defined aromatic cage composed of two to four aromatic 
residues where H3K4me3 is stably positioned. They also have a binding pocket often 
composed of acidic residues to bind to Arg 2 and backbone carbonyl nets generating 
hydrogen-bonding interactions with Ala 1 of the histone H3 peptide (Li et al., 2006; Peña et 
al., 2006; Musselman and Kutateladze, 2011).  
 
 
Figure 1-7. The structure of histone recognition by the PHD fingers. PHD fingers are 
specific for (a) H3K4me3 or (b) unmodified H3K4. (c) Enhancement and inhibition 
mechanisms of PHD finger binding to H3 by flanking modifications are also described. 
Figure was taken from Musselman and Kutateladze (2011). 
 
PHD domains also bind to unmodified histone H3, such as BHC80 (Benign Hereditary 
Chorea 80) PHD domain or AIRE (human AutoImmune REgulator) PHD1 domain, also share 
some features that contain Ala 1 and Arg 2 binding pockets while they lack the aromatic cage 
(Figure 1-7 (b)). Instead, they have unique coordination with Lys 4 and some other basic 
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residues like Arg 8 and Lys 9 on the histone H3 tail, via the N-terminal acidic cluster forming 
salt bridges and hydrogen bonds with them. This interaction can be disrupted by methylation 
of Lys 4 (Lan et al., 2007; Chakravarty et al., 2009).  
 
On the other hand, the PHD2 domain of CHD4 (chromodomain helicase DNA–binding 
protein 4) interacts with H3K9me3 by forming a cationic interaction with the tri-methy group 
of Lys 9 (Mansfield et al., 2011), while the PHD1 domain of DPF3 recognises H3K14ac in a 
binding pocket composed of hydrophobic and charged residues (Zeng et al., 2010, Figure 1-7 
(c) below). Moreover, many studies are now showing the "cross-talk" between histone 
H3K4me3 and flanking modifications. For instance, a flanking di-methylated Arg 2 
modification can enhance the binding of RAG2 (Ramón-Maiques et al., 2007), whereas it 
inhibits the binding of TAF3 (Van Ingen et al., 2008) to H3K4me3, indicating that additional 
modifications surrounding H3 Lys 4 differentially affects the binding of PHD domains to 
histone H3 tail (Figure 1-7 (c) above).  
 
The PHD domains of NURF301 (from the N-terminus to C-terminus: PHD, PHD1 and PHD2) 
have sequence similarity, but it is possible that each domain has slightly different recognition 
specificities for histone modifications. Information of histone binding-specificity of NURF 
PHD domains was only available for the PHD2 domain, which has been shown to bind 
H3K4me3 (Li et al., 2006; Wysocka et al., 2006; Kwon et al., 2009). However, these 
experiments only addressed the binding of the PHD2 domain to a finite number of modified 
histone tails. The full spectrum of modified histone binding of the PHD2 domain has not been 
characterized. The binding properties of the PHD and PHD1 domains are unclear but BLAST 
comparison of the NURF301 PHD, PHD1 and PHD2 domains suggest that the NURF301 
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PHD domain is likely to be an unmodified histone H3 reader (Figure 1-8 A), while NURF301 
PHD1 and PHD2 showed high sequence similarity to tri-methylated histone binders as 
expected (Figure 1-8 B and C). 
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Figure 1-8. Protein sequence alignment of NURF301 (A) PHD, (B) PHD1 and (C) PHD2 
domains. The top 20-25 proteins showing sequence similarity were selected from BLAST 
search results. Proteins known to recognize histone H3K4me3 are highlighted in yellow and 
unmodified histone H3 tail highlighted in blue. Reference sequence numbers are indicated. 
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1.5.2 Bromodomain 
The bromodomain is commonly found in chromatin-associated proteins and specifically binds 
to acetylated lysine residues (Dhalluin et al., 1999). Many bromodomain structures have been 
determined, for example the bromodomain of the HATs P/CAF (Dhalluin et al., 1999; 
Mujtaba et al., 2002), Gcn5 (Hudson et al., 2000; Owen et al., 2000), Brd2,4 (Nakamura et al., 
2007; Vollmuth et al., 2009) and BPTF (Ruthenburg et al., 2011). These analyses have shown 
that the structure of bromodomain is highly conserved. The bromodomain is composed of 
four left handed alpha helix bundles (helices αZ, αA, αB and αC) with long loops between 
helices αB and αC, and between αZ and αA (BC loop and ZA loop) which form a hydrophobic 
pocket that binds acetylated lysine residues (Filippakopoulos et al., 2012, Figure 1-9 A). 
 
Most bromodomains can be categorized into three groups based on the functions of their 
associated proteins. The first bromodomain group are components of histone acetyltransferase 
(HAT) complexes and generally assist HAT complex recruitment to acetylated chromatin that 
could spread histone acetylations or recruit other transcription factors. For instance, GCN5 is 
a well known component of SAGA complex (Spt-Ada-Gcn5 acetyltransferase), contains a 
bromodomain and binds to acetylated H3 or H4K16ac (Barlev et al. 1998; Hassan et al., 
2007). CBP(CREB binding protein) and p300 are also HAT domains containing 
bromodomain proteins, but the bromodomain of p300 interacts with all the core histones 
while the bromodomain of CBP binds to H4K20ac (Zeng et al., 2008; Josling et al., 2012). 
They are also found to interact with acetylated MyoD (Ploesskaya et al. 2001).  
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Figure 1-9. General structure of the bromodomain and protein sequence alignment of 
the NURF301 bromodomain. (A) Bromodomains generally share a conserved four α helix 
bundle (αZ, αA, αB and αC) linked by variable loop regions (BC and ZA loops). Structure is 
from Filippakopoulos et al. (2012), (B) the top 20-25 proteins showing sequence similarity to 
the NURF301 bromodomain were identified by BLAST search. The conserved four α helices 
(αZ, αA, αB and αC) of the bromodomains are highlighted in green. Reference sequence 
numbers are indicated. 
 
Many other bromodomains are components of chromatin remodelling complexes. For 
example, Swi2/Snf2, the catalytic subunit of the SWI/SNF remodelling complex, contains a 
bromodomain that promotes its binding to chromatin containing H3K14ac (Hassan et al., 
2002; Chatterjee et al., 2011). Deletion of the Swi2/Snf2 bromodomain decreases binding to 
acetylated histone and chromatin remodelling activity, indicating that the bromodomain is 
critical for recruitment of the complex as well as its function (Awad and Hassan, 2008). 
Moreover, NURF301, a component of the NURF complex, contains a bromodomain at the C-
terminal region and binds to histone H4K16ac (Kwon et al., 2009). As expected, the 
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bromodomain of NURF301 also shows high sequence similarity with proteins known to 
recognize acetylated histones with conserved four alpha helix bundles (helices αZ, αA, αB and 
αC) in our protein sequence alignment result performed as described above (Figure 1-9 B). 
 
The other bromodomains are the BET (Bromodomain Extra Terminal) family, which 
generally contains two bromodomains at the N-terminal end and extra terminal protein 
interaction domain at the C-terminal end. In the mammalian BET family, there are four 
proteins including Brd2, Brd3, Brd4 and Brdt, and they recognize acetylated histones, for 
example Brd 4 binds to di- or tetra- acetylated histone H4 (H4K5,12ac or H4K5,8,12,16ac) 
(Dey et al., 2003; Hargreaves et al., 2009). In addition, they also interact with other 
transcription factors such as P-TEFb (positive transcription elongation factor b), TBP (TATA 
binding protein) or the hematopoietic transcription factor GATA1 (Yang et al., 2005; Peng et 
al., 2007; Lamonica et al., 2011). 
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1.6 Aims and objectives 
Epigenetics has been one of the fastest growing areas in science, and the understanding of 
epigenetic mechanisms related to chromatin remodelling and transcription regulation have 
made great impacts on developmental studies and the understanding of disease (Bernstein et 
al., 2007; Zahn and Travis, 2013). NURF is a highly conserved nucleosome remodelling 
enzyme, the recruitment of which has been speculated to be controlled by histone post-
translational modifications. However, the full spectrum of modified histone interactions with 
“reader” domains (PHD fingers and bromodomain) on the largest NURF subunit NURF301 
remains to be established. The main aim of this project is understanding the modified histone 
binding specificities of these functional modules in NURF301 and how chromatin localization 
of these specific histone modifications affects NURF recruitment. To do this we used a 
number of in vitro assays as well as in vivo immunostaining analysis. 
 
Our first objective was to identify histone modifications recognized by putative reader 
domains on NURF301. To do this we overexpressed and purified GST-conjugated NURF301 
PHD, PHD1, PHD2 and bromodomain respectively. Each purified domain was then applied to 
modified histone peptide library arrays to perform an unbiased screen to determine the full 
modified histone binding specificities, Binding was confirmed by peptide pull down assays, 
structure modelling analysis and Biacore analysis. The second objective was to characterize 
the in vivo localization of these modifications and NURF, and how histone modifying 
enzymes could affect NURF recruitment. This involved immunostaining of NURF and 
histone modifications in different cell types such as embryo, neuroblasts, polytene 
chromosomes, testes and ovaries from wild type and histone modifying enzyme mutant 
Drosophila animals. It also involved ChIP sequencing analysis to determine the genome-wide 
localization of NURF. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Medium 
2.1.1 Bacterial medium 
2.1.1.1 LB liquid and plate medium 
For bacteria cell culture, we used LB medium (10 g/L bacto tryptone (BD), 5 g/L bacto yeast 
extract (BD), 10 g/L NaCl). 1.8% bacto agar (BD) was added for plate medium if required 
and poured into petri dishes. The concentration of antibiotics for selection of plasmid DNA or 
bacterial strain was: ampicillin (100 μg/ml), chloramphenicol (12.5 µg/ml) and tetracycline 
(12.5 µg/ml). 
 
2.1.1.2 SOC medium 
For the recovery of bacterial cells after transformation, SOC (Super Optimal broth with 
Catabolite repression) medium (0.5% yeast extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgSO4, 10 mM MgCl2, 20 mM glucose) was used. A solution containing the first four 
reagents was sterilized at 121°C and cooled. Subsequently, MgCl2 and glucose sterilized with 
a 0.2 μm filter were added to complete the medium. 
 
2.1.1.3 M9 salts 
M9 salts were used for washing recombination induced bacteria cells before they were spread 
on the plate medium. 1x M9 salts was prepared by mixing 6 g Na2HPO4, 3 g KH2PO4, 1 g 
NH4Cl and 0.5 g NaCl in 1 L of distilled water as a total volume. Then the solution was 
autoclaved at 121°C for 15 minutes. 
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2.1.1.4 M63 minimal medium 
M63 minimal medium was used for galK selection in the recombineering system. 5x M63 
salts stock solution was prepared by dissolving 10 g (NH4)2SO4, 68 g KH2PO4 and 2.5 mg 
FeSO4·7H2O in 1 L distilled water and adjusting to pH 7.0 with KOH. The stock solution was 
autoclaved at 121°C for 15 minutes before use. Sterile stock solutions of 0.2 mg/ml biotin, 10 
mg/ml L-leucine, 1 M of MgSO4, 20% galactose, 20% glycerol, 20% 2-deoxy-galactose and 
25 mg/ml chloramphenicol were also prepared and filter sterilized separately. M63 minimal 
medium plates were prepared by adding 15 g bacto agar in 800 ml of H2O and autoclaved at 
121°C for 15 minutes. The solution was then cooled to 80°C. 200 ml of autoclaved 5x M63 
salts and 1 ml MgSO4 solution were added. The medium was cooled to 50°C. 5 ml of biotin, 
4.5 ml of L-leucine and 500 µl of chloramphenicol were mixed with the medium. For the 
galK+ selection 10 ml galactose was added, but for the galK- selection 10 ml of 2-deoxy-
galactose and 10 ml glycerol were added at this step. Finally, 15 ~ 20 ml of M63 agar medium 
was poured into petri dishes and plates allowed to cool for 30 minutes. 
 
2.1.1.5 McConkey agar medium 
To remove galK negative contaminants in galK positive selection, a few selected clones were 
streaked on McConkey agar containing galactose as the sole source of carbon. McConkey 
agar powder (BD) 40 g was added to 1 L of water and autoclaved at 121°C for 15 minutes. 
Before it was poured into plates, galactose and chloramphenicol were added to a final 
concentration of 1% and 12.5 µg/ml respectively. 
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2.1.2 Drosophila medium 
2.1.2.1 Dextrose and yeast medium 
For general Drosophila culture, we used dextrose and yeast medium. The medium was 
prepared by adding 4 L of cold water to stainless steel bucket. Then 550 g dextrose (Cargill) 
and 500 g yeast (Fermipan) were added and mixed thoroughly. 350 g wheat flour (W & H 
Marriage & Sons Ltd) was mixed with 2.5 L of water to make a paste in a separate beaker, 
and then added to the dextrose/yeast mixture. In a second stainless steel bucket, 4.5 L hot 
water and 80 g agar powder (B.T.P.) were mixed. Both mixtures were autoclaved at 121°C for 
15 minutes. After cooling to 70°C, the agar solution was added to dextrose/yeast/flour mixture. 
40 ml propionic acid (Sigma) was added. 25 g methyl 4-hydroxybenzoate (Sigma) dissolved 
in 250 ml ethanol was added and mixed thoroughly. Medium was poured into vials 10 ml or 
bottles 25 ml. When the medium had set, the vials and bottles were capped and stored in a 
4°C cold room before use. 
  
2.1.2.2 Apple medium  
To collect fresh Drosophila eggs for injection experiments, we used apple medium plate 
which was prepared by adding 250 ml apple juice (Sainsburys) and 250 ml distilled water in 1 
L plastic beaker. 10 g bacto agar was then added. The mixture was microwaved at full power 
for 5 minutes or longer if needed until the agar was melted completely. After it had cooled to 
70°C, 4 ml of propionic acid was added to apple agar mixture. 2.5 g methyl 4-
hydroxybenzoate dissolved in 25 ml ethanol was added and mixed thoroughly. The mixture 
was poured into 50 mm small petri dishes and stored at 4°C after it set. 
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2.2 General molecular biology 
All chemical reagents for buffers and media were molecular biology grade reagents obtained 
from Sigma-Aldrich.   
 
2.2.1 PCR  
2.2.1.1 Reaction conditions 
We used Taq DNA Polymerase PCR system (Roche) for short DNA fragment amplification 
and Expand Long Template PCR System (Roche) to amplify long DNA fragments (5-20 kb) 
like NURF301 C-terminal deleted regions in our study. For reactions, 1x PCR reaction buffer, 
0.5 mM dNTP, 25-50 ng of template DNA, 100 pmol forward/reverse primers and 1.25 units 
of DNA polymerase were used in 50 μl of reactions in a thin wall 0.2 ml PCR tube (Molecular 
BioProducts). 
 
2.2.1.2 Thermocycler conditions for PCR 
We used standard PCR conditions shown in Table 2-1, but the annealing temperature was 
altered depending on the primer's Tm value and GC-content. Extension time was varied 
depending on the length of DNA to be amplified, about 1 minute for each 1 kb of DNA. 
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Table 2-1. PCR programme for amplification. 
Step Temperature Time 
Initial denaturation 94°C 4 mins 
30-35 cycles 
94°C 30-50 secs 
50-65°C 30 secs - 1 min 
72°C 2 mins 
Final extension 72°C 5 mins 
Hold 4°C ∞ 
 
2.2.2 DNA purification 
2.2.2.1 Agarose gel electrophoresis 
We conducted 0.7% or 1.0% agarose gel electrophoresis (the percentage used depended on the 
size of the PCR fragment) to confirm our PCR reaction. We used 0.7 g or 1.0 g of agarose 
(Fisher Scientific) in 100 ml of 1x TAE buffer (40 mM tris-acetate, 1 mM EDTA). The 
agarose mixture was melted in a microwave oven for 50 seconds and poured into the gel tray 
after adding ethidium bromide (Invitrogen) to a 0.5 µg/ml final concentration. The gel was 
run in 1x TAE buffer. Each 5 μl PCR sample was mixed with 1 μl of 6x DNA loading buffer 
(0.25% bromophenol blue, 0.25% xylene, 30% glycerol) and loaded. The gel running 
condition was 120 Volts for 20 minutes.  
 
2.2.2.2 Gel extraction 
After the electrophoresis, the DNA was excised and purified by using a QIAquick Gel 
Extraction Kit (Qiagen). DNA fragments were excised from the agarose gel and visualized 
using the long-range UV light of a Compact UV Lamp (UVP) with a clean, sharp scalpel 
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blade. The gel slice was weighed in a 1.5 ml microcentrifuge tube and the DNA was extracted 
according to the supplier’s protocol. At the final elution step, DNA was eluted in 50 μl of 
distilled water.  
 
2.2.3 Plasmid DNA preparation 
2.2.3.1 Plasmid DNA miniprep 
Plasmid minipreps were performed using a QIAprep Spin Miniprep Kit (Qiagen). 1.5 ml of a 
overnight culture in LB medium (see 2.1.1.1) were pelleted by centrifugation at 21,000 g for 
one minute at room temperature, and plasmid DNA was purified according to the supplier’s 
protocol. 50 μl of buffer EB was added to elute DNA at the last step. 
 
2.2.3.2 Plasmid DNA midiprep 
Plasmid midipreps were performed using a NucleoBond Xtra Midi EF kit (Machrey-Nagel). 
100 ml of a overnight culture was pelleted at 7,900 g for five minutes at 4°C in a Beckman 
Coulter Avanti centrifuge (Rotor JLA 10.5, Beckman Coulter) and the plasmid DNA was 
isolated according to the supplier’s protocol. At the last step, DNA was dissolved in 150 μl TE 
buffer (10 mM tris-Cl at pH 8.0, 0.1 mM EDTA) or distilled water.  
 
2.2.4 Restriction enzyme digestion 
Table 2-2 lists restriction enzymes that we used in this study. 
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Table 2-2. Restriction enzyme list. 
Name Description Suppiler 
BamHΙ 
GST fusion cloning 
New England Biolabs 
(NEB) 
EcoRΙ 
Spe І 
CTAP tag check 
 
For each reaction, 10 units of restriction enzyme, 1 x NEB buffer, 1 µg of PCR fragment and 
plasmid DNA for GST fusion cloning or 2 µg fly genomic DNA for inverse PCR were used in 
50 µl of reaction, and the sample was incubated for two hours at 37ºC in water bath. 
 
2.2.5 DNA ligation 
DNA ligation was conducted with 2,000 units of T4 DNA ligase (New England Biolabs), 1x 
NEB T4 DNA ligase buffer, 1:5 ratio of plasmid and insert DNA in a reaction volume of 20 µl 
overnight at 16ºC. 
 
2.2.6 Bacterial strains and transformation  
2.2.6.1 Bacterial strains 
Bacterial strains used in our study are listed in Table 2-3 below. 
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Table 2-3. Bacterial strains. 
Name Genotype 
Transformation 
method used 
Description Supplier 
DH5α 
F- φ80lacZΔM15 
Δ(lacZYA-argF)U169 deoR 
recA1 endA1 hsdR17(rk-, 
mk+) phoA supE44 thi-1 
gyrA96 relA1 λ- 
Heat shock 
Plasmid DNA 
amplification and 
purification 
Invitrogen 
 
BL21 
CodonPlus 
RIL 
E. coli B F– ompT 
hsdS(rB– mB–) dcm+ Tetr 
gal endA The [argU ileY 
leuW Camr] 
Heat shock 
GST fusion 
protein expression 
Stratagene 
DH10 
F- mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80dlacZΔM15 
ΔlacX74 endA1 recA1 deoR 
Δ(ara,leu)7697 araD139 
galU galK nupG rpsL λ- 
Electroporation 
Strain delivering 
BAC plasmid 
DNA 
P[acman] 
Resources 
EPI300 
F- mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80dlacZΔM15 
ΔlacX74 recA1 endA1 
araD139 Δ(ara, leu)7697 
galU galK λ- rpsL (StrR) 
nupG trfA dhfr 
Electroporation 
BAC plasmid 
DNA constructs 
amplification 
EPICENTRE 
SW102 
F- mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80dlacZ M15 
ΔlacX74 deoR recA1 endA1 
araD139 Δ(ara, leu) 7649 
galU galK rspL nupG 
[λcI857 (cro-bioA) tet] 
Electroporation 
BAC 
recombineering 
strain 
National 
Cancer Institute 
Frederick 
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2.2.6.2 Preparation of SW102 competent cells 
SW102 E.coli strain (Warming et al., 2005) was streaked on to a LB agar plate containing 
tetracycline (12.5 µg/ml) and incubated overnight at 30ºC. A single colony was inoculated and 
cultured as a seed culture in 3 ml of LB medium containing tetracycline (12.5 µg/ml) 
overnight at 30ºC in a shaking incubator (INFORS HT) at 250 rpm. The culture was 
transferred into 100 ml LB medium without antibiotics and grown for three hours at 30ºC 
until the OD600 reached 0.6. The cultured cells were cooled on ice slurries for five minutes. 
The cells were harvested by centrifugation at 3,200 g for 10 minutes at 4ºC and as much as 
possible of the LB medium was removed. 1 ml of sterilized ice-cold MiliQ water was added 
to the collected cells to wash, and the cells were resuspended by gentle swirling on ice. We 
added 1 ml more of sterilized ice-cold MiliQ water before the cells were centrifuged at 3,200 
g for 10 minutes at 4ºC. The cells were washed one more time with 1 ml of sterile ice-cold 10% 
glycerol and pelleted. We removed all of the supernatant and added 125 µl of sterile ice-cold 
10% glycerol to resuspend the cells, so that the final volume was equal to 1/800 volume of 
original cell culture volume. 
 
2.2.6.3 Heat shock transformation  
1-50 ng of DNA was incubated with 50 μl of host bacteria competent cells (see Table 2-3) for 
30 minutes on ice. A heat-pulse was conducted for each transformation reaction in a 42°C 
water bath for 45 seconds. The reaction samples were incubated on ice for two minutes. SOC 
medium (see 2.1.1.2) was added to each transformation reaction for recovery and incubated 
for one hour at 37°C in water bath. Each reaction sample was spread on to LB plates 
containing ampicillin (100 μg/ml) and incubated overnight at 37°C. 
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2.2.6.4 Electroporation 
1-50 ng of DNA was added to 40 μl host bacteria electrocompetent cells (see Table 2-3) in a 
microcentrifuge tube and mixed by gentle pipetting. After 30-60 seconds to allow DNA 
adsorption to the cells, the mixture was placed in a 0.1 cm electroporation cuvette (Bio Rad) 
chilled on ice. Electroporation was performed using GenePulser Xcell System (Bio Rad) with 
a pulse of 1.8 kV, capacitance at 25 µF and resistance at 200 Ω. For the cell recovery, 1 ml of 
SOC medium was added and incubated for one hour at 30°C in a shaking incubator at 250 
rpm. The cells were pelleted in 1.5 ml microcentrifuge tube at 21,000 g for 15 seconds, 
resuspended with 100 μl of LB medium and then spread on the LB medium plate containing 
antibiotics. The plates were incubated for two days at 30°C. 
 
2.2.7 DNA and Protein quantification 
The Quant-iT Broad-Range DNA assay kit (Invitrogen) was used for DNA quantification after 
DNA extraction or PCR. The Quant-iT Protein assay kit (Invitrogen) was used for protein 
quantification after protein purification. The samples were mixed with fluorophores in the kit 
that become fluorescent upon binding to DNA or proteins, and then the fluorescence intensity 
was quantified by a Qubit Fluorometer (Invitrogen) giving sample concentrations. These 
assays were performed according to the supplier’s protocol.  
 
2.2.8 DNA sequencing 
2.2.8.1 Template preparation 
We followed the sequencing method supplied from Functional Genomics Laboratory in the 
University of Birmingham. Template DNA was prepared as genomic DNA, plasmid DNA or 
PCR product purified by method of choice (see 2.2.3). Different DNA template quantities 
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were used for cycle sequencing reaction as shown in Table 2-4 below. 
 
Table 2-4. Quantities of template DNA required for cycle sequencing reaction.  
Template type Quantity 
PCR product: 
 100 – 200 bp 
 200 – 500 bp 
 500 – 1000 bp 
 1000 – 2000 bp 
 >2000 bp 
 
1 – 3 ng 
3 – 10 ng 
5 – 20 ng 
10 – 40 ng 
40 – 100 ng 
Plasmid Single Stranded 50 – 100 ng 
Plasmid Double Stranded 200 – 500 ng 
Cosmid BAC 0.5 – 1.0 μg 
Bacterial Genomic DNA 2 – 3 μg 
 
2.2.8.2 PCR reaction  
We used the Big Dye Cycle Sequencing Kit (Applied Bioscience) for sequencing. The 
reaction sample was prepared with 8 μl of terminator ready reaction mix previously diluted 
1:3 in dilution buffer (200 mM tris-Cl at pH 9.0, 5 mM MgCl2), 3.2 pmol of primer, the 
required amount of template DNA and the volume adjusted to 20 μl with distilled water. The 
PCR programme used for Big Dye Cycle Sequencing reaction is described below (Table 2-5).  
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Table 2-5. Big Dye Cycle Sequencing programme. 
Step Temperature Time 
Initial denaturation 96°C 1 min 
25 cycles 
96°C 10 secs 
50°C 5 secs 
60°C 4 mins 
Hold 4°C ∞ 
 
2.2.8.3 Purification of DNA for sequencing 
After the PCR reaction, DNA was purified. The reaction sample was entirely transferred into 
a 1.5 ml microcentrifuge tube. Subsequently, 2 μl of 250 mM EDTA and 64 μl of non-
denatured 95% ethanol were added. The sample was vortexed briefly and then left for 15 
minutes at room temperature for precipitation. The tube was centrifuged at 17,400 g for 20 
minutes at 4°C in a Hawk 15/05 centrifuge (MSE). The orientation was marked on the tube 
for the next step. Immediately, we carefully aspirated and discarded the supernatant. 250 µl of 
70% ethanol was then added and mixed briefly by vortexing. This step was repeated once and 
the sample was centrifuged in the same orientation at 17,400 g for 10 minutes at 4°C. The 
supernatant was removed carefully and the pellet was air dried for 20 minutes. After drying, 
the purified DNA was dissolved with 20 µl of Hi Di formamide and denatured in a heating 
block at 95°C for four minutes. Finally, DNA samples were sent for sequencing by a high-
throughput automated capillary electrophoresis machine (Applied Biosystems) which has 
fluorescence-based detection. 
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2.2.9 GST fusion protein overexpression and purification.  
2.2.9.1 GST fusion cloning 
A DNA fragment encoding the NURF301 PHD domain (Figure 2-1) was PCR amplified using 
the PHD F and PHD R primers described in Table 2-6 using Drosophila embryonic cDNA as 
a template. A 205 bp PCR product was purified and then digested using the restriction 
enzymes BamHI and EcoRI. The digested DNA fragment was cloned into BamHI and EcoRI 
digested pGEX-2T vector (Millipore) to create an in-frame fusion with GST. Three plasmids 
encoding GST fusions with the NURF301 Bromodomain and, PHD1 and PHD2 fingers that 
have previously been generated (Wysocka et al. 2006) were also utilized. All GST fusion 
constructs were amplified in E.coli strain DH5α (see Table 2-3) and purified using the plasmid 
midiprep procedure as described above (see 2.2.3.2). These constructs were confirmed by 
sequencing (see 2.2.8) using the PHD F and PHD R primers, and this sequencing data was 
analyzed by BLAST (Basic local alignment search tool, Altschul et al., 1990) searches. 
 
Table 2-6. PCR primers used to amplify and sequence Nurf301 PHD domain gene.  
All primers were obtained from Eurofins MWG Operon. 
Primer sequence (5' to 3') Name Description 
CGCGGATCCATGCTGCAGGAGGGACCTAT PHD F 
Amplify Nurf301-PHD 
forward 
CCGGAATTCCCACTACGCCACTTACCTTAT PHD R 
Amplify Nurf301-PHD 
reverse 
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Figure 2-1. GST fusion NURF301 domain cloning structure in the pGEX-2T plasmid 
vector. GST conjugated NURF301 PHD was generated by cloning, and other domain 
plasmids encoding GST fusions with the NURF301 PHD1, PHD2 and Bromodomain had 
previously been generated (Wysocka et al. 2006). 
 
2.2.9.2 Protein overexpression 
E.coli strain BL21 CodonPlus RIL (see Table 2-3) was used as the host for GST-fusion protein 
over-expression. 5 ml overnight cultures of each strain were grown at 30°C and diluted into 
1L LB medium containing ampicillin (25 µg/ml) in a 2 L conical flask. For each construct, 3 
L of cells were grown at 32°C in a shaking incubator at 230 rpm, until the cell culture had 
reached an OD660 of 0.5~0.6. Protein expression was induced by adding isopropyl β-D-1-
thiogalactopyranoside (IPTG, Promega) to 0.5 mM, and the cells were incubated for two and 
a half hours at 32°C in a shaking incubator at 230 rpm.  
43 
2.2.9.3 Purification 
Cells were harvested by centrifugation at 7,900 g for five minutes in an Avanti J20XP 
centrifuge (JLA10.5 rotor). Harvested cells were washed once with 1x PBS, and the cell pellet 
was frozen at -80°C until needed. Cell pellets were resuspended in resuspension buffer (12 
mM hepes at pH 7.9, 12.5 mM MgCl2, 2 mM EDTA, 5 mM DTT, 20% glycerol, 0.1% NP-40). 
Cells were lysed by sonication on ice (30% power, for one minute, 10 repeats) using a Vibra 
cell VC130 sonicator (Sonics & Materials). The lysate was cleared by centrifugation twice at 
27,000 g for 30 minutes at 4°C in an Avanti J20XP centrifuge (JA25.5 rotor). The cleared 
lysate was applied to 0.5 mL of Glutathione Sepharose 4B beads (Amersham) in a Poly-Prep 
Chromatography Column (Bio Rad). The column was washed with wash buffer (12 mM 
hepes pH 7.9, 12.5 mM MgCl2, 2 mM EDTA, 5 mM DTT, 0.15 M KCl, 20% glycerol, and 0.1% 
NP-40). Bound proteins were then eluted in elution buffer (12 mM hepes pH 7.9, 12.5 mM 
MgCl2, 2 mM EDTA, 5 mM DTT, 20% glycerol, 0.1% NP-40, 0.15 M KCl, 10 mM 
glutathione). The purity and yield of protein was analysed by SDS PAGE. 
 
2.2.10 SDS PAGE and western blot 
2.2.10.1 10% Acrylamide gel preparation 
A Gel was prepared in a Invitrogen gel cassette (Mini, 1.0 mm). The lower resolution gel was 
prepared by mixing 4.96 ml distilled water, 2.5 ml 4x lower buffer (2 M tris-Cl at pH 8.8), 2.5 
ml 40% acrylamide:bis-acrylamide solution (Fisher Scientific), 100 µl freshly made 10% 
ammonium persulfate and 10 µl TEMED, which was poured into a cassette. The resolving gel 
was allowed to polymerize for 20 minutes. Then the stacking gel was made with 2.47 ml 
distilled water, 1 ml 4x upper buffer (1.3 M tris-Cl at pH 6.8), 450 µl 40% acrylamide:bis-
acrylamide solution, 68 µl freshly made 10% ammonium persulfate and 4 µl TEMED and 
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layered on the top of the resolving gel. A 10 well comb was inserted into the stacking gel, and 
the gel was allowed to polymerize for about 45 minutes. 
 
2.2.10.2 Sample preparation 
Protein samples were prepared for polyacrylamide gel electrophoresis by mixing 20 µl of 
each elution sample and an equal volume of 2x tris-glycine SDS sample buffer (126 mM tris-
Cl pH 6.8, 20% glycerol, 4% SDS, 0.005% bromophenol blue, Invitrogen) with 10% β-
mercaptoethanol and denatured at 100°C for five minutes. After cooling on ice, 30 µl of each 
sample was loaded per well. Precision Plus Protein All Blue Standards (Bio Rad) were used to 
determine the molecular weight. 
 
2.2.10.3 SDS PAGE electrophoresis  
The gel was run in a XCell SureLock Mini-Cell Electrophoresis System (Invitrogen) with tris-
glycine running buffer (25 mM tris, 192 mM glycine, 0.1% SDS) at a constant voltage of 120 
for two hours or until the 10 kDa prestained marker band reached the bottom of the resolving 
gel. Then the gel was removed from the cassette and stained with Brilliant Blue R 
Concentrate (Sigma) for two minutes. Subsequently, the gel was put into destaining solution 
(20% methanol, 10% acetic acid) to reveal protein bands. 
 
2.2.10.4 Western blot 
After SDS PAGE, PVDF membrane (Bio Rad) activated in 99% methanol, six fibre pads 
(Invitrogen) and two whatman papers (pre-cut, Whatman) were prepared and thoroughly 
soaked in cold tris-glycine transfer buffer (12 mM tris, 96 mM glycine) with 20% methanol 
for few minutes in a shallow tray. PAGE gel was disassembled from the gel cassette, and the 
45 
stacking gel was removed with a clean razor blade. The gel was then transferred and soaked in 
the tris-glycine transfer buffer with 20% methanol for few minutes. The transfer sandwich 
was prepared as following orders: three fibre pads, one whatman filter paper, polyacrylamide 
gel, PVDF membrane, one whatman paper, three fibre pads, stacked from the bottom of XCell 
II blot module (Invitrogen). The module with the transfer sandwich was placed into the 
electrode module and transfer was conducted at 30 Volt for two hours. Subsequently, the 
membrane was removed from the module, and blocked in 20 ml of TBST (50 mM tris-Cl pH 
7.4, 150 mM NaCl, 0.1% tween 20) containing 5% dried skimmed milk powder overnight at 
4°C on a shaker. Antibody incubation was carried out with HRP conjugated rabbit anti-GST 
antibody (1:5000, Novus Biologicals) in 10 ml of TBST buffer containing 5% dried skimmed 
milk powder for three hours at room temperature. The membrane was then washed with 20 ml 
TBST buffer four times for 10 minutes at room temperature. Supersignal West Pico 
Chemiluminescent Substrate (ECL substrate, Thermo Fisher Scientific) was applied to 
membrane and allowed to react for five minutes at 25°C on a shaker. Finally, protein bound 
spots were visualised by direct exposure to Hyperfilm ECL (Amersham). 
 
2.3 Histone modified peptide library array analysis 
2.3.1 Histone H3 peptide library array and Histone H3, H4 N-terminal peptide library 
array analysis 
Histone H3 peptide library array (Alta Bioscience) and Histone H3, H4 N-terminal peptide 
library array (Alta Bioscience) assays were conducted with purified GST-conjugated Bromo, 
PHD, PHD1 and PHD2 domain proteins respectively. The proteins were dialysed in Slide-A-
Lyzer Dialysis Cassettes (10K MWCO, Thermo Fisher Scientific) in binding buffer (50 mM 
tris-Cl pH 7.5, 150 mM NaCl, 0.1% NP-40) to remove the glutathione. The protein 
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concentrations were determined before they were applied to the peptide arrays. The array was 
blocked with blocking buffer (50 mM tris-Cl pH 7.5, 150 mM NaCl, 0.1% NP-40, 20% FBS, 
5 mg/ml biotin) containing protease inhibitor cocktail (one Tablet per 50 ml, Roche) for five 
minutes at room temperature. The array was washed twice with binding buffer containing 20% 
FBS for five minutes at room temperature. Each domain protein (concentration range: 1 
mg/ml to 2 mg/ml) was then introduced to the array, and the binding reaction was performed 
with binding buffer in a hybridization gasket slide kit overnight at 4°C on a rotator in a 
microarray Hybridization chamber (Agilent Technologies). Subsequently the chip was washed 
with wash buffer (50 mM tris-Cl pH 7.5, 150 mM NaCl, 0.1% NP-40) three times for five 
minutes. The array was incubated with rabbit anti-GST HRP conjugated antibody (1:5000 
dilution in binding buffer containing 20% FBS) for one hour at 25°C. Subsequently, the array 
was washed with wash buffer three times for five minutes. Supersignal West Pico 
Chemiluminescent Substrate was applied to the array and allowed to react for five minutes at 
25°C in the chamber on a rotator. Finally, protein bound peptide spots were detected by direct 
exposure to Hyperfilm ECL film. 
 
2.3.2 MODified histone H3, H4, H2A and H2B peptide array analysis 
MODified histone H3, H4, H2A and H2B peptide array (Active Motif) assays were conducted 
as above (see 2.3.1), except for that the domain protein and array binding reaction was 
performed in a small shallow tray. Moreover, the array slide was washed in a large volume 
wash chamber we designed for this experiment. To visualize protein bound peptide spots, the 
primary antibody reaction was performed with HRP conjugated rabbit anti-GST antibody 
(1:5000 dilution) followed by a secondary antibody reaction with IRDye 800 CW rabbit anti-
HRP antibody diluted in Chemi IR diluent (1 µg/ml, LI-COR Biosciences) for one hour at 
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room temperature in the dark. The array was washed three times as described above, rinsed 
with PBS and spun down briefly in a centrifuge to remove residual buffer on the array. The 
protein bound peptide spots were visualized by direct exposure to 800 nm channel of Odyssey 
scanner (with Odyssey V3.0 programme, LI-COR Biosciences). 
 
2.4 Peptide pull down assay 
2.4.1 Peptide pull down  
Peptide pull down was carried out to confirm the peptide array data as described in Wysocka 
2006. Standard reactions contained 1 µg of biotinylated peptide (see Table 2-7) and 5 µg 
purified GST-conjugated protein (Bromo, PHD, PHD1 and PHD2 domain) with 300 µl 
binding buffer (50 mM tris-Cl at pH 7.5, 150 mM NaCl, 0.1% NP-40). However, the amount 
of peptide in the reaction was varied from 0.1 µg to 50 µg depending on the binding affinity 
of the domain protein to the peptide. Binding reactions were incubated overnight at 4°C on a 
rotator. Streptavidin Plus Ultralink resin (Thermo Fisher Scientific) was equilibrated by 
washing with binding buffer four times, and 30 µl of 50% bead slurry was added to each 
binding reaction. Beads were allowed to bind to biotinylated peptides for two hours at 4°C on 
a rotator. Unbound protein was removed by washing with binding buffer four times for five 
minutes at 4°C. In the last wash, buffer was completely removed, and 60 µl of 1x tris-glycine 
SDS sample buffer with 10% β-mercaptoethanol was added to the sample for SDS PAGE and 
western blot (see 2.2.10).  
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Table 2-7. Histone peptide samples.  
Histone peptide samples used in this study are listed below 
Name Peptide sequence (N-terminal to C-terminal) Suppiler 
Histone H3(1-21) ARTKQTARKSTGGKAPRKQLAGGK(Biotin) Millipore 
Histone H3(1-21) 
K4me3 
ARTK(me3)QTARKSTGGKAPRKQLA Anaspec 
Histone H3(1-21) 
K4me3 
ARTK(me3)QTARKSTGGKAPRKQLAGGK(Biotin) Millipore 
Histone H3(1-21) 
T3p/K4me3 
ART(pho)K(me3)QTARKSTGGKAPRKQLAGGK(Biotin) Cambridge Peptides 
Histone H3(1-21) 
K4me3/K9ac 
ARTK(me3)QTARK(ac)STGGKAPRKQLAGGK(Biotin) Anaspec 
Histone H3(1-21) 
K4me3/K9ac/S10p 
ARTK(me3)QTARK(ac)S(pho)TGGKAPRKQLAGGK(Biotin) Anaspec 
Histone H3(21-44) ATKAARKSAPATGGVKKPHRYRPGGGK(Biotin) Anaspec 
Histone H3(18-36) KQLATKAARKSAPATGGVK(Biotin) 
Johns Hopkins 
School of Medicine, 
USA 
Histone H3(18-36) 
K23me3 
KQLATK(me3)AARKSAPATGGVK(Biotin) 
Johns Hopkins 
School of Medicine, 
USA 
Histone H3(14-34) 
K23me3 
(Biotin)KAPRKQLATK(me3)AARKSAPATGG Alta Bioscience 
Histone H3(21-44) 
K23me3 
ATK(me3)AARKSAPATGGVKKPHRYRPGGGK(Biotin) Anaspec 
Histone H3(21-44) 
K36me2 
ATKAARKSAPATGGVK(me2)KPHRYRPGGGK(Biotin) Anaspec 
Histone H3(21-44) 
K36me3 
ATKAARKSAPATGGVK(me3)KPHRYRPGGGK(Biotin) Anaspec 
Histone H3(21-44) 
K36ac 
ATKAARKSAPATGGVK(ac)KPHRYRPGGGK(Biotin) Anaspec 
Histone H4(1-21) SGRGKGGKGLGKGGAKRHRKVGSGSK(Biotin) Millipore 
Histone H4(1-21) 
K16ac 
SGRGKGGKGLGKGGAK(ac)RHRKVGSGSK(Biotin) USBiological 
Histone H4(1-25) 
K16ac 
SGRGKGGKGLGKGGAK(ac)RHRKVLRDNGSGSK(Biotin) Anaspec 
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Histone H4(1-18) 
K5/8/12/16ac 
SGRGK(ac)GGK(ac)GLGK(ac)GGAK(ac)RHGSGSK(Biotin) Millipore 
Histone H4(1-25) 
K5/8/12/16ac 
SGRGK(ac)GGK(ac)GLGK(ac)GGAK(ac)RHRKVLRDNGSG
SK(Biotin) 
Anaspec 
 
2.4.2 Peptide competition pull down assay 
Peptide competition pull down assay was conducted to determine the relative affinities of the 
NURF301 PHD2 domain to different histone modifications on the peptides. Each sample 
contained 0.1 µg of biotinylated histone modified peptide (H3(1-21) K4me3, H3(1-21) 
K4me3/K9ac, H3(1-21) K4me3/K9ac/S10p, see Table 2-7) and 5 µg of purified GST 
conjugated PHD2 domain protein with 300 µl of binding buffer and was incubated overnight 
at 4°C on a rotator. Streptavidin plus ultralink resins were equilibrated by washing with 
binding buffer four times, and 30 µl of 50% bead slurry was added to each sample. The 
streptavidin resins and protein-biotinylated peptides were allowed to bind to each other for 
two hours at 4°C on a rotator. Unbound proteins were removed by washing with binding 
buffer four times for five minutes at 4°C. Competitor peptides, H3(1-21) K4me3 peptide un-
biotinylated (see Table 2-7), at a 0, 100, 250, 500 times concentration (0 µg, 10 µg, 25 µg, 50 
µg) were then added to each sample and incubated for one hour at room temperature. 
Unbound peptides were washed with binding buffer four times for five minutes at room 
temperature, followed by SDS PAGE and western blot were performed as above (see 2.2.10). 
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2.5 Biacore 
2.5.1 Sample preparation 
GST conjugated PHD2 domain protein, which contains a cleavage site for the prescission 
protease (Amersham) between GST and the PHD2 domain, was dialysed in protease digestion 
buffer (50 mM tris-Cl pH 7.0, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.01% NP-40) 
overnight at 4°C. Dialysed protein concentration was measured by Quant-iT™ protein assay 
(see 2.2.7). For our studies, 0.7-1 mg of protein was digested with prescission protease (2 
units per 100 µg protein) for four hours at 5°C. After digestion, the sample was applied to a 
mini-column (Bio Rad) containing 200 - 250 µl of glutathione sepharose (Amersham) 
equilibrated with Biacore running buffer (10 mM HEPES pH 7.9, 150 mM NaCl, 0.005% NP-
40) to separate the PHD2 domain protein from uncleaved protein, cleaved GST and 
prescission protease. 
  
2.5.2 Chip preparation and peptide binding 
A Biacore 3000 (Amersham) was used to confirm whether binding of PHD2 to H3K4me3 
could be affected by a flanking histone post-translational modification like H3T3p. Sensor 
chip CM5 (Amersham) was used, and the surface of the chip was activated by injection of 
EDC (0.4 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, Amersham)/NHS (0.1 M N-
hydroxysuccinimide, Amersham) (1:1) mixture at 10 µl/min for six minutes. Next, 10 mg/ml 
streptavidin in 10 mM sodium acetate (pH 5.0) was injected at a flow-rate of 10 µl/min for 
seven minutes to immobilize the streptavidin. The remaining activated sites were then blocked 
by injection of 1 M ethanolamine-HCl pH 8.5 (Amersham) followed by a low pH wash with 
0.1 M glycine (pH 2.5). Finally, 0.1 ng/µl of biotinylated H3(1-21), H3(1-21) K4me3 and 
H3(1-21) T3p/K3me3 peptides were injected to flow cells Fc2, Fc3 and Fc4 on the 
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streptavidin coated biosensor chip respectively. Fc1 was a control served as reference for F2, 
F3 and F4. The immobilization response units of H3(1-21), H3(1-21) K4me3 and H3(1-21) 
T3p/K4me3 peptides were 167, 191 and 173, respectively. 
 
2.5.3 Loading programme 
The previously published Kd for the PHD2 domain binding to H3K4me3 is 2.7 µM (Li et al. 
2006). We injected a serial dilution of the PHD2 domain protein over all four flow cells that 
spanned this concentration, from 78 nM (-32x) to 40 µM (16x). A 10 minute-sample injection 
was performed under the flow rate of 10 µl/min, followed by a 10 minute-wash step was 
carried out with running buffer to allow determination of the on and off rates. 
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2.6 Drosophila genetics 
The table below shows the Drosophila strains that we used for our studies. 
 
Table 2-8. Drosophila strains.  
The following strains were provided from Bloomington Drosophila Stock Centre (BDSC) 
Genotype  Description 
w
1118
 Control 
y
1 
w
67
c
23
; In(2LR)Gla, wgGla-1/CyO, P{hsH\T-2}CyO-1 Delivering heat shock transposase 
y
1 
w
67
c
23
; P{wHy}CG
16971
DG
23208
 Delivering hobo transposon 
y
1
 w
67
c
23
; In(3L)D, D
1
/TM3, Sb
1
, Ser
1
 Chromosome 3 balancer 
y
1
 M{vas-int.Dm}ZH-2A w
*
; M{3xP3-RFP.attP}ZH-86Fb 
Delivering attP docking site/ φC31 
integrase expression in germline cell 
w
1118
; Gcn5
E333st
 P{FRT(w
hs
)}2A e
1
/TM3, 
P{ActGFP}JMR2, Ser
1
 
Gcn5 mutant stop codon generated at 
E333 (E333st) 
y
1
 w
1118
; Gcn5
Q186st
 P{FRT(w
hs
)}2A e
1
/TM3, 
P{ActGFP}JMR2, Ser
1
 
Gcn5 mutant stop codon generated at 
Q186 (Q186st) 
w
1118
; Gcn5
C137T
 P{FRT(w
hs
)}2A e
1
/TM3, 
P{ActGFP}JMR2, Ser
1
 
Gcn5 mutant delivering substitution 
of cysteine to trosine (C137T) 
y
1
 w
1118
; Gcn5
ΔT280-F285
 P{FRT(w
hs
)}2A e
1
/TM3, 
P{ActGFP}JMR2, Ser
1
 
Gcn5 small deletion mutant from 
tyrosine 280 to phenylalanine 285 
(ΔT280-F285) 
y
1
 w
*
; Df(3L)sex204/TM6C, Sb
1
 Tb
1
 
Large gene deletion with sex204 gene 
(contains Gcn5 exon) gene deficiency 
y
1
 sc
*
 v
1
; P{TRiP.HMS01468}attP2 Haspin RNAi 
UAS-Dcr 2; hml-Gal 4, UAS-GFP 
Dicer 2 expression in blood cells for 
RNA interference 
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2.6.1 Transposon-induced NURF301 mutant fly generation 
To generate Nurf301 C-terminal excision lines, we used the P{wHy} transposon system 
(Mohr and Gelbart, 2002; Huet et al., 2002). As the first step, heat shock transposase  y
1 
w
67
c
23
; In(2LR)Gla, wgGla-1/CyO, P{hsH\T-2}CyO-1 male flies were crossed with y
1 
w
67
c
23
; 
P{wHy}CG
16971
DG
23208
 virgin females that contain a hobo transposon 15 kb downstream of 
Nurf301 (Figure 2-2). Transposon excision was induced by heat shocking the flies three times 
every two days for 30 minutes at 38°C in a water bath. When the F2 progeny emerged, white 
eye deletion males were selected. These potentially contain an excision that removed parts of 
Nurf301. Individual males were crossed with virgin y
1
 w
67
c
23
; In(3L)D, D
1
/TM3, Sb
1
, Ser
1 
females delivering a TM3 balancer to stabilize the excision events on chromosome 3. Finally, 
we made F3 brother-sister crosses to stabilize the mutant lines. 
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Figure 2-2. The p{wHy} transposon system to generate NURF301 c-terminal excised fly 
lines. Transposase was activated by heat shock, so transposon excision was induced. Excised 
regions were then confirmed by sequencing.  
 
2.6.2 Drosophila genomic DNA preparation 
Twenty frozen adult flies were put into a 1.5 ml eppendorf tube on dry ice, and 500 μl of HB 
buffer (7 M urea, 2% SDS, 50 mM tris-Cl pH 7.5, 10 mM EDTA, 0.35 mM NaCl) was added. 
Flies were immediately homogenized using a pellet pestle, and then 500 μl phenol/chloroform 
was added and mixed by gentle inversion. The tube was placed on a rotator for 30 minutes at 
room temperature. The reaction sample was centrifuged at 21,000 g for 10 minutes at room 
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temperature. The upper aqueous phase was transferred to a clean 1.5 ml tube. Subsequently, 1 
ml 100% ethanol was added and centrifuged at 21,000 g for one minute at room temperature. 
The supernatant was removed, and pellet was washed with 1 ml of 70% ethanol. The tube was 
centrifuged again at 21,000 g for one minute at room temperature. The supernatant was 
removed and the pellet was briefly air dried. The dried genomic DNA was resuspended with 
500 μl of TE buffer (10 mM tris-Cl pH 8.0, 1 mM EDTA). Subsequently, 50 μl 3 M sodium 
acetate solution and 1 ml 100% ethanol were added to the sample, and the DNA was 
precipitated overnight at -80°C. The sample was centrifuged at 21,000 g for 10 minutes at 
room temperature. The supernatant was removed and 1 ml of 70% ethanol was added for 
washing. The sample was centrifuged at 21,000 g for one minute at room temperature. The 
supernatant was eliminated and the pellet was air dried. Finally, the genomic DNA was 
resuspended with 50 μl TE buffer and kept at -20°C until needed. The Nurf301 C-terminal 
excision regions were analysed by sequencing (see 2.2.8) with primers (Figure 2-2, Table 2-9) 
and BLAST (Altschul et al., 1990).  
 
Table 2-9. PCR primers used to amplify and  
sequence Nurf301 C-terminal deleted regions.  
All primers were obtained from Eurofins MWG Operon. 
Primer sequence (5' to 3') Name Description 
GCGACGCAAAACACCGTATTGATT  hob-amp amplify from hobo element 
CCACTCGACTCACACCCTACA hob-seq sequence out from hobo element 
ACCTTTCCTCTCAACAAGCAA  5P-seq  sequence out from 5P-element  
 
GAACAACTTTGCTCCGATTAGCTT 
GAGCCCGTTGTCGCACATCGAATC 
CATCGTCCGAGAAATCGCCCAACT 
 
Nurf-238 
Nurf-248 
Nurf-258 
amplify from Nurf-RF/RC region 
 [238439-238416] 
 [248514-248491] 
 [258558-258535] 
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2.7 galK recombineering and gap repair system 
2.7.1 Transferring BAC plasmid DNA into SW102 
2.7.1.1 BAC plasmids 
We ordered CH321(85D11) and CH322(169D05) BAC plasmid DNA for recombination 
(P[acman] Resources). The clones deliver Nurf301 genomic DNA (E(bx)) with some flanking 
DNA on both 3' and 5' sides in the BAC vectors as shown in figure 2-3. To ensure that the 
necessary flanking regulatory elements were present, both long and short Nurf301 genomic 
constructs were tested.  
 
 
Figure 2-3. Map of CH321(85D11) and CH322(169D05) BAC plasmid DNA. CH321 and 
CH322 BAC plasmid DNA clones contain Nurf301 genomic DNA (E(bx)) with some 
flanking DNA on both 3’ and 5’ sides in the BAC vectors as indicated. 
 
2.7.1.2 BAC plasmid DNA miniprep 
CH321 and CH322 BAC clones in E.coli strain DH10 were streaked onto LB agar plate 
containing chloramphenicol (25 µg/ml) respectively and incubated for two days at 30ºC. A 
single colony was picked from each plate and cells were grown in 7.5 ml of LB medium with 
chloramphenicol (25 µg/ml) in a shaking incubator at 250 rpm for two days at 30ºC. Then the 
cells were pelleted at 4,500 g for five minutes at 4ºC, and the remaining medium was 
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removed. The BAC plasmid DNA was prepared by plasmid miniprep (see 2.2.3.1). Air dried 
CH321 and CH322 BAC DNA pellets were resuspended with 40 µl double distilled water. We 
stored the DNA samples at 4ºC until needed. 
 
2.7.1.3 Transfer of BAC DNA into the recombinogenic E.coli strain SW102 
Isolated BAC DNA was then transferred into the SW102 strain which contains the lambda 
prophage based recombineering system. SW102 competent cells were prepared (see 2.2.6.2), 
and BAC DNA constructs were delivered into the host strain by performing electroporation as 
described above (see 2.2.6.4). Cells were plated on LB agar plates containing tetracycline 
(12.5 µg/ml) and chloramphenicol (12.5 µg/ml) as selective markers. 
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Table 2-10. Primers for galK/CTAP containing Nurf301 50 bp/500 bp homology arms. 
All primers were supplied from Eurofins MWG Operon. 
Primer sequence (5’ to 3') Number/Name Description 
TTGTGCAAAAAATTAAAAATTTTCGCGAAAATGTT
TTTGACCAAAGAACACCTGTTGACAATTAATCATC
GGCA 
1 galK-full-5p 
galK/CTAP 
recombineering DNA 
templates of  
Nurf301variant A/B 
CTTTATAAACTATAATCATTTGTTCTAAAGTTTTCAA
GGGCTATTATTTCTCAGCACTGTCCTGCTCCTT 
2 galK-full-3p 
TTGTGCAAAAAATTAAAAATTTTCGCGAAAATGTT
TTTGACCAAAGAACAGAGCAGAAGCTTATCTCCG
AG 
3 GSTAP-full-5p 
CTTTATAAACTATAATCATTTGTTCTAAAGTTTTCAA
GGGCTATTATTTCCTATTCAGTGACATGAAAGT  
4 GSTAP-full-3p 
GTGAATCAAATATCCAATTCGTTC 5 Lomgarm 5-3  
GTTCTTTGGTCAAAAACATTTTCG 6 Longarm 5-5 
TAGCCCTTGAAAACTTTAGAACAA 7 Longarm 3-3 
AGTCCAATGAGCAGTAAACAAACC 8 Longarm 3-5 
GTTCACCAATCGGCTGCGCATCAGCAAGTGAGTAG
TTTTCCTGTTGACAATTAATCATCGGCA 
1' galK-NurfC-5p 
galK/CTAP 
recombineering DNA 
templates of  
Nurf301variant C 
CTGTTCCTATTCCTCATTTATACTTTTACATTATAATT
ATAATCAGCACTGTCCTGCTCCTT 
2' galK-NurfC-3p 
GTTCACCAATCGGCTGCGCATCAGCAAGTGAGTAG
TTTTGAGCAGAAGCTTATCTCCGAG 
3' GSTAP-NurfC-5p 
CTGTTCCTATTCCTCATTTATACTTTTACATTATAATT
ATAACTATTCAGTGACAGTGAAAGT  
4' GSTAP-NurfC-3p 
TCCCACCACAAAGTCCACAACAAG 5' CLongarm 5-3 
AAAACTACTCACTTGCTGATGC 6' CLongarm 5-5 
ATAATTATAATGTAAAAGTATAAATGAGG 7' CLongarm 3-3 
GCTTAATGTGCTTCCTACTCACT 8' CLongarm 3-5 
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Figure 2-4. Generation of DNA templates for galK recombineering. (A) The galK +/- 
selection templates and (B) C-terminally TAP tagging of NURF301 templates used 50 bp or 
500 bp homology arms on both 3' and 5', so they can be incorporated into the C-terminal of 
Nurf301 genomic region during recombination. The primers utilized are listed and numbered 
as in Table 2-10 above (both NURF full A/B and NURF C isoforms). 
 
2.7.2 Preparation of the recombination DNA templates 
2.7.2.1 galK positive and negative selection templates  
To generate a galactokinase (galK) recombination template DNA with the Nurf301 full A/B 
isoform that contains 50 bp length homology arms on both 3' and 5', we conducted PCR (see 
2.2.1) with the galK-full-5p and galK-full-3p primers described in Table 2-10 and pgalK 
plasmid (Addgene) as a template. After the reaction, the 1.2 kb of galK PCR product 
delivering 5'/3' 50 bp homology arms was run on a 1.0% agarose gel electrophoresis and gel 
purified (see 2.2.2). 5' and 3' 500 bp homology arm DNA fragments were also prepared by 
PCR amplification with Longarm 5-5/Longarm 5-3 for 5' end 500 bp homology arm and 
Longarm 3-5/Longarm 3-3 for 3' end 500 bp homology arm using CH321 BAC plasmid DNA 
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as a template (see Figure 2-4, Table 2-10). Subsequently, we performed another PCR to 
generate a galK recombination template DNA with Nurf301 full A/B isoform 500 bp 
homology arms on both the 3’ and 5’ ends. Three different templates were required namely: 1) 
5’ end 500 bp arm DNA fragment, 2) 3’ end 500 bp arm DNA fragment and 3) the galK 
recombination DNA delivering 50 bp homology arms generated above. The three templates 
were mixed in equimolar ratios. The final galK recombination template DNA with Nurf301 
full A/B isoform 500 bp length homology arms on both the 3’ and 5’ ends was generated by 
PCR with the Longarm 5-3/3-5 primers as shown in figure 2-4 A. The resultant 2 kb of PCR 
product was purified by DNA purification (see 2.2.2). We performed the same procedures for 
generation of Nurf301 C isoform galK recombination templates delivering 50 bp or 500 bp 
homology arms on both 3' and 5' ends (see Table 2-10). 
 
2.7.2.2 Templates for C-terminally TAP-tagged NURF301 
To generate templates for C-terminally TAP tagging recombination of Nurf301 full A/B 
isoform with 50 bp length homology arms on both 3’ and 5’ ends, we conducted PCR with the 
GSTAP-full-5p and GSTAP-full-3p primers described in Table 2-10. The pCeMM CTAP 
plasmid (Research Centre for Molecular Medicine of the Austrian Academy of Sciences) was 
used as a template for this reaction. The CTAP PCR product delivering 5'/3' 50 bp arms (673 
bp) was run on a 1.0% agarose gel and gel purified (see 2.2.2). Next, we performed another 
PCR to make CTAP recombination template DNA of Nurf301 full A/B isoform with 500 bp 
length homology arms on both 3’ and 5’ ends. The same 5’ and 3’ 500 bp arm DNA fragments 
prepared above (see 2.7.2.1) were used to this reaction. Three different templates were 
required namely: 1) 5’ 500 bp arm DNA fragment, 2) 3’ 500 bp arm DNA fragment and 3)' the 
CTAP recombination DNA delivering 50 bp homology arms generated above. The three 
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templates were then mixed in equimolar ratios, and a PCR reaction was carried out with the 
Longarm 5-3/3-5 primers as shown in figure 2-4 B. The final PCR product, approximate size 
1.5 kb, was purified (See 2.2.2). We performed the same procedures for generation of Nurf301 
C isoform CTAP recombination templates delivering 50 bp or 500 bp homology arms on both 
3' and 5' ends. 
 
2.7.3 BAC recombineering using galK selection 
2.7.3.1 Induction of recombineering function in SW102 
SW102 single colonies delivering the CH321/CH322 BAC construct were selected from the 
plates respectively (see 2.7.1.3) and cultured in 3 ml LB containing chloramphenicol (12.5 
µg/ml) for two days at 30°C. The culture was transferred into 100 ml fresh LB without 
antibiotics and grown for three hours at 250 rpm at 30°C in a shaking incubator until the 
OD600 reached 0.6 - 0.7. 50 ml of culture was transferred into a sterile falcon tube and 
reserved at 32°C as an uninduced control. The rest of the culture (50 ml) was incubated for 15 
minutes exactly at 42°C in a shaking incubator to induce the expression of the recombineering 
function. Subsequently, we prepared uninduced and induced SW102 electrocompetent cells as 
described in session 2.2.6.2.  
 
2.7.3.2 Introducing the galK containing cassette 
Uninduced and induced competent cells were transformed with 300 ng of galK template DNA 
(Nurf301 full A/B and C isoforms) with either 50 bp or 500 bp arms by electroporation (see 
2.2.6.4). After recovery in SOC for one hour at 37°C, 1 ml of cells was transferred into a 1.5 
ml eppendorf tube and centrifuged at 21,000 g for 15 seconds at room temperature. All the 
medium was removed, and cells were resuspended with 1 ml M9 salts (see 2.1.1.3). The 
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sample was then pelleted and the supernatant was discarded followed by another two washes 
with 1 ml M9 salts. This M9 salt wash was necessary to remove any rich medium from the 
bacterial culture. Finally, 100 μl of the uninduced control and 100 μl of the induced sample 
with serial dilutions (1/1, 1/10 and 1/100) were plated on galK+ selection M63 minimal 
medium (see 2.1.1.4). The plates were incubated for 2-4 days at 30°C. Subsequently, the eight 
colonies of galK+ from each plate were selected and streaked on McConkey agar plate (see 
2.1.1.5), containing galactose as the sole source of carbon, in order to select against galK- 
contaminating "hitchhikers".  
 
2.7.3.3 Removal of the galK containing cassette and TAP tagging 
One of the galK+ SW102 red colonies from the McConkey agar plate, containing galK tagged 
CH321/CH322 BAC construct, was selected for another round of recombineering to replace 
the galK cassette with CTAP at either the C-terminus of full length Nurf301 or at the C-
terminus of the Nurf301 C variant. The colony cell was cultured, and uninduced/induced 
electrocompetent cells were prepared as described in section 2.2.6.2. This time, uninduced 
and induced competent cells were transformed with 300 ng of CTAP template DNA (Nurf301 
full A/B and C isoforms) with either 50 bp or 500 bp arms by electroporation (see 2.2.6.4). 
Finally, 100 μl of the uninduced control and 100 μl of the induced sample with serial dilutions 
(1/1, 1/10 and 1/100) were plated on galK- selection M63-DOG minimal medium (see 
2.1.1.4). The plates were incubated for 2-4 days at 30°C. Twelve DOG-resistant colonies were 
analysed by Spe І restriction enzyme digestion and also by PCR to verify the presence of the 
CTAP tag with Nurf301 genes. 
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2.7.4 C-terminally TAP tagged BAC DNA amplification 
 Each of the CTAP-tagged CH321 full length NURF301, CH322 full length NURF301, 
CH321 NURF301-C variant and CH322 NURF301-C variant DNA in host SW102 was 
purified by plasmid DNA miniprep (see 2.2.3.1). The DNA constructs were then transformed 
into the amplification host E.coli strain EPI300 (Epicentre) by electroporation (see 2.2.6.4). 
Cells were plated on LB agar plates medium containing chloramphenicol (12.5 µg/ml) as a 
selective marker. Single colonies were selected from each plate, and seed cell cultures were 
performed in 3 ml of LB medium containing chloramphenicol (12.5 µg/ml) overnight at 30 ºC 
in a shaking incubator. Cells were then transferred to 200 ml of LB medium containing 
chloramphenicol (12.5 µg/ml) and incubated at 30°C until the cell culture reached an OD600 of 
0.4~0.6. The DNA was amplified by addition of copycontrol induction solution (Epicentre) to 
a 1x final concentration. The cells were incubated for two hours at 30°C in a shaking 
incubator. Finally, all CTAP-tagged NURF301 BAC DNA constructs were purified by 
Nucleobond Xtra midi Endotoxin Free kit (see 2.2.3.2). At the final step, DNA was dissolved 
in 100 µl double distilled water by gentle pipetting. The purified DNA samples were 
visualized by 0.7% agarose gel electrophoresis and quantified using a UV spectrometer 
(Ultrospec 2100 pro, Amersham). 
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Figure 2-5. Overview of the generation of CTAP tagged Nurf301 constructs by using 
BAC recombineering system and transgenic fly expressing CTAP tagged NURF301. 
CH321 and CH322 BAC plasmids delivering Nurf301 genomic DNA (E(bx)) were used as 
templates for recombination, and y
1
 M{vas-int.Dm}ZH-2A w
*
; M{3xP3-RFP.attP}ZH-86Fb 
Drosophila strain was prepared for embryo injection. 
 
2.7.5 Injection of CTAP tagged NURF301 BAC DNA constructs 
To generate CTAP-tagged NURF301 transgenic lines, the φC31 integrase system was utilized 
(Venken et al., 2006; Bischof et al., 2007). DNA was injected into embryos of the strain y
1
 
M{vas-int.Dm}ZH-2A w
*
; M{3xP3-RFP.attP}ZH-86Fb (see Table 2-8), which carries an attP 
docking site, at 86F on chromosome 3R and a construct that expresses φC31 integrase in the 
germline cells. To prepare embryos for injection, approximately 500 young flies (2-3 days) 
were transferred to an egg-laying cage and fed with yeast paste on apple agar collection plates 
overnight. The next day, embryos were collected every 20-30 minutes, hand dechorionated 
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and lined up on a glass slide coated with double-sided tape (3M). Embryos were injected with 
0.8 µg/µl purified endonuclease free BAC plasmid DNA using an Eppendorf FemtoJet 
Microinjector and Leitz Labovert FS Inverted Microscope with injection stand and needle 
holder. Injected embryos were incubated at 18°C for recovery. Larvae were collected after 2-3 
days and transferred to fresh vials with food at 25°C. Viable adults were singly mated to w
1118
 
flies of the corresponding sex, and then the progenies were examined for red-eyed transgenic 
founders (Figure 2-5). 
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2.8 Immunostaining of Drosophila embryos, polytene chromosomes, testes and ovaries 
2.8.1 Fixation and permeabilization of Drosophila embryos 
Drosophila embryos were collected on the apple agar collection plates and rinsed with water 
onto a nitex mesh sieve to remove residual yeast. Then they were then dechorionated in 5% of 
sodium hypochlorite solution (Sigma) for three minutes. The embryos were transferred to a 
1.5ml eppendorf tube containing 50% of n-heptane (Sigma) and 50% of PEM-formaldehyde 
solution (0.1 M PIPES pH 6.95, 2 mM EGTA, 1 mM MgSO4, 4% formaldehyde). Embryos 
were fixed for 25 minutes at room temperature on a rotator. The aqueous (bottom) layer was 
removed, 1 volume of 99% methanol was added, and the tube was vortexed for one minute to 
remove the vitelline membrane. The heptane/methanol phases were allowed to separate and 
the heptane (top layer), all of the interface and the methanol above the devitellinised embryos, 
were removed. Two washes were performed with 1 ml methanol and then with 1:1 dilution of 
99% methanol and PBTw (0.1% Tween 20 in PBS). Embryos were washed with 1ml PBTw 
three times for five minutes on a rotator, and single or double immunostaining was performed 
(see 2.8.4 and 2.8.5)  
 
2.8.2 Immunostaining of Drosophila polytene chromosomes 
2.8.2.1 Culturing of third instar larvae 
About fifteen female flies were allowed to lay eggs in a vial containing normal fly medium 
(see 2.1.2.1) and transferred to a new vial every two days. In order to get optimal polytene 
chromosome morphology, larvae were raised at 22°C and uncrowded culturing of larvae was 
essential. The wandering stage third instar larvae were used for all polytene chromosome 
squash techniques. 
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2.8.2.2 Conventional squash 
The third instar larvae were washed in water to remove residual culture medium. The salivary 
glands of larvae were dissected in solution 1 (PBS containing 0.1% Triton X-100 (pH 7.5)). 
Glands were transferred to a 20 µl drop of solution 2 (PBS containing 3.7% formaldehyde, 1% 
triton X-100 (pH 7.5)) on a 22 mm x 22 mm Sigmacote-treated coverslip and incubated for 
two and a half minutes. The solution was replaced with solution 3 (3.7% formaldehyde, 50% 
acetic acid). The glands were crushed into small pieces with a tungsten needle during three 
minutes of incubation. Then a poly-L-lysine-coated microscope slide was overlaid to the 
sample and inverted. The chromosomes were spread with gentle tapping on the coverslip 
followed by drawing a trace over the coverslip. The slide was put into liquid nitrogen to 
freeze and the coverslip was removed using a razor blade. The slide was stored in PBS until 
ready to perform immunostaining. 
 
2.8.2.3 Acid free squash 
Wandering third instar larvae were washed in water and used for the preparation of polytene 
chromosome squashes. The larvae were transferred to Brower’s fixation buffer (Blair, 2000) 
(0.15 M Pipes, 3 mM MgSO4, 1.5 mM EGTA, 1.5% NP40 at pH 6.9) containing 2% 
formaldehyde, and salivary glands were directly dissected in this solution. The glands were 
fixed for 2-3 minutes and transferred to PBT (PBS containing 0.1% triton X-100) for another 
2-3 minutes. They were moved into 50% glycerol and soaked for five minutes. The glands 
were transferred to 13 µl 50% glycerol on a 22 mm x 22 mm Sigmacote-treated coverslip and 
broken down to small pieces using a tungsten needle. A poly-L-lysine-coated microscope 
slide was gently placed onto the coverslip. Then the microscope slide was inverted, lightly 
tapped on the coverslip followed by drawing a trace over the coverslip and squashed to spread 
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the chromosomes. The slide was directly submerged in liquid nitrogen for a few seconds to 
freeze, and the coverslip was removed using a razor blade. The frozen slide was quickly 
submerged in PBS until needed for immunostaining.   
 
2.8.3 Drosophila testis/ovary immunostaining 
Young healthy two to three day old adult flies were prepared to isolate male testes or female 
ovaries. They were dissected in 0.7% NaCl, and a small number of testes or ovaries were 
pooled in one tube. The sample was fixed in PBT containing 4% formaldehyde for 30 minutes 
at room temperature on a rotator. The fixed sample was washed with PBT three times for 10 
minutes on a rotator. To increase the antibody penetration of tissue, the tissues were treated 
with higher concentration of detergent (0.3% Triton X-100 in PBS) for one hour at room 
temperature on rotator. Primary antibody binding reaction was performed in blocking solution 
(PBT containing 10% FBS) at 4°C overnight on a rotator. The sample was washed with PBT 
three times for 10 minutes. Secondary antibody binding was conducted using Cy3 conjugated 
donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories) at a 1:400 dilution in PBT 
for two hours at room temperature on a rotator in the dark. The sample was washed with PBT 
three times for 10 minutes and mounted in Vectashield mounting medium with DAPI (Vector 
Laboratories). Microscope slides were visualized by confocal microscopy (Zeiss Axiovert 
100M Confocal Laser Scanning Microscope (LSM), Zeiss). 
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Table 2-11. Antibodies used for either single or double immunostaining. 
Primary antibodies used 
Antibody Host Source Dilution 
Anti- Phospho-Histone H3 (Thr3), ChIPAb+ Rabbit Millipore 1:1500 
Anti-Histone H3 (phospho T3, tri metyl K4) Rabbit Abcam 1:500 
Anti-Histone H3 (tri methyl K4), ChIP Grade Rabbit Abcam 1:2000 
Anti- Acetyl-Histone H3 (Lys9) Rabbit 
Prof. Bryan Turner 
(University of 
Birmingham, UK) 
1:250 
Anti- Acetyl-Histone H3 (Lys9), ChIPAb+ Rabbit Millipore 1:250 
Anti-Histone H3 (acetyl K9, phospho S10), 
ChIP Grade 
Rabbit Abcam 1:250 
Anti- Phospho-Histone H3 (Ser10), ChIPAb+ Rabbit Millipore 1:1000 
Anti-Histone H3 (tri methyl K23) Rabbit 
Dr. Sean Taverna  
(Johns Hopkins School 
of Medicine, USA) 
1:100 
Anti-NURF301 (Kwon5) Rabbit 
Dr. So Yeon Kwon 
(University of 
Birmingham, UK) 
1:25 
Anti-Protein G [HRP] Rabbit Novus Biologicals 1:500 
Secondary antibodies used 
Antibody Host Source Dilution 
Anti-rabbit IgG, Cy3-conjugated Donkey 
Jackson 
ImmunoResearch 
Laboratories 
1:500 
AffiniPure Fab Fragment Anti-Rabbit IgG, 
Cy3-conjugated 
Goat 
Jackson 
ImmunoResearch 
Laboratories 
1:400 
AffiniPure Fab Fragment Anti-Rabbit IgG Goat 
Jackson 
ImmunoResearch 
Laboratories 
1:20 
AffiniPure Fab Fragment Anti-Rabbit IgG, 
FITC-conjugated 
Goat 
Jackson 
ImmunoResearch 
Laboratories 
1:400 
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2.8.4 Single immunofluorescence staining  
Samples/slides were incubated with the primary antibody (see Table 2-11) in PBTw 
containing 10% BSA at 4°C overnight. Samples then were washed with PBTw four times for 
5-10 minutes at room temperature. Secondary antibody incubation was performed using Cy3 
conjugated donkey anti-rabbit IgG (see Table 2-11) in PBTw for three hours at room 
temperature in the dark. The samples were washed with PBTw four times for 5-10 minutes at 
room temperature. The samples were mounted in Vectashield mounting medium with DAPI. 
Confocal microscopy was performed using a Zeiss Axiovert 100M Confocal Laser Scanning 
Microscope (LSM).    
 
2.8.5 Double immunofluorescence staining 
This protocol was used for immunostaining using two primary antibodies from the same host 
species. All the primary and secondary antibodies with dilutions used in this study are 
described in Table 2-11. Stored samples/slides were incubated with the first primary antibody 
(host rabbit) in PBTw containing 10% BSA overnight at 4°C. The samples were washed with 
PBTw three times for 10 minutes. Then the first secondary antibody reaction was conducted 
using Cy3-conjugated AffiniPure Fab Fragment Goat Anti-Rabbit IgG in PBTw for two hours 
at room temperature in the dark. The samples were washed with PBTw three times for 10 
minutes then fixed in 1% formaldehyde for 10 minutes in the dark. Samples were washed 
three times with PBTw for 10 minutes in the dark. Samples were incubated with unconjugated 
AffiniPure Fab Fragment Goat Anti-Rabbit IgG in PBTw for two hours at room temperature 
in the dark. The first rabbit IgG is blocked in this step, so that the second secondary antibody 
would not be able to bind to it. The samples were washed with PBTw three times for 10 
minutes, and the second primary antibody (host rabbit) reaction was performed in PBTw 
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containing 10% BSA overnight at 4°C. The samples were washed with PBTw three times for 
10 minutes on the following day. The second secondary antibody reaction was performed 
using FITC-conjugated AffiniPure Fab Fragment Goat Anti-Rabbit IgG in PBTw for two 
hours at room temperature in the dark. Finally, the samples were washed with PBTw three 
times for 10 minutes, mounted in Vectashield mounting medium with DAPI and examined by 
confocal microscopy. 
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2.9 Chromatin immunoprecipitation (ChIP) sequencing 
2.9.1 Drosophila primary blood cell preparation 
Fresh primary blood cells were collected manually by ripping 50 third instar larvae in a tube 
containing HyQ-CCM3 insect medium (Thermo Fisher Scientific) and protease inhibitors 
(Roche). The cells were fixed with 1% formaldehyde solution in PBS for 15 minutes at 25°C 
and pelleted at 410 g for five minutes in a benchtop centrifuge. The supernatant was removed. 
Then the cells were washed three times with cold PBS containing protease inhibitors and spun 
down. After the final wash, all buffer was removed, and the tube was kept at -80°C until 
required. Fifteen to twenty tubes were prepared in this way for each male and female sample.  
 
2.9.2 Micrococcal nuclease (MNase) digestion 
The stored blood samples were thawed on ice and transferred to one tube. The cells were 
resuspended with buffer A (15 mM tris-Cl pH 7.4, 15 mM NaCl, 60 mM KCl, 0.34 M sucrose 
mixed with freshly made 1 mM DTT, 25 mM sodium metabisulfite, 0.5 mM spermidine, 0.15 
mM spermine). Then the cells were homogenized with pellet pestle. CaCl2 and MNase 
(Worthington) were added for final concentrations of 1 mM and 100 unit/µl respectively, and 
the sample was incubated for 12 minutes at 16°C in water bath. As soon as the reaction was 
completed, an equal volume of STOP buffer (0.1 M tris-Cl at pH 8.5, 0.1 M NaCl, 50 mM 
EDTA, 1% SDS) was added to stop the reaction. The sample was centrifuged at 17,400 g for 
three minutes at 4°C. Subsequently, the supernatant was transferred to a new tube and diluted 
with ChIP dilution buffer (0.01% SDS, 1.1% triton X-100, 1.2 mM EDTA, 16.7 mM tris-Cl 
pH 8.1, 167 mM NaCl). This process produced mononucleosomal DNA fragments about 146 
base pairs in size. 
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2.9.3 Chromatin immunoprecipitation (ChIP) 
Antibody coated beads were prepared the day before ChIP. 25 µl of the Dynabeads®  M-280 
Sheep anti-Rabbit IgG antibody (Invitrogen) was prepared for each sample in a 1.5 ml LoBind 
tube (Eppendorf). The beads were washed five times with freshly made PBS containing 5 
mg/ml BSA and protease inhibitors. After the final wash, the beads were resuspended with the 
same buffer, and 4 µg rabbit anti-protein G antibody (Novus Biologicals) was added per 25 µl 
of beads. The antibody and beads were incubated overnight at 4°C on a rotator. Antibody 
coated beads were then washed five times with PBS containing 5 mg/ml BSA and protease 
inhibitors in a magnetic rack. Pre-cleared beads, that lack antibody, were also simultaneously 
prepared as above. The MNase digested chromatin prepared as described above (see 2.9.2) 
was incubated with pre-cleared beads for 15 minutes, and then the supernatant was incubated 
with antibody coated beads for two and a half hours at room temperature on a rotator. The 
beads were washed once with Low salt buffer (0.1% SDS, 1% triton X-100, 2 mM EDTA, 20 
mM tris-Cl pH 8.1, 150 mM NaCl), once with High salt buffer (0.1% SDS, 1% triton X-100, 
2 mM EDTA, 20 mM tris-Cl pH 8.1, 500 mM NaCl), once with LiCl immune complex wash 
buffer (0.25 M LiCl, 1% IGEPAL CA-630, 1% deoxycholic acid, 1 mM EDTA, 10 mM tris-
Cl pH 8.1) and twice with TE buffer for five minutes each at room temperature. The 
precipitated DNA was eluted by incubation of the beads with Elution buffer (1% SDS, 0.1 M 
NaHCO3) for 15 minutes at room temperature on a rotator. The residual proteins in the sample 
were removed by treating with proteinase K (Invitrogen) and NaCl for final concentrations of 
100 µg per sample and 80 mM respectively, and the sample was incubated overnight at 65°C 
in a heat block. The immunoprecipitated DNA was purified using a volume of Agencourt 
AMPure XP beads (Beckman Coulter) equal to 1.8x the volume of the sample following the 
supplier’s protocol. 
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2.9.4 End repair and P1 adaptor/barcode ligation 
Our ChIP library DNA preparation was based on the barcoded fragment library preparation 
method of the SOLiD 4 sequencing system (Applied Biosystems). The ChIP DNA fragments 
were end repaired using SOLiD™ Fragment Library Construction Kit (Life Technologies) 
following the supplier's protocol. For the reaction, purified ChIP DNA fragments, 1x End-
polishing buffer, 0.4 mM dNTP mix, 5 units End polishing enzyme 1 and 40 units of End 
polishing enzyme 2 were used in 50 µl reaction in a 1.5 ml LoBind tube, and the sample was 
incubated for 30 minutes at 25°C. After the reaction, the end repaired DNA was purified using 
Agencourt AMPure XP beads equal to 1.8x the volume of the sample according to the 
supplier’s protocol. The purified and end-repaired DNA was then ligated with multiplex P1 
and P2 adaptors making a reaction with end-repaired DNA, 25 pmol of Multiplex library P1 
adaptor, 0.5 µM of Barcode, 1x T4 ligase buffer and 25 units of T4 ligase in 100 µl of ligation 
reaction. The sample was incubated for 10 minutes at 25°C, and then another DNA 
purification was performed using Agencourt AMPure XP beads equal to 1.3x the volume of 
the sample following the supplier's protocol. 
 
2.9.5 Sequencing library preparation with barcodes 
The barcoded and purified library DNA was then nick-translated and amplified by PCR 
reaction using 1 µM of Multiplex library PCR primer-1, 1 µM of Multiplex library PCR 
primer-2, barcoded library DNA and 200 µl of Platinum PCR amplification mix in a total 
reaction volume of 250 µl. The reaction mix was split into two PCR tubes, and the PCR was 
performed with the thermocycler conditions as suggested in the supplier's protocol (see Table 
2-12). After PCR amplification, the amplified barcoded library DNA was purified twice using 
Agencourt AMPure XP beads and visualized quickly using a flash gel (Lonza) in a flash gel 
dock (Lonza).  
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Table 2-12. PCR conditions for nick-translation and  
amplification of the barcoded library DNA 
Step Temperature Time 
Nick translation 72°C 20 mins 
Denaturation 95°C 5 mins 
15-17 cycles 
95°C 15 secs 
62°C 15 secs 
70°C 1 min 
Final extension 70°C 5 mins 
Hold 4°C ∞ 
 
2.9.6 SOLiD sequencing 
Clonal amplification of library fragments on the sequencing beads surface was done by 
emulsion PCR (ePCR) according to the manufacturer’s instructions (Applied Biosystems). 
500 pM of double stranded library DNA was added to 5.6 ml PCR mix (1x PCR buffer, 3.5 
mM of each deoxynucleotide, 25 mM MgCl2, 40 nM ePCR primer 1, 3 µM ePCR primer 2, 
3000 U AmpliTaq Gold DNA Polymerase, 1.6 billion SOLiD sequencing P1 DNA beads). 
The PCR mix was added to SOLiD ePCR Tube containing 9 ml of oil phase while swirling on 
ULTRA-TURRAX Tube Drive. The emulsion was then transferred to a 96-well PCR plate 
and run for 30 cycles on the 96-Well Thermal cycler. The emulsion was broken with 2-butanol 
and washed with 1x Bead wash buffer. Beads were enriched in 60% glycerol for template 
positive beads selection, and 3’ end modified to apply onto sequencing slides. Work Flow 
Analysis (WFA) was performed before the actual full sequencing run to confirm the beads 
quality. Finally, a full sequencing run was conducted using cycled ligation sequencing on a 
SOLiD 4 general analyzer.      
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CHAPTER 3. IDENTIFICATION OF THE MODIFIED HISTONE 
BINDING SPECIFICITIES OF THE NURF301 PHD DOMAINS AND 
BROMODOMAIN in vitro 
3.1 Introduction 
Previous studies showed that Drosophila NURF301 can bind to the histone H3K4me3 and 
histone H4K16ac post-translational modifications (Wysocka et al., 2006, Kwon et al., 2009). 
Such binding enables functional cooperation between two of the principal mechanisms of 
encoding epigenetic information in the genome, histone post-translational modifications and 
ATP-dependent chromatin remodelling. In this way histone modifications could provide a 
mark to recruit the NURF ATP dependent chromatin remodelling enzyme to specific sites in 
the genome. Significantly, Drosophila NURF301 contains three PHD domains and a 
bromodomain, all of which have potential to bind additional modified histone marks. 
 
Previous research had shown that Drosophila NURF301 and human BPTF bind to the 
H3K4me3 post-translational modification via the PHD2 domain. NMR and crystal structure 
analysis of the interaction between the BPTF PHD2 domain and H3K4me3 defined a cage 
composed of four aromatic amino acids (Y10, Y17, Y23 and W32) that interacts with 
trimethylated Lys 4 residues. (Li et al., 2006), but which in principle could bind to other 
trimethylated lysine residues. In the initial reports, the binding specificity of the PHD2 
domain to a limited number of trimethylated lysine containing peptides was analysed and 
showed that the PHD2 interaction was specific to H3K4me3. However, the full-binding 
specificity had not been determined. We first proposed to characterise the full modified 
histone-binding specificity of the PHD2 domain to determine if there were additional histone 
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post-translational modifications that could recruit NURF.  
 
In addition, NURF contains three other domains that have the potential to bind to modified 
histone residues. These include a single bromodomain and two additional PHD fingers. The 
bromodomain is an evolutionally conserved motif that has been shown to interact with 
acetylated lysine residues in N-terminal tails of histones H3 and H4 in vivo and in vitro 
(Ornaghi et al. 1999; Jacobson et al. 2000; Ladunder et al. 2003). Previously in our lab, it was 
also shown that purified NURF301 bromodomain binds to histone H4 peptide acetylated at 
Lys 16 (Kwon et al. 2009). However, as with the PHD2 domain the full-binding specifity of 
this domain had not be exhaustively characterised. It was still possible that the bromodomain 
could interact with other modifications on histone tails. 
 
Drosophila NURF301 contains an additional PHD domain at the C-terminus of the protein 
that has been designated PHD1 (Wysocka et al., 2006). The PHD1 domain is not present in 
the annotated BPTF protein isoforms, but is only identified in annotated Drosophila 
NURF301 protein isoforms. The PHD1 domain showed amino acid sequence similarity with 
PHD2 and also contains the highly conserved aromatic amino acids (Y10, Y17, Y23 and 
W32), which have been proposed to form a cage that potentially binds to metylated lysine 
residues as described in figure 1-8. However, the modified histone binding specificity of the 
PHD1 domain has not been determined. 
 
Finally, both Drosophila NURF301 and human BPTF contain an additional PHD domain at 
the N-terminal region of the protein, designated PHD (Wysocka et al., 2006). Unlike the 
PHD1 and PHD2 domains, this PHD domain does not contain the aromatic cage required for 
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binding to trimethylated histone residues. Rather the sequence of the PHD domain resembles 
more closely that of the PHD domain of BHC80 which has been shown to bind to unmodified 
histone tails (Lan et al. 2007). 
 
To elucidate the complete modified histone binding specificities of these domains of 
NURF301, we separately purified the PHD, PHD1, PHD2 and Bromodomain of NURF301 as 
GST fusion proteins. These domains were then used to screen peptide arrays that contained 
spots decorated with the principal reported histone modifications. These peptide arrays deliver 
histone modifications both singly and in conjunction with other flanking histone 
modifications. By using peptide arrays containing combinations of histone tail modifications, 
we were able to investigate the effect of combinations of histone modifications on the binding 
ability of the domain. 
 
An emerging theme in research on the binding of histone post-translational modifications has 
been the concept that combinations of histone modifications can provide “rheostats” that can 
modify binding to a core histone post-translational modification. In the case of the PHD2-
H3K4me3 interaction for example, flanking modification of H3K4me3-modified histone tails 
could mask PHD2 binding, and act as a rheostat to control NURF recruitment without the loss 
of the H3K4me3 mark. Thus, four states could be envisaged, in which i) the unmodified H3 
tail is not bound by PHD2 (off), ii) the H3K4me3 modified tail is bound by PHD2 (on), iii) 
further flanking modification of the H3K4me3 tail blocks binding (off) or iv) enhances 
binding. 
 
Binding-specificities determined using peptide arrays were then confirmed by peptide pull 
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down, peptide competition pull down and Biacore assays. The goal of this work was to define 
specific modifications and combinations of modifications that would allow the NURF 
complex to be recruited to sites of action in the genome. 
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3.2 Results 
3.2.1 Expression and purification of GST fusions with NURF301 domains  
All GST fusion proteins were expressed at high levels in the E.coli BL21 strain and purified 
using GST-sepharose columns. As shown in the figure 3-1, purified proteins migrated at the 
predicted molecular masses of the GST fusion: bromodomain (37 kDa), PHD (33 kDa), PHD1 
(31 kDa) and PHD2 (31 kDa). Eluted proteins were of high yield and high purity with one 
single band or minimal background protein bands. In the case of the PHD domains, additional 
bands of approximated 26 kDa were detected below the expected protein bands. These 
corresponded to the size of GST protein alone and probably came from either protease 
cleavage of the link between the PHD domain and GST during lysis or ribosome stalling at 
this location during protein synthesis. Nevertheless, the purified GST domain protein does not 
pose a problem to the peptide array screening as we have shown that GST domain alone does 
not react with the peptide arrays (Figure 3-3). Of all the domains purified, the GST-
Bromodomain fusion exhibited the best yield and purity. After dialysis to remove the 
glutathione from the samples, the purified GST fusion domain proteins were applied to 
modified histone peptide library arrays.  
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Figure 3-1. SDS PAGE gel image of GST column elution fractions of GST fusion 
proteins. The predicted molecular size of GST fusion domains are indicated in red arrows: 
Bromodomain (37 kDa), PHD (33 kDa), PHD1 (31 kDa) and PHD2 (31 kDa). The elution 
fractions are indicated (E1, E2, E3, E4), and additional bands detected below the expected 
GST fusion domains are GST proteins (26 kDa). 
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3.2.2 Characterisation of the histone modification targets of the PHD domains and 
Bromodomain by modified histone peptide library array analysis 
Modified histone peptide array analysis was performed using the purified GST fusion domain 
proteins. In a first series of experiments, we used custom-generated modified histone peptide 
arrays produced by a University of Birmingham spin-off company, Alta Bioscience, as there 
were no existing commercially available arrays available at the start of this work. Two series 
of arrays were used: H3 peptide library arrays and histone H3, H4 N-terminal peptide library 
arrays. During the course of this work, commercially available histone peptide arrays were 
generated by Active Motif (Modified histone H3, H4, H2A and H2B peptide array), and were 
also used. The binding of GST-domain fusion proteins to peptide spots was visualized in two 
different ways, either using anti-GST HRP-conjugated antibody followed by ECL substrate 
reaction and ECL film exposure, or using anti-GST HRP-conjugated antibody as a primary 
antibody, followed by IRDye 800CW-conjugated anti-HRP antibody as a secondary antibody 
and visualized by 800 nm channel scanning using an Odyssey scanner (Figure 3-2). 
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Figure 3-2. Overview of histone peptide library array assays. Purified GST conjugated 
fusion domain proteins (PHD, PHD1, PHD2 and Bromodomain) and the three different 
histone peptide arrays were used in these assays, (A) Modified histone H3 peptide array (Alta 
Bioscience), (B) Modified histone H3, H4 N-terminal peptide array (Alta Bioscience), (C) 
Modified histone H3, H4, H2A and H2B peptide array (Active Motif). GST fusion domain 
protein bound peptide spots were visualized as described above. 
 
3.2.2.1 GST fusion PHD2 domain and bromodomain binding to the histone H3 peptide 
library array 
We first tested the binding of GST-PHD2 domain protein to the histone H3 peptide library 
array as described above (Figure 3-2 A). GST-PHD2 was used as we already know that PHD2 
can bind at least to the H3K4me3 mark. This provides a positive control to validate the array 
screening protocol. Both undialized purified GST-PHD2 and dialysed GST-PHD2 proteins 
were applied to arrays at a concentration of 0.1 mg/ml in the binding reaction to determine 
whether reduced glutathione affected the interaction of PHD2 domain with histone 
modifications. Purified GST domain protein alone was also used as a negative control. We 
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expected to see signals at peptide spots containing the H3K4me3 modification in both panels 
of the array, as the array is duplicated on each slide (see Appendix 1). However, we were 
unable to detect binding to any spots on the arrays (Figure 3-3). Moreover, the array 
background was increased when reduced glutathione was present, so all fusion proteins were 
dialysed before peptide binding reaction with these peptide library arrays. To validate that 
modified histone peptides were present on the arrays, we washed the slides to remove proteins 
and performed control immunostainings using an antibody that recognizes histone H3 
phosphorylated at Serine 10 (anti-H3S10p antibody). As shown in figure 3-4, strong signals 
corresponding to H3S10p-containing peptide spots on the modified histone H3 peptide library 
array slides (see Appendix 2) were detected.  
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Figure 3-3. Modified histone H3 peptide library array assays of GST and GST-PHD2 
domain proteins. The histone H3 peptide array grid is shown on the top. Binding of GST 
(control), GST-PHD2 (purified neat) and GST-PHD2 (dialysed) to this array was tested 
respectively and did not show any binding. 
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Figure 3-4. Modified histone H3 peptide library array validation using anti-H3S10p 
antibody. The array slides from figure 3-3 were immunostained with anti-H3S10p antibody 
followed by HRP conjugated anti-rabbit IgG secondary antibody staining to validate that 
modified histone peptides were present on the peptide arrays. 
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Figure 3-5. Modified histone H3 peptide library array assays of GST-Bromodomain and 
GST-PHD2 domain proteins using higher protein concentration. No binding was detected 
with anti-GST HRP-conjugated antibody. 
 
To exclude that the concentration of GST-PHD2 protein used in the first experiments was not 
high enough to stabilize and detect GST-PHD2 binding, we repeated the hybridizations but 
increased the protein concentration to 0.2 mg/ml in the binding reaction. Assays were 
performed with dialyzed GST-Bromo and GST-PHD2 with new modified histone H3 peptide 
library array slides. However, no binding was detected by either GST-Bromo or GST-PHD2 
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peptide array assays (Figure 3-5). We suspected that although modified histone peptides are 
present on the arrays, they were not accessible to be bound by GST-PHD2 and GST-
Bromodomain. Inspection of the array design (Appendix 2) revealed that peptides on the slide 
were immobilized to the slide surface via N-terminal biotin modifications. We hypothesized 
that the histone modifications on the peptides may not be recognized by our domain proteins 
because of steric hindrance, with the modifications too close to the slide surface. Therefore, 
we generated new histone peptide library arrays in which the peptides were bound to the slide 
surface via C-terminal biotin modifications, leaving the N-terminal sequences freely exposed. 
 
3.2.2.2 Different interaction profiles of NURF301 domains with histone H3 and H4 
modifications on histone H3, H4 N-terminal peptide library arrays 
As described in Appendix 3, modified histone H3 peptides and H4 peptides were arrayed via 
the C-terminus (Modified Histone H3, H4 N-terminal peptide library array, Figure 3-2 B). 
These slides also contained modified histone H4 peptides allowing us to analyze the binding 
of domains to modifications on the histone H4 N-terminal tail. Agilent slide gaskets, 
chambers and a rotating hybridization chamber were also used for these binding reactions to 
maximize the protein concentration and hybridization efficiency. First modified histone 
binding assay was performed using purified GST-PHD2 protein. Significant binding of the 
PHD2 domain protein to H3K4me3 were observed. However, the slides contained significant 
background (data not shown). To improve signal to noise ratios, we asked the array supplier to 
generate arrays with larger peptide spots that would have greater potential for binding of 
domain fusion proteins. We also improved wash conditions to minimize backgrounds by using 
a slide stand and a wash bucket with 500-600ml of wash buffer stirred using a magnetic stirrer 
bar.  
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PHD2 domain peptide array binding assay was conducted again using these optimized 
conditions and with a higher concentration of protein sample in binding reaction (1-2 mg/ml). 
As expected, the PHD2 domain showed strong binding to peptide spots containing H3K4me3. 
No binding was detected to peptides that contained methylation of other residues or the mono- 
and di-methylation states of H3K4 indicating that PHD2 domain specifically binds H3K4me3 
(Figure 3-6). Interestingly, however, the binding of PHD2 domain to H3K4me3 was 
prevented by additional modifications at the Thr 3 position. Thus the PHD2 domain failed to 
bind a peptide that was both phosphorylated at H3 Thr 3 and trimethylated at H3 Lys 4 
(H3T3p/K4me3). In contrast, methylation at Arg 2 and acetylation or methylation of Lys 9 did 
not prevent PHD2 binding to H3K4me3. This indicated that PHD2 binding to H3K4me3 was 
hindered by the phosphorylation at Thr 3, but not by other flanking modifications such as Arg 
2 di-methylation or Lys 9 trimethylation/acetylation. This data suggested that phosphorylated 
histone H3 threonine 3 could act as a rheostat function to control PHD2 binding to H3K4me3. 
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Figure 3-6. Binding of PHD2-GST fusion protein to histone H3, H4 N-terminal peptide 
library arrays. H3, H4 N-terminal peptide library arrays containing N-terminal free peptides 
were probed using PHD2-GST fusion proteins and showed specific binding to H3K4me3. 
PHD2-GST fusion protein bound spots were detected using anti-GST HRP-conjugated 
antibody. 
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Figure 3-7. Binding of PHD1-GST fusion protein to histone H3, H4 N-terminal peptide 
library arrays. H3, H4 N-terminal peptide library arrays were probed using PHD1-GST 
fusion protein and showed binding to H3K23me3. PHD1-GST fusion protein bound spots 
were detected using anti-GST HRP-conjugated antibody. 
 
We next examined the binding specificity of the PHD1 domain. Like the PHD2 domain, the 
PHD1 domain contains the core aromatic cage structure including the key residue Trp 32 
which is critical for methylated lysine recognition (Li et al. 2006). Based on this, we 
anticipated that the PHD1 domain would also be able to bind to tri-methylated lysine residue. 
Indeed, the PHD1 domain specifically interacted with peptide trimethylated at histone H3 Lys 
23 (H3K23me3) but did not recognize the mono- or di-methyl states of H3K23 (Figure 3-7). 
Binding to H3K23me3 was not influenced by acetylation at Lys 18 but was prevented by 
asymmetric dimethylation at Arg 26. As observed during our PHD2 domain analysis, these 
marks represent additional di-modification states that can act as a rheostat regulating 
recruitment of the PHD1 domain to H3K23me3.  
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Figure 3-8. Schematic of binding of PHD-GST fusion proteins to histone H3, H4 N-
terminal peptide library array. No clear modified histone binding specificity was observed.  
 
Unlike PHD1 and PHD2 domains, the NURF301 PHD domain does not contain the aromatic 
cage required for binding to trimethylated lysine residues. Rather the sequence resembles 
more closely that of the BHC80 PHD domain which binds to unmodified histone tails (Lan et 
al. 2007). To identify residues to which the PHD domain could bind or that could potentially 
inhibit the PHD domain binding, the same peptide array assay was carried out with the GST-
PHD domain. As expected, we did not observe specific binding of PHD domain. However 
interestingly, the PHD domain appeared to interact with the histone H3 and H4 N-terminal 
tails generally. As shown in the figure 3-8, a broad range of peptide spots were bound by the 
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PHD domain. Although no clear modification binding specificity was observed, there was a 
clear sequence preference of the PHD domain binding as the binding was only detected to 
peptides containing the N-terminal tails of histone H3(1-21) and H4(1-21). 
 
3.2.2.3 Identification of the modified histone-binding specificities of NURF301 PHD 
domains and Bromodomain using MODified histone H3, H4, H2A and H2B peptide 
arrays 
Histone peptide array analysis using arrays from Alta Bioscience identified some potential 
histone post translational modifications that could be recognized by the NURF301 PHD 
domains. However, the peptide arrays showed a high level of background and variability 
between arrays. It remained possible that weak binding would not be detected using these 
arrays and that some potential recruiting modifications could be overlooked. To clarify this, 
we used commercially available histone peptide arrays from another supplier (MODified 
histone H3, H4, H2A and H2B peptide array, Active Motif) for binding analysis with the PHD 
domains and bromodomain (Figure 3-2 C). These peptide arrays contain 59 histone 
modifications, including acetylation, methylation, phosphorylation and citrullination 
modifications on the H2A, H2B, H3 and H4 N-terminal tails. The arrays deliver 384 different 
combinations of those markers from single to quadruple modifications on the peptide 
(Appendix 4. and 5.) and are duplicated on the slide. Moreover, peptides are bound to the 
slide surface via C-terminal biotin modifications allowing domain fusion proteins to access 
more easily free N-terminal sequences. The existence of proprietary software also allowed us 
to analyse signal intensities from peptide spots and binding specificities to be calculated 
automatically. 
The new arrays displayed significantly better binding efficiency and a lower background level. 
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Using these arrays, the PHD2 domain was screened again with 1-2 mg/ml of protein sample 
in the binding reaction. As expected, the PHD2 domain showed significant binding to peptide 
spots containing H3K4me3. No binding was detected to peptides that contained mono- and di-
methylation states of H3 Lys 4 indicating that PHD2 specifically binds to tri-methylation of 
H3 Lys 4 (Figure 3-9 A and B). No significant binding was observed to any other singly 
methylated or acetylated histone marks (Figure 3-9 B and C). Moreover, as we observed from 
our previous peptide arrays, binding of PHD2 to H3K4me3 was prevented by additional 
modification at the Thr 3 position (H3T3p). Thus the PHD2 domain failed to bind to the 
peptides containing phosphorylated H3T3 and trimethylated H3K4 (H3T3pK4me3). 
Dimethylation of Arg 2 (H3R2me2s, H3R2me2a) also showed a minor inhibitory effect on 
PHD2 binding to H3K4me3. Relative binding intensity analysis revealed that compared to 
H3K4me3 alone, PHD2 binding was decreased to 12% when Thr 3 was also phosphorylated. 
Histone H3 Arg 2 dimethylation (H3R2me2s, H3R2me2a) also decreased the binding to 30% 
and 60% (Figure 3-9 D). Therefore, our data suggest that PHD2 domain has strict binding 
specificity for H3K4me3, but this binding can be inhibited by phosphorylation of Thr 3. 
 
Interestingly, the new peptide array data also showed that flanking trimethylation or 
acetylation of the histone H3 Lys 9 significantly increased the binding of the PHD2 domain to 
H3K4me3. Although the PHD2 domain did not bind to H3K9me3 or H3K9ac alone, these 
modifications increased binding when combined with H3K4me3. Compared with the binding 
signal intensity of H3K4me3 alone, peptides combining H3K4me3 with methylations or 
acetylation of H3K9 showed 300-400 % stronger binding (Figure 3-9 E). We speculate that 
methylation or acetylation at H3 Lys 9 can increase the binding capacity of PHD2 domain to 
H3K4me3. In combination, these results identified flanking histone modifications that could 
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inhibit or enhance the binding of NURF301 PHD2 domain to H3K4me3 and provide possible 
epigenetic rheostats that could control NURF binding to chromatin.  
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Figure 3-9. Binding of PHD2-GST fusion protein to MODified histone H3, H4, H2A and 
H2B peptide arrays. (A) Modified histone peptide arrays containing different modification 
combinations were probed with PHD2-GST fusion protein. PHD2-GST domain bound spots 
were detected using anti-GST HRP-conjugated primary antibody and IRDye 800CW-
conjugated rabbit anti-HRP secondary antibody. (B) The domain bound peptide spot signal 
intensities were analysed by using the Array Analyse software program (Active Motif). The 
top 10 modifications often detected from the domain bound peptides are listed on the graph. 
The PHD2 binding specificity factor list shows that PHD2 binds most specifically to 
H3K4me3 (yellow circle). H3K9me3 (green circle) or H3K9ac (blue circle) modifications 
along with H3 K4me3 also appeared to be weaker binding sites. (C) Relative binding intensity 
of singly modified histone H3 peptides in comparison to unmodified H3 peptide. (D) Relative 
binding intensity analysis showed that H3T3p (red circle), H3R2me2s and H3R2me2a marks 
inhibit PHD2 binding to H3K4me3. (E) H3K9me1, H3K9me2, H3K9me3 and H3K9ac marks 
enhance binding of PHD2 to H3K4me3. (D, E) The PHD2 binding to these combinatorial 
marks was calculated relative to the binding to the singly modified H3K4me3 peptide. 
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We next examined the binding specificity of the PHD1 domain to the modified histone 
peptide arrays. Like the PHD2 domain, the PHD1 domain also contains the core aromatic 
cage structure including the key Trp 32 residue that is critical for binding to trimethylated 
histone tails (Li et al. 2006). We observed that PHD1 was able to bind trimethylated histone 
tails but also to acetylated histone tails. The PHD1 domain bound modifications were distinct 
from our previous PHD1 domain peptide array data (Figure 3-7). It is important to note that 
the H3K23me3 mark is not found on these arrays and as such it was not possible to confirm 
our previous PHD1 domain binding data. Thus, array analysis showed that the PHD1 domain 
mainly interacted with histone H3 acetylated H3K36 (H3K36ac) and also independently 
bound to di- and tri-methylated Lys 36 (H3K36me2 and H3K36me3) (Figure 3-10 A and B). 
The binding of the PHD1 domain to H3K36ac was two times stronger than that of unmodified 
H3(26-45) peptide, followed by H3K36me2 and H3K36me3 as 1.75 times and 1.25 times 
stronger respectively (Figure 3-10 C). By comparison binding of the PHD2 domain to 
H3K4me3 peptide was 8 times stronger than the unmodified reference peptide.  
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Figure 3-10. Binding of PHD1-GST fusion protein to MODified histone H3, H4, H2A 
and H2B peptide arrays. (A) Peptide arrays were probed with PHD1-GST fusion proteins 
and protein bound spots were detected as described previously. (B) PHD1 binding specificity 
factor analysis shows that the PHD1 domain potentially binds to H3K36ac (blue circle), 
followed by H3K36me2 (yellow circle) and H3K36me3 (green circle). (C) Relative binding 
intensity analysis shows that of peptides present on the array, H3K36ac is the preferred 
binding site relative to the unmodified H3 (26-45) peptide. 
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To identify residues that the PHD domain could potentially bind, we performed peptide array 
binding analysis with the PHD-GST fusion protein. While we did not observe highly specific 
binding of PHD domain, some binding was detected to H3K36me2, H3K36me3 and 
H3K36ac which is similar to PHD1 domain binding specificity. In addition, the PHD domain 
also interacted with histone H4 N-terminal sequences that contained acetylated H4K16 
residue (Figure 3-11 A and B). Though PHD domain does not have strong binding specificity, 
it still appears to be some sequence preference of histone H4 N-terminal free sequences, as 
PHD domain binding was not observed to peptide spots having modifications beyond H4K20 
peptide sequences. 
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Figure 3-11. Binding of PHD-GST fusion protein to MODified histone H3, H4, H2A and 
H2B peptide arrays. (A) Peptide arrays were probed with PHD-GST fusion proteins and 
protein bound spots were detected as described above. (B) PHD binding specificity factor list 
shows that PHD domain binds to H3K36ac (green circle), H3K36me2 (red circle), 
H3K36me3 (yellow circle) and H4K16ac (blue circle), but more likely binds generally to 
histone H4 N-terminal free sequences. (C) ) Relative binding intensity of modified histone H3 
peptides in comparison to unmodified H3 peptide. 
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Finally, to investigate the interaction of the bromodomain with modified histones, MODified 
histone H3, H4, H2A and H2B peptide arrays were incubated with purified GST-
bromodomain protein. The array analysis showed that bromodomian binds to the acetylated 
H4K16 as expected, but other singly acetylated lysine residues were also detected to bind 
including H4K5ac, H4K8ac and H4K12ac (Figure 3-12 A and B), H4K12ac actually was 
shown as more specific binding site (Figure 3-12 C). However, interestingly, our peptide array 
and relative binding analysis data indicated enhanced binding of the bromodomain to di-, tri- 
or tetra- acetylation combinations of those modifications (Figure 3-12 D). Among peptides 
that bound, tetra-acetylated at H4K5, K8, K12 and K16 (H4K5, 8, 12, 16ac) showed the 
strongest binding and appeared to be the most significant binding site of the NURF301 
bromodomain. This data was consistent with a recent study showing that bromodomain 
binding pocket is able to bind to two acetylated lysines (Filippakopoulos et al. 2012) raising 
the possibility that the binding strength of NURF301 bromodomain was also increased by 
multiple acetylations on histone H4 N-terminal tail.  
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Figure 3-12. Binding of Bromo-GST fusion protein to MODified histone H3, H4, H2A 
and H2B peptide arrays. (A) Peptide arrays were probed with Bromo-GST fusion proteins 
and protein bound spots were detected as described previously. (B) Bromodomain binding 
analysis shows that the bromodomain binds to residues including H4K5ac (red circle), 
H4K8ac (yellow circle), H4K12ac (green circle) and H4K16ac (blue circle) with a distinct 
preference for tetra-acetylated H4 tails (H4K5/K8/K12/K16ac). (C) Relative binding intensity 
of modified histone H4 peptides in comparison to unmodified H4 peptide. (D) Relative 
binding intensity analysis showed that multiple acetylations enhance binding of the 
bromodomain to H4 N-terminal peptides in comparison to the binding to the singly modified 
H4K16ac peptides. 
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3.2.3 Validation of modified histone interactions by peptide pull down assays  
3.2.3.1 PHD2 domain 
To confirm the interaction of PHD2 domain with binding markers identified in our peptide 
library array assays, peptide pull down assay was performed using both the Drosophila 
NURF301 PHD2 domain and the human BPTF PHD2 domain. This was prepared to confirm 
whether binding was functionally conserved. The GST--conjugated PHD2 domain proteins 
were allowed to bind to modified histone peptides (biotinylated). Peptide bound PHD2 
proteins were recovered on streptavidin-coated agarose beads, and the amount of copurified 
PHD2 domain proteins were determined by western blotting. In addition to modifications 
detected on arrays, we also examined the effect of flanking phosphorylation at histone H3 Ser 
10, located next to H3K9ac, which was found as an enhancing marker on PHD2 binding to 
H3K4me3 in our study. H3S10p is well known histone marker involved in mitotic/meiotic 
chromosome condensation (Prigent and Dimitrov, 2003). We initially postulated that 
phosphorylation of H3S10 could antagonize H3K9ac like H3T3p does to H3K4me3, and 
mask the enhancing effect on PHD2 domain binding to the H3K4me3/K9ac mark. 
 
As we expected, both NURF301 (Drosophila) and BPTF (Human) PHD2 domains bound to 
H3K4me3, but the flanking phosphorylation of H3T3 significantly inhibited the binding of 
PHD2 domains to H3K4me3 (H3T3p/K4me3) showing no detectable binding to 
H3T3pK4me3 peptides. In contrast, the flanking acetylation of H3K9 resulted in enhanced 
binding of PHD2 domains to H3K4me3 (H3K4me3/K9ac). Interestingly additional 
phosphorylation of H3S10 resulted in a greatly enhanced binding (H3K4me3/K9ac/S10p). 
Differences in peptide-PHD2 domain binding affinities were only seen with 0.1 µg of peptide 
pull down reactions, while these were not seen when 1µg of peptides were supplied in our 
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standard reactions suggesting that higher levels of peptide can override any differences in the 
affinity of the PHD2 domain (Figure 3-13 A).  
 
 
Figure 3-13. The PHD2 domain peptide pull down and peptide competition pull down 
assays. The binding specificities of the Drosophila NURF301 PHD2 domain and the human 
BPTF PHD2 domain (GST conjugated) to histone markers identified from peptide library 
array assays were determined by peptide pull down and peptide competition pull down assays. 
(A) Interactions between GST-PHD2 domains and either 0.1 μg or 1 μg of biotinylated 
histone peptides were analysed by peptide pull down and visualized by western blot using 
rabbit anti-GST (HRP) antibody. (B) Relative affinities of PHD2 domains to different histone 
modifications were analysed by peptide competition pull down, in which constant 0.1μg of 
biotinylated peptides (H3K4me3, H3K4me3/K9ac and H3K4me3/K9ac/S10p) and 0 to 500 
molar excess of competitor H3K4me3 peptide mixed in the GST-PHD2 fusion protein 
binding reactions. Bound proteins were then visualized by western blot using rabbit anti-GST 
(HRP) antibody.  
 
To further determinate differences in binding affinities for these peptides, we also performed 
peptide competition pull down assays to determine the relative affinities of both NURF301 
PHD2 domain and BPTF PHD2 domain to different histone modifications on the peptides. In 
particular, relative PHD2 binding affinities between H3K4me3 and H3K4me3/K9ac, between 
H3K4me3 and H3K4me3/K9ac/S10p were examined. In each PHD2 domain peptide pull 
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down reaction, a 0 fold, 100 fold, 250 fold and 500 fold molar excess of H3K4me3 peptide as 
competitor over biotinylated H3K4me3/K9ac or H3K4me3/K9ac/S10p peptide was added. 
The same reactions between H3K4me3 and biotinylated H3K4me3 peptide were also 
conducted as controls. Even in the 250 and 500 fold excess of H3K4me3 peptides, binding of 
PHD2 domain to biotinylated H3K4me3/K9ac and H3K4me3/K9ac/S10p peptides was still 
observed, while binding to the control biotinylated H3K4me3 peptide was lost at 100 fold 
excess of the competitor (Figure 3-13 B). Titration of competitor H3K4me3 peptide indicates 
that the binding specificity of PHD2 to either H3K4me3/K9ac or H3K4me3/K9ac/S10p are 
about 100 times and 250 times respectively stronger than the binding to the singly modified 
H3K4me3 histone H3 peptides. In addition, the binding affinity of PHD2 to 
H3K4me3/K9ac/S10p is stronger in comparison to H3K4me3/K9ac. This result contradicted 
our initial hypothesis that phosphorylation of H3S10 would block PHD2 binding. Instead, this 
suggests that phosphorylation itself does not antagonize the PHD2 binding to H3K4me3 as 
phosphorylation of H3T3 inhibits binding, whereas phosphorylation of H3S10 enhances 
binding. It is the location of the phosphorylated residue that determines the affect on binding. 
 
The X-ray crystal and NMR based structures of the human BPTF PHD2 domain in complex 
with H3(1-15)K4me3 modified histone tail peptide (Li et al., 2006) exist. We sought to 
examine if there were features of the H3K4me3 binding pocket that could account for the 
antagonistic effect of the H3T3p and H3K9ac/S10p residues. The structure was visualized, 
modified and analysed using Accelrys Discovery Studio Visualizer 2.0 (Accelys). In the 
original structure, the trimethyl group of K4me3 is stably positioned within a cage composed 
of four aromatic amino acids, Tyr 10, Tyr 17, Tyr 23 and Trp 32 (Y10, Y17, Y23 and W32), as 
described in the previous study (Li et al., 2006). We then modified the structure of the H3 tail 
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peptide to model the addition of a negatively charged phosphate group at Thr 3. Analysis of 
electrostatic charge distribution in the PHD2 binding pocket shows that negatively charged 
phosphate at Thr 3 is possibly repulsed by negatively charged amino acids, Glu 44, Glu 46, 
Asp 49 and Glu 50 (E44, E46, D49 and E50), in the PHD2 binding pocket. This provides a 
structural basis of how the binding of PHD2 to H3K4me3 can be inhibited by flanking 
phosphorylation of H3T3 (Figure 3-14 A).  
 
We also attempted to modify the H3 tail peptide from the NMR structure to model the 
addition of an acetyl group at Lys 9 and negatively charged phosphate group at Ser 10. Due to 
the flexibility of this region of the H3 peptide, these residues are not localised in the X-ray 
crystal structure precluding similar analysis of the X-ray structure. However, this region of the 
H3 peptide can be visualized in the related NMR structures. When we looked at the potential 
binding region of BPTF PHD2 binding pocket and unmodified or modified H3K9/S10 
peptides, we observed that H3K9ac and S10p, which are neutralized by acetylation and 
negatively charged by phosphorylation respectively, were surrounded by positively charged 
amino acids, Lys 21 and Arg 36 (K21 and R36) (Figure 3-14 B). Electrostatic interaction 
between the residues could enhance the binding capacity of PHD2 domain to H3K4me3, as an 
additional negatively charged phosphate group at Ser 10 would favourably interact with 
positively charged regions in the PHD2 domain when it binds to H3K4me3 on the peptide. 
Altough we can not localise this region of the H3 peptide in the X-ray crystal structure, 
analysis of the region where the peptide would be predicted to exit (based on the NMR 
sructures) shows clear representation of the favourable electrostatic surface. 
 
Finally, the protein sequence alignments of the PHD2 domains in Drosophila NURF301, 
107 
human and mouse BPTF showed high conservation of these amino acid residues that we 
postulate are essential for binding of the rheostat histone modifications (Figure 3-14 C). One 
exception is the positively charged Lys 21 residue that may be a critical residue for interaction 
with negatively charged Ser 10. This residue is not present in Drosophila, which may explain 
the differences in our peptide competition pull down analysis data (Figure 3-13 B), which 
showed weaker binding of Drosophila NURF301 PHD2 to H3K4me3/K9ac/S10p peptide in 
comparison to human BPTF PHD2.  
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Figure 3-14. Structure modelling of the interaction between rheostat modifications and 
the human BPTF PHD2 domain. (A) Crystal structure of the BPTF PHD2 binding pocket 
with H3K4me3 and H3T3p/K4me3 peptides. Thr 3 residue is coloured by element of the atom, 
and trimethylated Lys 4 residue is in purple on the tail peptide backbone. (B) NMR and 
crystal structure modelling of the BPTF PHD2 binding pocket with H3K4me3 and 
H3K4me3/K9ac/S10p peptides. In (A) and (B), the PHD2 domain binding pocket is displayed 
in electrostatic surface representation coloured in red as negatively charged and blue as 
positively charged. (C) Protein sequence alignments of the NURF PHD2 domains in 
Drosophila, human and mouse show highly conserved amino acid residues that are critical for 
binding of these histone modifications. Amino acid residues important for H3K4me3 binding 
are indicated in green(*), negatively charged residues involved in repulsion of H3T3p in red(-) 
and positively charged residues involved in H3K9ac/S10p binding in blue(+). 
  
110 
3.2.3.2 PHD1 domain 
 
 
Figure 3-15. The PHD1 domain peptide pull down assays. The binding specificities of the 
Drosophila NURF301 PHD1 domain (GST conjugated) to histone modifications identified 
from peptide library arrays were validated by peptide pull down and western blot analysis 
using rabbit anti-GST (HRP) antibody.  
 
To verify that the observed interaction between the NURF301 PHD1 domain and histone 
modifications in the peptide array data, we performed a peptide pull down assay using 
biotinylated histone H3K23me3 peptides or H3K36 peptides delivering acetyl-, di-methyl or 
tri-methyl groups at Lys 36. Unmodified histone H3(21-44) peptide was used as a control. No 
binding of PHD1 was observed to H3K36ac, H3K36me3 and H3K36me3 peptides (Figure 3-
15), even when the bindings were repeated with excess amount of peptide to 25 μg (data not 
shown). As shall be shown later, increasing peptide amounts can reveal lower affinity 
interaction. This contrast with what we observed from peptide arrays. However, analysis of 
peptide array data of the PHD domains and the bromodomain suggests that binding to H3K36 
peptides may result from non-specific binding. In contrast, we could detect robust binding of 
PHD1 domain to H3K23me3. Two H3K23me3-containing peptides were used. Strong binding 
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was observed when the H3(14-34)K23me3 peptide was used. In this peptide the modification 
is located in the middle of the peptide. Binding was also observed to a peptide, H3(21-
44)K23me3, in which the modification is positioned near to N-terminal end of the peptide, but 
binding required higher peptide amounts of at least 25 μg. 
 
In the previous studies, it has been known that human BPTF contains only two PHD finger 
domains: the N-terminal PHD domain and a single (PHD2) domain at the C-terminus. The 
PHD1 domain that is present in Drosophila NURF301 is not present in annotated mammalian 
BPTF transcripts. However, we have shown that PHD1 shows a unique modified histone-
binding specificity and we wanted to determine if human BPTF may in fact contain a PHD1 
domain. We examined the genomic region that includes BPTF using the UCSC genome 
browser (http://genome.ucsc.edu). This browser provides genome annotation data by 
graphically displaying assembly contigs and gaps, mRNA and expressed sequence tag (EST) 
alignments, multiple gene predictions, cross-species homologies, single nucleotide 
polymorphisms, sequence-tagged sites, radiation hybrid data and transposon repeats (Kent et 
al., 2002). Although a BPTF PHD1 domain was not annotated in the reference sequence genes 
(RefSeq), we identified the PHD1 domain in two N-terminal truncated short isoforms 
highlighted in pink (Figure 3-16 A) and in some mRNAs and ESTs. The amino acid and DNA 
sequence of the putative BPTF PHD1 were highly conserved in different species and 
resembled the Drosophila PHD1 sequence. The aromatic cage residues, Tyr 10, Tyr 17, Tyr 23 
and Trp 32 (Y10, Y17, Y23 and W32) that are required for methylated lysine binding were 
present in the human BPTF PHD1 domain (Figure 3-16 B and C). 
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Figure 3-16. Identification of a human BPTF PHD1 domain. (A) Genomic view of human 
BPTF using the UCSC genome browser.. The genomic location of Bptf gene is indicated in a 
red box on the chromosome 17 map. The BPTF PHD1 domain was identified in two of the 
predicted BPTF isoforms (in pink box) and in some mRNAs (BC050566 and BC067234). (B) 
Enlarged image of BPTF PHD1 domain (in pink) and its amino acid sequence. (C) Protein 
and DNA sequence alignments of conserved PHD1 domains in most vertebrates. The amino 
acid residues in green boxes indicate critical residues forming aromatic cage of PHD1 domain, 
and the DNA bases in gray indicate wobble positions. 
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3.2.3.3 Bromodomain 
 
 
Figure 3-17. The bromodomain peptide pull down assays. The binding specificities of the 
Drosophila NURF301 bromodomain (GST conjugated) to histone modifications identified 
from peptide library arrays were validated by peptide pull down and western blot using rabbit 
anti-GST (HRP) antibody. 
 
The interaction of the NURF301 bromodomain with histone modifications from the peptide 
array data was also confirmed by peptide pull down assay using biotinylated histone H4 
peptides. Affinities of singly acetylated H4K16 and multiply acetylated H4K5, 8, 12 16 
peptides were validated and unmodified H4(1-25) peptide used as a control. As observed in 
peptide arrays, peptide pull down showed interaction between NURF301 bromodomain and 
H4K16ac. However, binding to multiply-acetylated peptide (H4K5,8,12,16ac) was stronger 
(Figure 3-17). This was more apparent when excess peptide was used (50 μg). The result 
suggests that binding of the NURF301 bromodomain is higher to peptide that contains the 
multiple acetylations at histone H4 N-terminal tail than to singly acetylated H4K16.  
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3.2.4 Biacore  
From our peptide array, peptide pull down and structure modelling analysis, we found that the 
binding of NURF301 PHD2 domain to H3K4me3 could be inhibited by phosphorylation of 
Thr 3 and enhanced by acetylation of Lys 9 and phosphorylation of Ser 10. To analyse the 
kinetics of these interactions, we performed biacore analysis. The injection PHD2 
concentration was from 78 nM (-32x) to 40 µM (16x) for each peptide. The binding of PHD2 
was monitored using surface plasmon resonance and the binding affinity of PHD2 to 
H3T3p/K4me3 decreased dramatically in comparison to H3K4me3 alone at different PHD2 
concentrations (Figure 3-18). We explored models to calculate the dissociation constants (Kd) 
for binding of H3K4me3 and H3T3pK4me3 from the biacore plots, but the analysis indicated 
that the binding does not follow simple first order kinetics. Biacore analysis with 
H3K4me3/K9ac peptide was not successful (data not shown).  
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Figure 3-18. Surface plasmon resonance-based studies of the binding of the NURF301 
PHD2 domain to H3(1-21) K4me3 and H3(1-21) T3pK4me3 peptides. Surface plasmon 
resonance-based binding and elution curves for the NURF301 PHD2 domain at different 
concentrations with biotin labelled H3(1-21) peptides as a function of K4 methylation and T3 
phosphorylation states.  
  
117 
3.3 Conclusion 
Taken together these data imply that PHD domains and bromodomain of NURF301 can make 
a broad range of interactions with histone modifications on the histone H3 and H4 N-terminal 
tails. Here we found the NURF301 PHD2 domain specifically binds to H3K4me3. However, 
the binding to this primary recognition site can also be influenced by interaction with flanking 
modifications. The flanking phosphorylation of H3T3 inhibits the PHD2 domain binding to 
H3K4me3 while acetylation of H3K9 enhances the binding. Moreover, the additional 
phosphorylation of H3S10 with H3K9ac can increase affinity of the PHD2 domain binding to 
H3K4me3. Together, these modifications provide rheostats to control NURF binding. 
Structural modelling analysis also suggested the electrostatic interactions between the PHD2 
binding pocket and these modifications. The negatively charged surface of the PHD2 repulses 
the negatively charged phosphate group of H3T3, so PHD2 binding to H3K4me3 is inhibited. 
This was confirmed by Biacore assay which showed dramatic decrease of binding affinity of 
PHD2 domain to H3T3p/K4me3 in comparison to H3K4me3. In contrast, the neutralization of 
H3K9 by acetylation and the addition of a negative charge on H3S10 by phosphorylation 
(H3K9ac/S10p) can interact with positively charged surfaces on the PHD2 binding pocket, 
which enhances the binding capacity of the PHD2 domain to H3K4me3. We also revealed that 
the NURF301 PHD1 domain interacts with H3K23me3 specifically and identified that this 
PHD1 domain also exists in human BPTF and is highly conserved. The NURF301 PHD 
domain does not have any modified-histone binding specificity, but still showed binding 
preference to histone H4 N-terminal free sequences. Finally, we observed that NURF301 
bromodomain binds to H4K16ac and this binding affinity can be increased by multiple 
acetylations at Lysine 5,8,12,16 (H4K5,8,12,16ac) of the histone H4 N-terminal tail. These 
data allow us to derive a model of the PHD domains and bromodomain with their specific 
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interactions of modifications on histone H3, H4 N-terminal tails of nucleosome.  
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CHAPTER 4. IMMUNOFLUORESCENCE MICROSCOPY TO 
LOCALIZE THE HISTONE MODIFICATIONS: H3K4me3, H3T3p, 
H3K9ac, H3S10p, H3K23me3 and NURF301 in Drosophila in vivo AND 
ChIP SEQUENCING OF NURF301 ISOFORMS 
 
4.1 Introduction 
4.1.1 In vivo localization of NURF and histone modifications 
In work in the previous chapter we have used modified histone peptide arrays and in vitro 
histone peptide pull-down assays to define the binding specificities of each of the PHD 
domains and bromodomain of NURF301. However, it is important to verify whether these 
histone modifications are involved in targeting of NURF in vivo. In this chapter we examine 
the tissue distribution of NURF301 and histone modifications as well as co-localization of 
NURF and histone modification on chromatin.  
 
Previous research has shown that Drosophila NURF, as a chromatin remodelling enzyme, 
generally localizes to the nucleus in cells. For instance, immunofluorescence on testes showed 
NURF301 is expressed within the primary spermatocytes although it is enriched on two of the 
three bivalents in mature primary spermatocytes (Kwon et al., 2009). Human BPTF has also 
been shown to localize to the nucleus although some expression is also detected in the 
cytoplasm (Jones et al., 2000). While BPTF appears to be expressed ubiquitously, the highest 
levels of expression have been observed in the testis (Jones et al., 2000). 
 
The distribution of the histone marks we have shown to be bound by NURF301 (or influence 
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its binding) have been characterized to varying degrees. One of the best-studied is the histone 
H3K4me3 modification, which is found to be enriched at many transcriptionally active genes 
in yeast, Drosophila and mammals (Pokholok et al., 2005, Schuettengruber et al., 2009, 
Bernstein et al., 2005). On Drosophila polytene chromosomes, the majority of H3K4me3 
staining colocalizes with Pol II and dSet1, which is known as a component of a conserved 
H3K4 trimethyltransferase (Ardehali et al., 2011).  
 
Histone H3 phosphorylation is a well-known mark involved in regulation of gene expression 
and chromatin reorganization during mitosis. High levels of phosphorylation of histone H3 
Thr 3 (H3T3p) are detected on mitotic chromosomes. Strong H3T3p staining commences at 
early prophase, spreads to pericentromeric chromatin during prometaphase but is fully 
reversed by late anaphase in mitotic cells (Polioudaki et al., 2004). Haspin is the major 
histone H3 Thr 3 kinase in mammalian cells, required for phosphorylation of Thr 3 at inner 
centromeres and normal metaphase chromosome alignment (Dai et al., 2005). 
Phosphorylation of histone H3 Ser 10 (H3S10p) is also detected at high levels during mitosis 
and meiosis (Prigent and Dimitrov, 2003), and structural alterations of chromatin are found to 
be related to dephosphorylation of H3S10p in Drosophila (Cai et al., 2008). However, 
H3S10p is also detected in interphase nuclei, albeit at lower levels, where it is associated with 
induction of gene expression (Mahadevan et al., 1991; Barratt et al., 1994; Sassone et al., 
1999; Anest et al., 2003; Soloaga et al., 2003; Yamamoto et al., 2003). In Drosophila, higher 
levels of H3S10p are also detected on the male X-chromosome (Johansen and Johansen, 
2006), where it is associated with structural changes and increased transcription from the male 
X-chromosome. 
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Acetylation of histone residues also correlates with transcription activation. Genome-wide 
profiling indicates that acetylation of histone H3 Lys 9 (H3K9ac) is corresponds with 
transcriptional activity and occurs predominantly at the 5’ end of genes (Pokholok et al., 2005, 
Bernstein et al., 2005). This overlaps with the reported distributions of H3K4me3 and 
H3S10p (Schübeler et al., 2004; Roh et al., 2006). In particular the double modification 
H3K9acS10p mark occurs at promoters and is correlated with gene expression (Clayton et al., 
2000; Kellner et al., 2012). Localisation of the histone H3K9ac mark in vivo in Drosophila 
has also been characterized using transgenic flies expressing GFP conjugated to an anti-
H3K9ac antibody. These results reveal the distribution of H3K9ac in the nucleus during late 
embryogenesis and in euchromatic bands on polytene chromosome (Sato et al., 2013). The 
H3K9ac mark is established through the action of the acetyltransferase Gcn5, which when 
part of multisubunit complexes such as the Spt-Ada-Gcn5-acetyltransferase (SAGA) and 
ADA complexes (Grant et al., 1999), particularly acetylates histone H3 lysine 9 and lysine 14 
(Qi et al., 2004). Loss of Gcn5 or other the Ada2b component of the SAGA complex results in 
the loss of H3K9ac on polytene chromosomes and in embryos, and cell cycle defects and 
apoptosis (Carré et al., 2005).  
 
Of the modifications that were identified during our binding studies, the least characterized is 
the H3K23me3 modification. To a large extent studies of this modification have been limited 
by the absence of available antibodies. However, recently anti-H3K23me3 antibodies have 
been generated and used to show H3K23me3 on heterochromatic H3 from Tetrahymena, and 
that levels of H3K23me3 increase during meiosis in Tetrahymena micronuclei, C. elegans, 
and mice (Papazvan et al., 2013). To visualize the distribution of H3K23me3 in Drosophila, 
we obtained the anti-H3K23me3 antibody in a collaboration with the Taverna group in Johns 
Hopkins School of Medicine that generated this antibody. 
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4.1.2 Chromatin immunoprecipitation (ChIP) sequencing 
The development of new techniques such as chromatin immunoprecipitation (ChIP) have 
been important in understanding how the dynamic properties of chromatin can be altered by 
modification of the DNA and histones. In particular, ChIP followed by hybridization to 
microarrays (ChIP-chip) or by high-throughput sequencing (ChIP-seq) has been widely used 
to characterize histone modifications as well as chromatin binding regulatory proteins. For 
example, most of the key modifications, such as H3K4me3, H3K9me3, H3K9ac and 
H3K27me3, have been mapped using S2 cells and adult flies in Drosophila (Kharchenko et al., 
2011, Nègre et al., 2011, Yin et al., 2011).  
 
In previous work in the laboratory, NURF was immunoprecipitated from testis and hemocytes, 
and the distribution of NURF was determined by semi-quantitative PCR analysis. This work 
identified that NURF binds to the transcriptional start site of the fuzzy onions (fzo) gene and 
that this was correlated with the distribution of the H3K4me3 and H4K16ac modifications 
(Kwon et al., 2009). In hemocytes, NURF301 was found to interact with the Drosophila Bcl6 
homologue Ken and NURF-binding was shown to overlap Ken binding sites in hemocytes 
(Kwon et al., 2008). However, beyond these two studies, little is known about genome wide 
localization of NURF isoforms as it has been difficult to generate ChIP grade antibodies that 
target NURF301 and the only anti-NURF301 antibody available recognizes both NURF 
isoforms (Kwon and Badenhorst, unpublished data). 
 
To identify differences in localization between the NURF301-A/B and NURF301-C isoforms, 
here we performed ChIP-Seq using CTAP tagged NURF301-A/B and NURF301-C transgenic 
flies. Hemocytes were isolated from 3rd instar larvae for ChIP as this provides a pure 
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population of cells and also allow us to collect male and female samples separately which 
would be useful to look at the sex-dependent differences in recruitment. 
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4.2 Results 
4.2.1 H3K4me3 and NURF301 localisation in vivo  
4.2.1.1 Detection of Histone H3K4me3 and NURF301 in embryos by immunostaining 
Data from the PHD2 domain histone peptide arrays and peptide pull down assays suggested 
that the NURF301 PHD2 domain binds primarily to the H3K4me3 modification on histone 
tails, but this binding can be inhibited by flanking H3T3p or enhanced by flanking H3K9ac 
and H3S10p modifications. To understand the localisation of NURF and H3K4me3 and its 
interaction on chromatin in vivo, immunostaining of Drosophila embryo was performed using 
anti-H3K4me3, anti-NURF301(Kwon5), anti-H3T3p and anti-H3T3pK4me3 antibodies. The 
embryos are nearly transparent and can be easily visualized by microscopy and deliver 
representatives of each cell type at different developmental stages. These characters allow us 
to analyse the spatial and temporal distribution of histone modifications and NURF301 during 
development. 
 
First, we examined the distribution of the single H3K4me3 modification across the time-
course of embryonic development. Overnight collections of embryos (which includes stages 
from 0-18 hr) were analysed. Among the different stages of embryos, minimal antibody 
staining is detected during early embryonic stages, prior to cellularization. After 
cellularization (Fig 4-1, St 4), weak H3K4me3 could be observed, after which expression rose 
progressively during development with intense staining of tri-methylation at H3K4 detected 
in cells of late embryonic stages (Fig 4-1, St 7-9). The appearance of high levels of H3K4me3 
at cellularization were striking as this corresponded with the large scale activation of zygotic 
transcription that occurs at this stage (Edgar and Schubiger, 1986). Significantly, anti-
H3K4me3 staining was not only observed in interphase nuclei but also detected on the 
chromosomes in dividing cells (Figure 4-1, stage 7 dividing).  
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Figure 4-1. The histone H3K4me3 modification was detected after cellularizaton. w
1118
 
embryos were fixed and immunostained using rabbit anti-H3K4me3 antibodies (green in 
merge), and DNA was visualized by DAPI staining (red in merge). The embryos at the 
different developmental stages (from stage 3 to stage 13) were observed. Scalebar represents 
10µm. 
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Figure 4-2. Drosophila NURF301 is delocalized from chromatin during mitosis. w
1118 
embryos were fixed and stained with rabbit anti-NURF301 antibodies (green in merge), and 
DNA was visualized by DAPI staining (red in merge). NURF301 is localized to chromatin 
during interphase, is not chromatin-bound during metaphase and anaphase, but starts to re-
localize to chromatin during late telophase. Scalebar represents 10µm. 
 
We next examined NURF301 distribution in embryos collected in the same manner to 
compare with the localisation of H3K4me3. Rabbit anti-NURF301 antibodies that had been 
generated in the laboratory (Kwon, unpublished data) were used. NURF301 staining was 
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detected in nuclei in embryos throughout development (data not shown). This corresponds 
with the high maternal contribution of Nurf301 transcripts that has been observed previously 
(Badenhorst et al., 2002). However, NURF301 was only detected on chromatin during 
interphase (Figure 4-2, Interphase). During metaphase and anaphase, NURF301 was 
delocalized from chromosomes. NURF301 begins to associate with chromatin again during 
late telophase. NURF301 staining was detected in all cell types, however expression is higher 
in gastrulating cells, and the lowest levels were detected in primordial germ cells (Figure 4-2).  
 
Consistent with the NURF301 PHD2 binding specificity data, we observed colocalization of 
NURF301 with H3K4me3 at least in interphase cells, but not in the dividing cells. The H3T3p 
mark, which we identified as an inhibitory marker of NURF PHD2 domain binding, has been 
reported to be elevated on mitotic chromatin (Polioudake et al. 2004; Dai et al. 2005). We 
therefore tested whether the delocalisation of NURF301 during mitosis was linked to H3T3p 
levels. 
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4.2.2 Identification of H3T3p as an inhibitor of the Drosophila NURF301 binding to 
H3K4me3 in vivo 
4.2.2.1 Embryo immunostaining of Histone H3T3p, H3T3p/K4me3 and NURF301 in 
dividing cells 
The distribution of the H3T3p mark in Drosophila embryos was examined using rabbit anti-
H3T3p antibodies. Previous studies in human Hela cells had indicated high levels of H3T3p 
occur on metaphase chromosomes, declining substantially during anaphase and telophase, 
with H3T3p comparatively absent during interphase (Polioudake et al., 2004; Dai et al., 2005). 
We observed similar results using Drosophila embryos. The phosphorylation of H3T3 is 
barely detectable in interphase cells (Figure 4-3, Interphase). However, significant staining of 
H3T3p is detected on metaphase chromosomes, which then declines during anaphase and 
telophase as shown in figure 4-3. 
 
 
Figure 4-3. High levels of anti-H3T3p staining were detected on mitotic chromatin. w
1118
 
embryos were fixed and stained with rabbit anti-H3T3p antibodies (green in merge), and 
DNA was visualized by DAPI staining (red in merge). Scalebar represents 10µm. 
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To investigate whether phosphorylation of H3T3 could affect the binding of NURF301 to 
H3K4me3 in vivo, we double-stained embryos using antibodies specific for Drosophila 
NURF301 and histone H3T3p/K4me3 respectively, to determine the extent of overlap. As 
noted previously, NURF301 is detected in interphase nuclei but is delocalized during 
metaphase and anaphase. NURF301 then starts to come back onto chromatin in late telophase 
(Figure 4-4 A). In contrast, H3T3p/K4me3 staining is detected significantly during metaphase 
and anaphase, but is absent during interphase (Figure 4-4 B). Double immunostaining with 
antibodies against H3T3p/K4me3 and NURF301 shows no colocalization during any stage of 
the cell cycle (Figure 4-4 C). 
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Figure 4-4. Distribution of NURF301 relative to H3T3p/K4me3 in Drosophila embryos 
at different stages of mitosis. (A) w
1118
 embryos were fixed and stained with rabbit anti-
NURF301 antibodies (green in merge) and DAPI (purple in merge), (B) with rabbit anti-
phospho-methyl-histone H3 (H3T3p/K4me3) antibodies (green in merge) and DAPI (purple 
in merge). (C) Cells sequentially double-stained using anti-NURF301 antibodies (green in 
merge) and anti-phospho-methyl-histone H3 antibodies (H3T3p/K4me3, red in merge). DNA 
was visualized by DAPI staining (purple). Scalebar represents 10 m. 
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4.2.2.2 Visualization of Histone H3T3p, H3T3p/K4me3 and NURF301 in neuroblast cells 
by immunostaining 
Immunostaining of Drosophila embryonic cells with anti-NURF301, anti-H3K4me3, anti-
H3T3p and anti-H3T3p/K4me3 antibodies at different mitotic stages showed that binding of 
NURF301 could potentially be regulated by the histone H3T3p modification in chromatin in 
vivo. To confirm whether this also occurred at other stages of development and to profile 
localisation on chromatin at higher resolution, Drosophila third instar larval neuroblasts were 
immunostained using the same antibodies. Drosophila larval neuroblasts are well-established 
model for visualizing mitotic chromasomes (Gatti et al., 1994). They divide asymmetrically 
and following mitosis generates two cells, a larger daughter cell, which retains neuroblast 
identity, and smaller ganglion mother cell (GMC) that generates neurons (Doe and Bowerman, 
2001). The larger size of neuroblasts allows mitotic figures to be observed easily at high 
resolution.  
 
We examined the distributions of NURF301 and the H3T3p/K4me3 modification on double-
immunostained interphase nuclei and mitotic chromosomes from larval neuroblasts. As 
expected, NURF301 was detected during interphase nuclei but was delocalized during 
metaphase, while H3T3p/K4me3 was detected at high levels on metaphase choromosomes 
(Figure 4-5 A and B). In interphase nuclei, lower levels of H3T3p/K4me3 were observed, 
distributed in a punctate manner. Double labelling with anti-NURF301 antibodies suggested 
no overlap with H3T3p/K4me3 foci in interphase neuroblasts. These data suggested that two 
populations of H3T3p exist. The first is the broadly expressed modification that occurs during 
mitosis. The second is a more restricted modification during interphase. This suggested that 
the H3T3p mark could also play a role on interphase chromatin in ejecting NURF at specific 
loci.  
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Figure 4-5. Distributions of NURF301 and H3T3p/K4me3 on interphase nuclei and 
mitotic chromosomes of Drosophila larval neuroblasts. (A) Double immunostaining 
images of NURF301, H3T3p/K4me3 and DAPI in interphase and metaphase neuroblasts from 
w
1118
 shown in separate panels in black and white. (B) Merged double immunostaining 
images of NURF301 (red)/H3T3p/K4me3 (green) and NURF301 (red)/DAPI(purple). 
Scalebar represents 10 m. 
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4.2.2.3 Visualization of Histone H3T3p, H3T3p/K4me3 and NURF301 in polytene 
chromosomes by immunostaining 
To resolve loci at which H3T3p antagonizes NURF-binding in interphase chromatin, 
Drosophila third instar larval polytene chromosomes were immunostained using the same 
antibodies. As the polytene chromosomes are non-mitotic interphase chromosomes consisting 
of thousands of copies of the DNA strands and display specific banding patterns, we expected 
to understand and visualise the more detailed distributions of NURF and histone 
modifications on chromosomes in vivo. 
 
We first used the conventional polytene chromosome squash technique in which highly acidic 
fixation conditions are employed (Badenhorst et al., 2002). However, the resultant antibody 
staining was poor and we were unable to detect good single antibody staining with either anti-
NURF301, anti-H3T3p or anti-H3T3pK4me3 antibodies (data not shown). We reasoned that 
the highly acidic (45% acetic acid) step that is used to spread polytene chromosomes in the 
conventional squash procedure strips chromatin of NURF301 and the histone modifications.  
To address this we adopted an alternative squash procedure that has been shown to result in 
reliable antibody staining of the H3S10p histone phosphorylation mark (Cai et al., 2008). This 
acid-free procedure uses glycerol instead of acetic acid to spread chromosomes after fixation 
(DiMario et al., 2006) and has been used for all subsequent polytene chromosome 
immunostaining.  
 
The immunostainings of NURF301, H3T3p and H3T3p/K4me3 were performed respectively 
with the acid-free protocol. We detected significant staining of NURF301 on the non-mitotic 
interphase polytene chromosomes. NURF301 was predominantly localized to inter-bands 
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which are in the decondensed state on chromosomes, or to the interface between bands and 
interbands (Figure 4-6 A, green bands in the merge). However, there was no significant 
staining of H3T3p detected on polytene chromosomes (Figure 4-6 B). Low levels of 
background staining were detected using anti-H3T3p/K4me3 antibodies (Figure 4-6 C). This 
data was consistent with the embryo immunostaining results above, where significant 
chromatin localisation of NURF301 was observed during interphase when H3T3p and 
H3T3p/K4me3 staining was absent. However, it did not allow us to address the interphase 
function(s) of the H3T3p mark as it is absent from polytenized chromosomes. 
  
135 
 
Figure 4-6. Distribution of NURF301 relative to H3T3p and H3T3p/K4me3 in 
Drosophila non-mitotic interphase polytene chromosomes. For immunostaining, w
1118
 third 
instar larvae were used. The polytene chromosomes were immunostained using (A) rabbit 
anti-NURF301, (B) anti-H3T3p and (C) anti-phospho-methyl-histone H3 (H3T3p/K4me3) 
antibodies (green). DNA was visualized by DAPI staining (red). Scalebar represents 50 m. 
 
Overall, these immunostaining data support the idea that the flanking phosphorylation of 
H3T3 has an inhibitory effect on the binding of NURF301 to H3K4me3 during mitosis. The 
H3T3p mark is established by the atypical kinase Haspin (Dai et al., 2006). In a next set of 
experiments we attempted to generate mutants in the Drosophila Haspin gene and examine 
NURF localization to chromatin during mitosis in Haspin mutants. We obtained fly lines 
containing transposon insertions in Haspin and attempted to generate imprecise excision 
mutants from these. However, this was not successful. In addition, we also tried to generate 
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small deletions in the Haspin locus by X-ray mutagenesis. These experiments also failed to 
generate a Haspin mutant line. Haspin is an example of a rare type of gene in Drosophila that 
is expressed even though it is embedded in pericentric heterochromatin (location 
2RHet:3,199,376..3,234,607). Given its location near the centromere of the second 
chromosome we postulate that deletion of Haspin may disrupt the centromere making it 
difficult to recover mutations through conventional excision techniques.  
 
To overcome this we also attempted to knock-down Haspin expression using inducible RNAi 
(siRNA). The Drosophila Transgenic RNAi Project at Harvard Medical School (TRiP) has 
generated transgenic fly strains that express short hairpin interfering RNAs (siRNAs) under 
the control of the GAL4 UAS sequence. By crossing these strains to GAL4 driver fly strains 
that express the GAL4 transcription factor in specific tissues, tissue specific knockdown can 
be achieved. The TRiP project has generated TRiP lines that target most Drosophila genes (Ni 
et al., 2008). We used a strain that is designed to target Haspin (y
1
 sc
*
 v
1
; 
P{TRiP.HMS01468}attP2) to attempt to knock-down Haspin levels. As a first test we used the 
hemocyte-specific GAL4 driver Hemolectin-GAL4 to drive expression of Haspin siRNAs in 
blood cells to test whether this siRNA strain could knockdown Haspin expression. No 
antibodies against Drosophila Haspin exist but we could assay knockdown by looking for 
effects on H3T3p staining of hemocytes. However, as shown in figure 4-7, the Haspin siRNA 
strain was unable to significantly affect H3T3p levels, precluding the use of this strain for 
functional analysis of the effect of H3T3p on NURF301 localization. 
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Figure 4-7. Expression of Haspin siRNAs in blood cells. A Haspin siRNA strain was 
crossed to w
1118
 as control, or Haspin siRNA expression was driven in blood cells by crossed 
it to Hemolectin-GAL4 strain. Staining using anti-H3T3p antibodies showed that the Haspin 
siRNA strain was unable to block H3T3p. Scalebar represents 20 m.  
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4.2.3 Identification of H3K9ac and H3K9ac/S10p as enhancing markers of Drosophila 
NURF binding to H3K4me3 in vivo 
4.2.3.1 Visualization of Histone H3K9ac, H3K9ac/S10p and NURF in polytene 
chromosomes by immunostaining 
Results obtained using peptide arrays and peptide pull down assays also identified two marks 
that enhanced NURF301 PHD2 domain binding to H3K4me3, the histone marks acetylated 
H3 Lys 9 (H3K9ac) and phosphorylated H3 Ser 10 (H3S10p). In a similar manner to that 
described for the H3T3p mark, we examined whether these modifications affect NURF 
localisation to chromatin using immunofluorescence microscopy of third instar larval 
polytene chromosomes. We have already demonstrated that the optimized acid-free polytene 
squash procedure preserves NURF301 staining of polytene chromosomes (Section 4.2.2.2). 
We first confirmed if this squash procedure was effective for H3K9ac and H3S10p. We 
examined the distribution of these histone modifications either alone or in combination on 
polytene chromosome using antibodies against H3K9ac, H3S10p and H3K9ac/S10p, before 
we analysed their correlation with NURF. The H3K9ac mark was detected at numerous loci 
on wild-type polytene chromosomes, and localized to both interbands and DAPI stained 
bands (Figure 4-8 A). Anti-H3S10p antibody staining displayed clearer banding patterns, 
mostly localised to interbands (Figure 4-8 B). Antibodies that detect the combined phospho-
acetyl H3K9ac/S10p modification showed restricted staining compared to H3K9ac or H3S10p, 
but which was localised to interbands (Figure 4-8 C). 
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Figure 4-8. The distribution of the histone H3K9ac, H3S10p and the combined phospho-
acetyl H3K9ac/S10p mark on wild-type w
1118
 Drosophila interphase polytene 
chromosomes. Polytene chromosomes were immunostained with (A) rabbit anti-H3K9ac, (B) 
anti-H3S10p and (C) anti-H3K9ac/S10p antibodies (green in merge). DNA was visualized by 
DAPI staining (red). Scalebar represents 50 m. 
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4.2.3.2 Visualization of NURF301 in histone acetyl transferase Gcn5 knock-out condition 
by polytene chromosome immunostaining 
If histone H3K9ac modification is required for NURF binding, we would expect to see that 
NURF301 and H3K9ac colocalize on chromatin. Conversely, we would also predict that 
mutation of the histone acetyl transferase Gcn5, which acetylates histone H3 Lys 9, would 
alter NURF301 localization. To test these predictions we looked at the relative distribution of 
NURF and acetylated histone H3 K9 on polytene chromosomes of wild-type (w
1118
) and Gcn5 
delete strains. We generated animals lacking Gcn5 by crossing Df(3L)sex204, a deficiency 
that removes Gcn5 and the flanking tra1 locus, to the EMS point mutant Gcn5
E333st
 which has 
previously been shown to be a Gcn5 null allele (Carre et al., 2005). Polytene chromosomes 
from mutant and wild-type third instar larvae were double stained using antibodies against 
NURF301 and H3K9ac. The same chromosome arm was then selected and observed at higher 
magnification to map the relative distribution of NURF301 and H3K9ac.  
 
We observed that NURF was mainly localized to interbands or the interface between bands 
(Figure 4-9A). H3K9ac staining was more generally distributed, but we were able to detect 
bands at which NURF301 and H3K9ac were co-localized on wild-type polytene chromosome 
(Figure 4-9A, merge). Clearly H3K9ac is not the sole determinant of NURF301 recruitment 
as bands were observed were H3K9ac positive but which showed no NURF301 binding 
(green bands in the merge in Figure 4-9A). This is not surprising given that we postulate that a 
combination of H3K4me3 and the H3K9ac mark determines recruitment. Significantly, we 
observed a more restricted number of bands that showed NURF301 staining but did not 
display high levels of H3K9ac (green bands in the merge in Figure 4-9A). However, the 
antibody we used to detect NURF301 recognizes both the full-length NURF301-A/B isoform 
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and the C-terminally truncated NURF301-C isoform, which does not contain PHD1, PHD2 
and the bromodomain. Bands that stain with NURF301 antibodies but do not show H3K9ac 
may reflect staining of the NURF301-C isoform. 
 
As predicted, H3K9ac was barely detectable on dGcn5 mutant polytene chromosomes 
compared to wild-type chromosomes (Figure 4-9 B). Staining of NURF301 on dGcn5 mutant 
polytene chromosomes was not prevented completely but did show reduced binding to a 
restricted set of bands(Figure 4-9 B, merge). We postulate that the sites of residual NURF301 
staining on dGcn5 mutant polytene chromosomes correspond to the NURF301-C isoform, 
which does not contain the C-terminal PHD2 domain. We conclude that NURF interacts with 
histone H3K9ac on polytene chromosomes and that binding is modified by loss of H3K9ac.  
 
As the antibody we used against NURF301 recognizes both the full-length NURF301-A/B 
isoform and the C-terminally truncated NURF301-C isoform which does not contain PHD1, 
PHD2 and bromodomain, it was possible that the residual NURF staining we observed in 
dGcn5 mutants may have come from staining of the NURF301-C isoform. To discriminate 
between staining of the NURF301-A/B and NURF301-C isoforms in vivo, we generated 
epitope-tagged NURF301-A/B and NURF301-C isoforms using BAC recombineering. These 
experiments will be discussed later in chapter 4.2.8.1.1. 
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Figure 4-9. Loss of Gcn5 reduces the binding of NURF to some chromatin sites. Double 
immunostaining using antibodies against NURF301 and H3K9ac of (A) wild-type (w
1118
) and 
(B) dGcn5 (Gcn5 Df crossed to Gcn5
E333st
) mutant polytene chromosome arms. In merged 
double immunostaining images, NURF301 (red), H3K9ac (green) and DAPI (purple). 
Scalebar represents 20 m. 
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4.2.4 Identification of H3K23me3 in vivo 
4.2.4.1 Immunostaining of embryos, testes and ovaries.  
Data from the NURF301 PHD1 domain histone peptide arrays and peptide pull down assays 
suggested that the PHD1 domain interacts primarily with the H3K23me3 modification. The 
H3K23me3 modification is a relatively novel modification having been first described in 
Papazvan et al. (2013). Before characterizing the interaction between NURF301 and 
H3K23me3 in vivo, we needed to test whether the histone H3K23me3 modification occurs in 
Drosophila. We tested anti- H3K23me3 staining using a range of cell types and 
developmental stages. We first performed immunostaining of wild-type Drosophila embryos 
collected as described in section 4.2.1.1. However, no anti-H3K23me3 antibody staining 
could be detected in embryos at any stages of development or the cell cycle including dividing 
cells (Figure 4-10).  
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Figure 4-10. Immunostaining of wild-type(w
1118
) Drosophila embryos using rabbit anti-
H3K23me3 antibodies. No H3K23me3 staining is detected in staged embryos (from stage 2 
to stage 9) and dividing cells of embryo in stage 9 indicated by yellow arrowheads. DNA was 
visualized by DAPI staining. Scalebar represents 50 m. 
 
As the H3K23me3 modification has been postulated to play a role in meiosis (Papazvan et al., 
2013), we also tested whether we could detect H3K23me3 in the adult testis or ovary. 
However, immunostaining of Drosophila testes and ovaries using anti-H3K23me3 antibodies 
failed to exhibit significant staining in both testes and ovaries (Figure 4-11 A and B). Use of 
the antibody at higher concentrations or with modifications to improve permeabilization of 
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the testes and ovaries (using higher concentrations of detergent treatment or squashing) did 
not alter these results (data not shown).  
 
 
Figure 4-11. Immunostaining of wild-type(w
1118
) Drosophila male testes and female 
ovaries using rabbit anti-H3K23me3 antibodies. No anti- H3K23me3 staining was detected 
in (A) male testes or (B) female ovaries. DNA was visualized by DAPI staining. Scalebar 
represents 100 m. 
 
4.2.4.2 Validation of the anti-H3K23me3 antibody by peptide dot blot analysis 
These data suggest that the H3K23me3 modification does not exist in flies. However, before 
being able to conclude this, it was important to confirm whether the antibody used was 
effective at detecting H3K23me3. To validate whether the anti-H3K23me3 antibody we 
obtained indeed recognizes the histone H3K23me3 modification, we performed peptide dot 
blot using biotinylated modified H3K23me3 peptides. These peptides all contain the 
H3K23me3 mark, but vary in peptide length and the position of the H3K23me3 mark relative 
to the N-terminus of the peptide. An unmodified histone H3 peptide was used as a control. 
Significantly, although the anti-H3K23me3 antibody was able to detect some peptides that 
contain H3K23me3, the antibodies only reacted against peptides that commenced after H3 
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residue 18 (Figure 4-12 B and C). No reaction was detected against a peptide that contained 
H3K23me3 but which initiated after H3 residue 14 (Figure 4-12 D). This suggests that the 
anti-H3K23me3 antibodies may not bind in the context of the full-length H3 tail. It has been 
shown previously that proteolytic cleavage of the H3 tail occurs in a number of systems, with 
cleavage (called tail-clipping) occurring after Ala 21 (Duncan et al., 2008; Santos-Rosa et al., 
2009). It is possible that anti-H3K23me3 staining that has been observed in other systems 
reflects H3K23me3 in the context of a clipped H3. In the absence of tail-clipping, the 
available anti-H3K23me3 antibody may not be able to detect genuine H3K23me3 marks. This 
may account for why we could not detect the H3K23me3 modification in our immunostaining.  
 
 
Figure 4-12. Peptide dot blot analysis was used to validate the binding specificity of anti-
H3K23me3 antibody (1:100 dilution). Peptides containing the H3K23me3 modification 
were obtained from different suppliers as indicated above, and also vary in length and biotin 
position. Antibody-bound peptides were probed with anti-rabbit HRP-conjugated antibody 
(1:10,000 dilution). The amount of peptides spotted was as follows: (lane 1: 1 μg, lane 2: 500 
ng, lane 3: 200 ng, lane 4: 40 ng, lane 5: 8 ng, lane 6: 1.6 ng, lane 7: 0.32 ng, lane 8: 0 ng) 
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4.2.5 Generation of transposon-induced Nurf301 mutant lines 
Research in our laboratory has previously shown that the Nurf301 locus encodes three 
NURF301 isoforms by alternative splicing (Kwon et al., 2009) and two of these, NURF301-A 
and NURF301-B, are essentially full-length isoforms. However, the third isoform NURF301-
C encodes a truncated variant that lacks the C-terminal PHD1 and PHD2 domains and the 
bromodomain. To establish the function of the NURF301-C isoform and to determine the 
function of the C-terminal PHD1, PHD2 domains and bromodomain, we attempted to 
generate mutations that specifically affect the C-terminus of NURF301 and thus NURF301-A 
and NURF301-B. To generate these we relied on the hobo deletion generator system (Mohr 
and Gelbart, 2002; Huet et al., 2002) to attempt to generate small deletions from a P{wHy} 
insertion (P{wHy}CG
16971
DG
23208
) inserted 15 kb downstream of the full-length Nurf301 3’ 
UTR.  
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Figure 4-13. P{wHy} transposon induced Nurf301 mutant lines. Black bars are showing 
different C-terminal deletion series of Nurf301 we generated. 
 
As the first step, heat shock transposase y
1 
w
67
c
23
; In(2LR)Gla, wgGla-1/CyO, P{hsH\T-
2}CyO-1male flies were crossed with y
1 
w
67
c
23
; P{wHy}CG
16971
DG
23208
 virgin females that 
contain a hobo transposon 15 kb downstream of Nurf301. The transposon excision was 
induced by heat shocking flies three times every two days in a 38°C water bath for 30 minutes. 
We obtained 25 potential Nurf301 C-terminal deleted lines and divided these into groups of 
10 to verify the extent of the deletions induced by hobo transposase by sequencing. (Figure 4-
13). Initially, mutant fly lines were sequenced by PCR amplifying the Nurf301 3’ region using 
the hob-amp primer and either primers Nurf-238, Nurf-248 or Nurf-258. We anticipated 
obtaining serial deletions running into the C-terminus of Nurf301 that would generate a 
sequential deletion series of different NURF301 domains. However, sequencing of the 
deletion lines revealed that we did not obtain a uniform series of deletions. Rather, it appeared 
that there were a small number of hotspots near the Nurf301 C-terminal region into which 
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hobo element preferentially inserted. These did not generate a smooth series of deletions but 
rather a stepped series of deletions. None selectively affected the NURF301 C-terminus and 
only NURF301-A or NURF301-B. Most of the deleted fly lines were homozygous fertile and 
viable, with the exception of one in which the whole Nurf301 locus was deleted, which was 
homozygous lethal. This confirmed former studies of Nurf301 deletion mutants which were 
homozygous lethal (Kwon et al., 2009). As we were unable to obtain the targeted deletions 
required, we switched our strategy to use a targeted approach using recombineering (Vencken 
et al., 2006) to tag each NURF301 isoform and analyse their distributions on chromatin. 
 
4.2.6 Recombineering to generate CTAP-tagged NURF301 isoforms  
Previous work in the laboratory had indicated that traditional methods of generating tagged 
proteins (cDNA constructs in P-element transformation vectors) are not successful for 
Nurf301. Firstly, Nurf301 cDNAs are toxic to bacteria and undergo high levels of 
recombination, presumably to inactivate the protein expressed at low levels from these 
cDNAs. Secondly, the large size of P-element transformation vectors after integration of the 
large Nurf301 cDNA (8.6 kb) results in plasmids that are poorly maintained in E.coli. To 
circumvent these problems, we decided to use BACs that contain the Nurf301 locus (and 
which are not toxic due to the presence of intron sequences) as a way of epitope-tagging the 
Nurf301 locus.  
 
These BACs were engineered using recombineering (Lee et al., 2001; Vencken et al., 2006) to 
introduce a C-terminal TAP (CTAP) tag to Nurf301. The CTAP tag contains two tandomly 
expressed copies of protein G and one streptavidin domain that allow purification and 
immunostaining of the resultant NURF301 protein. Two different BACs were selected for 
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initial tagging, CH321(85D11) and CH322(169D05). 85D11 contains a large insert including 
a number of flanking genes. 169D05 contains a smaller insert that spans the Nurf301 cDNA 
and approximately 3kb upstream and downstream. We used recombineering to introduce a 
CTAP tag at the C-terminus of either NURF301-A/B (the full-length isoform) or NURF301-C 
(the C-terminally truncated isoforms). Recombination was a two-step process in which first 
the selectable/counter-selectable marker galK was introduced at the C-terminus. Then the 
galK marker was replaced with the CTAP cassette and CTAP-containing BACs selected by 
counter-selection against galK by growing bacteria on the GalK substrate DOG that generates 
a toxic product if galK is present. We successfully generated CTAP tagged NURF301-A/B 
and NURF301-C constructs for both the large CH321 BAC and small CH322 BAC rescue 
constructs.  
 
4.2.7 Generation of CTAP tagged Drosophila NURF301 transgenic flies  
As an additional tool to examine NURF distribution in cells and on chromatin, we generated 
CTAP-tagged NURF301-A/B and CTAP-tagged NURF301-C BAC constructs for injection 
into flies as described above. Using the φC31 integrase system (Venken et al., 2006; Bischof 
et al., 2007), embryo injection was performed with purified BAC constructs into embryos of 
y
1
 M{vas-int.Dm}ZH-2A w
*
; M{3xP3-RFP.attP}ZH-86Fb mothers expressing the φC31 
integrase in germline cells. However, the survival rate of injected embryos was too low and 
no transgenic flies were recovered. We suspected that the BAC DNA samples purified using 
standard plasmid DNA midi-prep kit contained low level of endotoxin, which could affect the 
survival of embryos after injection. To resolve this, we utilized endotoxin-free plasmid DNA 
midi-prep reagents (Macherey-Nagel) to purify BAC DNA and performed injections again. 
This time, survival rate of larvae was increased up to 20-25 %, and injection of CH322 
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construct delivering smaller size of Nurf301 genomic DNA in the BAC had a better survival 
rate than that of the CH321 construct. Red-eyed transgenic founder lines were obtained. We 
generated CTAP tagged NURF301-A/B: three different lines of CH321 and seven lines of 
CH322 from injection of 500 embryos for each construct. We also generated CTAP tagged 
NURF301-C: one line of CH321 and three lines of CH322 from injection of 500 embryos for 
each construct. 
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4.2.8 Functional discrimination of NURF301-A/B and NURF301-C isoforms  
4.2.8.1 Visualization of CTAP tagged NURF301-A/B and NURF301-C distributions on 
polytene chromosomes 
The CTAP-tagged NURF301-A/B and C transgenic flies we generated above (see 4.2.7) were 
used to confirm distributions of NURF301-A/B and C isoforms in cells. We first performed 
immunostainings of salivary gland polytene chromosomes using anti-protein G antibodies that 
recognise the CTAP tag to show the distributions of the NURF301-A/B and NURF301-C 
isoforms on polytene chromosomes. As shown in figure 4-12, both NURF301-A/B and C 
were localized to interbands or the interface between bands. However, comparisons of anti-
protein G antibody staining indicated that the relative expression of the NURF301-A/B 
isoform was lower than that of the NURF301-C isoform (Figure 4-14 A and B). This was 
more apparent when double immunostaining of either NURF301-A/B or NURF301-C strains 
was performed using anti-protein G antibodies (to detect tagged proteins) and anti-NURF301 
antibodies (to detect all NURF301 isoforms). Merged images of the NURFA/B or NURF301-
C tag staining together with the anti-NURF301 staining (Figure 4-14 C and D) suggests that 
the NURF301-C isoform is the predominant variant on polytene chromosomes. More bands 
are shared between NURF301-C-CTAP and anti-NURF301 (visible as yellow merged bands) 
than with NURF301-A/B-CTAP and anti-NURF301.  
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Figure 4-14. Immunostaining of polytene chromosome to reveal the distributions of the 
NURF301-A/B and NURF301-C isoforms. A) Double immunostaining of polytene 
chromosomes from the CH322 NURF301-A/B CTAP transgenic line that expresses CTAP-
tagged NURF301-A/B. Anti-protein G antibody reveals the CTAP tag, anti-NURF301 
antibodies (show all NURF301 isoforms). DAPI staining reveals DNA. (B) Double 
immunostaining of polytene chromosomes from the CH322 NURF301-C CTAP transgenic 
line that expresses CTAP-tagged NURF301-C. Anti-protein G antibody reveals the CTAP tag, 
anti-NURF301 antibodies. (show all NURF301 isoforms. DAPI staining reveals DNA. (C,D) 
Merged images of the corresponding panels in A and B to show tag and anti-NURF301 
overlap and overlap between DAPI and tags. Higher magnifications of chromosome arms are 
shown on the right to allow better discrimination of chromosome banding patterns. Scalebar 
represents 50 m. 
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To determine whether there are any localization sites specific for either NURF301-A/B or 
NURF301-C isoform, magnifications of double immunostained polytene chromosome arms 
described above (Figure 4-14 C and D, right) were shown as “split” chromosome images. 
Displaying multiple staining patterns in a ‘‘split’’ format helps avoiding visual artefacts when 
high levels of one protein can mask low levels of another (Corona et al., 2004; Wysocka et al., 
2006). We identified some NURF301-A/B or NURF301-C isoform specific binding sites by 
looking for bands that are detected by anti-NURF301 staining but were not present in anti-
protein G staining that targets the CTAP tagged NURF301-A/B or NURF301-C isoforms. As 
expected, more NURF301-C isoform specific sites were identified on chromosome arms 
(Figure 4-15 A). Relatively few NURF301-A/B isoform specific sites were found on 
chromosome arms when using the NURF301-C CTAP transgenic line(Figure 4-15 B) which 
were double immunostained using anti-protein G and anti-NURF301 antibodies. Most of 
those sites were non-overlapping but specific to the NURF301-A/B or NURF301-C isoforms. 
This could mean that NURF301-A/B and NURF301-C isoforms work independently on 
chromatin as NURF301-C isoforms do not contain PHD1, PHD2 and the bromodomain, 
which are critical to interact with histone modifications we identified above. However, it was 
difficult to conclude this given the level of resolution provided by immunostaining. To 
confirm this, these results need to be validated by more precise and high resolution mapping 
techniques such as ChIP sequencing, which will be discussed in chapter 4.2.9. 
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Figure 4-15. Double immunostained chromosome arms are shown as "split" 
chromosome images. Distribution of (A) the NURF301-A/B isoform (red) and anti-
NURF301 antibody staining (green), (B) NURF301-C isoform (red) and anti-NURF301 
antibody staining (green) on salivary gland polytene chromosome arms from CH322 
NURF301-A/B CTAP and CH322 NURF301-C CTAP transgenic lines respectively. The 
"spilt" images are also shown in black and white (below) for better discrimination of banding 
patterns, which are not distinguished in the color image. The white and yellow arrowheads 
indicate the bands missing in anti-protein G antibody staining, but yellow shows more 
significant bands. Scalebar represents 20 m. 
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4.2.8.1.1 Visualization of histone H3K9ac, H3K9acS10p and NURF301-A/B isoform 
distributions on polytene chromosome by immunostaining 
As shown in figure 4-9, some of bands on polytene chromosomes recognized by anti-
NURF301 staining colocalized with histone H3K9ac sites. However, it was unclear whether 
the NURF301-A/B isoform was responsible for this colocalization with H3K9ac, as the 
antibody we used recognized both NURF301-A/B isoform and the NURF301-C isoform 
which lacks the PHD2 domain. Using the NURF301-A/B CTAP transgenic line we generated, 
we could resolve this as we could specifically visualize the NURF301-A/B isoform with 
respect to the histone H3K9ac and phospho-acetyl H3K9ac/S10p modifications on polytene 
chromosomes. 
 
Double immunostainings of polytene chromosomes from the NURF301-A/B CTAP transgenic 
line were performed. As we identified previously, the NURF301-A/B isoform was localized 
mainly at interbands or the interface between bands. Histone H3K9ac and H3K9ac/S10p 
modifications were detected at numerous loci over the polytene chromosomes, but 
H3K9ac/S10p displayed a more restricted distribution (Figure 4-16 A and B). We observed 
clear overlap between NURF301-A/B isoform binding sites and the distribution of the 
H3K9ac or H3K9ac/S10p modifications (Figure 4-16 C and D), in comparison to the previous 
anti-NURF301 staining performed previously (Figure 4-9 B, left). Unlike the previous anti-
NURF301 staining, no bands that were only stained by anti-protein G antibody staining were 
detected. These data confirmed that recruitment of the full-length NURF301-A/B isoform to 
chromatin could be correlated with the presence of histone H3K9ac or H3K9ac/S10p 
modifications. 
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Figure 4-16. The full-length NURF301-A/B isoform colocalizes with the histone H3K9ac 
and H3K9ac/S10p modifications. The double immunostained chromosome images show the 
distributions of histone H3K9ac, H3K9ac/S10p modifications and the CTAP-tagged 
NURF301-A/B isoform (revealed by anti-protein G antibody). (A) Double immunostaining 
images of H3K9ac, NURF301-A/B and DAPI on polytene chromosome and (B) 
H3K9ac/S10p, NURF301-A/B and DAPI on polytene chromosomes from CH322 NURF301-
A/B CTAP transgenic line shown in separate panels in black and white. (C) Merged double 
immunostaining images of the NURF301-A/B isoform (red)/H3K9ac (green) and NURF301-
A/B isoform (red)/DAPI(purple), (D) NURF301-A/B isoform (red)/H3K9ac/S10p (green) and 
NURF301-A/B isoform (red)/DAPI(purple). Arrowheads indicate the male X-chromosome. 
Higher magnification images of the chromosome arms are shown on the right to better 
discriminate chromosome banding patterns. Scalebar represents 50 m. 
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4.2.8.2 Identification of localization of NURF301-A/B and NURF301-C isoforms in male 
testes and ovaries by immunostaining 
Previous research in the laboratory and by other groups has shown that NURF301 is required 
for testis and ovary development (Kwon et al., 2009; Cherry and Matunis, 2010; Ables and 
Drummon-Barbosa, 2010). In the male testis, spermatogenesis begins with germline stem cell 
division to produce a new stem cell and a gonialblast. The gonialblast then undergo four 
rounds of mitotic amplification divisions to generate 16 primary spermatocytes. This is 
followed by two meiotic divisions after which, spermatid differentiation occurs and mature 
sperm are produced (reviewed in Fuller, 1998). Previous data indicated differential 
requirements for the two NURF301 isoforms during testes development, with NURF301-C 
required for germline stem cell development and NURF301-A/B required for maturation of 
spermatocytes and oocytes (Kwon et al., 2009). One explanation for differential requirements 
of the two NURF301 isoforms at different stages of testis development is that these isoforms 
may be differentially expressed in testes tissues. To resolve this, we examined the distribution 
our CTAP tagged NURF301-A/B and NURF301-C isoforms respectively by immunostaining 
of testes.  
 
As shown in figure 4-17 A, the majority of NURF301-A/B staining was observed at later 
stages in primary spermatocytes and their descendants suggesting that NURF301-A/B 
isoforms more likely to be involved in later stage of spermatogenesis. In contrast, NURF301-
C isoforms were highly expressed at all stages including in germline stem cells and 
gonialblasts as well as primary spermatocytes (Figure 4-17 B). These data suggest that 
differential expression of the NURF301 isoforms accounts for the previously observed 
isoform tissue dependencies.  
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Figure 4-17. Different localizations of NURF301-A/B and NURF301-C isoforms 
observed in Drosophila male testes. CTAP tagged NURF301-A/B and NURF301-C 
transgenic fly male testes were dissected and immunostainined using anti-protein G antibody. 
DNA was visualized by DAPI staining. (A) NURF301-A/B isoform (green) and DAPI (red), 
(B) NURF301-C isoform (green) and DAPI (red). Schematic of spermatogenesis is indicated 
by yellow arrowheads: (a) germline stem cells, (b) gonialblasts, (c) primary spermatocytes. 
Scalebar represents 100 m. 
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We next tested whether the same differential expression was observed during ovary 
development. During ovary development, germline stem cells at anterior tip begin asymmetric 
divisions that give rise to one daughter stem cell and one cytoblast. The cytoblast then 
undergoes four rounds of cell division generating a cyst of 16 cells, one of which 
differentiates as oocyte while the other 15 cells become nurse cells (reviewed in Bastock and 
St Johnston (2008)). We tested whether the distributions of the NURF301-A/B and 
NURF301-C isoforms were distinct by immunostaining CTAP tagged NURF301-A/B and 
NURF301-C transgenic female ovaries. Unlike testes, the distribution of NURF301-A/B and 
NURF301-C isoforms in ovaries were similar. In each ovariole, we observed high levels of 
expression anteriorly in stem cells. For both isoforms expression was reduced in maturing egg 
chambers although expression of the NURF301-C isoform appeared to be higher (Figure 4-18 
A and B, left and middle panels). At vitellogenic stages staining of both NURF301-A/B and 
NURF301-C were lost from nurse cell nuclei but high level expression was retained in the 
nucleus of the single cell that has been singled out to become the oocyte (Figure 4-18 A and B, 
right panels). These results suggest that the both NURF301-A/B and NURF301-C isoforms 
could be involved in stem cell differentiation as well as oocyte differentiation and 
maintenance. 
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Figure 4-18. Similar localization of NURF301-A/B and NURF301-C isoforms in 
Drosophila female ovaries. CTAP tagged NURF301-A/B and NURF301-C transgenic fly 
female ovarioles were dissected and immunostainined using anti-protein G antibody. DNA 
was visualized by DAPI staining. (A) NURF301-A/B isoform (green) and DAPI (red), (B) 
NURF301-C isoform (green) and DAPI (red). The yellow arrowheads indicate the oocyte 
nuclei. Scalebar represents 50 m. 
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4.2.9 ChIP sequencing 
4.2.9.1 ChIP-seq DNA library preparation of NURF301-A/B and NURF301-C isoforms 
and work flow analysis (WFA)  
To map and accurately characterize the NURF isoforms-DNA interactions of an entire 
genome, we performed ChIP sequencing using CTAP tagged NURF301-A/B and NURF301-
C hemocytes. The samples were also prepared male and female separately to determine 
whether NURF301 isoforms have any characteristics of sex dependent regulation of gene 
expression as we observed such properties in our testes/ovaries immunostaining (see Figure 4-
17 and Figure 4-18). 
 
DNA for sequencing on the SOLiD sequencer needs to be fragmented in the range 100-300 bp 
for optimal sequencing. We used two approaches to fragment ChIP DNA for library 
preparation: i) sonication of chromatin using a Covaris S2 Adaptive Focused Acoustics 
ultrasonicator followed by DNA size selection or ii) micrococcal nuclease (MNase) digestion 
of chromatin to generate mononucleosome sized 146 bp DNA fragments.  
 
CTAP tagged NURF301-A/B male/female and NURF301-C male/female hemocyte samples 
were used for ChIP-seq DNA library preparations, and cross-linked chromatin was first 
sheared by sonication using Covaris. However, we were unable to obtain enough 
immunoprecipitated DNA after purification for library preparation (data not shown). This may 
be due to fragmentation of NURF301 as well as DNA during Covaris ultrasonication and the 
separation of antibody epitopes and DNA-crosslinking sites. To circumvent this, we next 
performed MNase digestion of cross-linked chromatin and were able to obtain reasonable 
amount of immunoprecipitated DNA. This was converted into P1 adaptor/barcode ligated 
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sequencing libraries, PCR amplified and purified. FlashGel electrophoresis of the resultant 
ChIP DNA libraries indicated that they were sized in the region of 250 bp, the expected size 
of a library that includes 146 bp MNase digested mononucleosomes and ~100 bp of 
adaptor/barcode fragments (Figure 4-19). 
 
 
Figure 4-19. FlashGel image showing purified barcoded ChIP DNA libraries. Each lane 
is labeled with the barcode (BC) number of the library sample (BC 1: NURF301-A/B male, 
BC 2: NURF301-A/B female, BC 3: NURF301-C male, BC 4: NURF301-C female, BC 5: 
NURF301-A/B input female, BC 6: NURF301-C input male). Purified library DNA was 
quantified as indicated. 
 
Templated beads were prepared using equal amounts of barcoded DNA fragment libraries 
were pooled into a single sample, and quality of templated beads was determined by work 
flow analysis (WFA) prior to full sequencing. We prepared two different sets of beads and so 
ran two WFA analyses. The first set of WFA data is shown in figure 4-20A and the second set 
is shown in figure 4-20 B. The quality of beads could be graphically visualized on a Satay 
plot (Figure 4-20 A and B above). These plots show the relative intensities of the signals for 
each bead and how well separated the signal is across the four fluorecent dye channels in four 
axes in a X, Y two dimension (red: Cy5, yellow: Texas Red, green: Cy3 and blue: 6-FAM). 
The P2:P1 ratio of our templated beads was in optimal level of 95-97%, which assess the 
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efficiency of emulsion and enrichment of template positive beads. The noise to signal ratio 
(N2S) was 11-16%, and beads on-axis were 56-64% which could have been higher for better 
sequencing. Titration meric value, which is percentage of P2 positive beads times percentage 
of beads on axis, was 53-62% lower than we expected. The Satay plot displayed these bead 
spectral purity and signal intensity graphically (Figure 4-20 A and B). In total, templated 
beads were qualified and applied to run full sequencing based on this data.  
 
 
Figure 4-20. WFA run report shows the quality of templated beads. Two different sets of 
beads were prepared (A) and (B), and the data displays P2_Rfu, P2_Exp, P2_Gain, P1 
positive beads, P2 positive beads, P2/P1 ratio, noise to signal ratio (N2S), beads on axis and 
titration metric value. 
 
4.2.9.2 ChIP sequencing and peak calling 
ChIP DNA libraries were sequenced on a SOLiD 4 genome analyser. Libraries were 
sequenced using a SOLiD ToP Fragment Barcoded Sequencing Kit MM50/5 (Life 
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Technologies). Beads in the pool are first assigned to a ChIP library after 5bp barcode 
sequencing, based on the unique barcode adaptor used to generate each library. Thereafter a 
50bp read is produced from every DNA fragment and assigned to the correct ChIP library 
based on the initial barcode sequence. Quality control of the sequencing run was analyzed 
using the SETS (Solid experiment trafficking system) software of the SOLiD 4 analyzer. The 
total number of reads generated for each library are shown in Table 4-1 (The 1st column). 
Subsequently the 50 bp DNA sequence reads were mapped onto the reference Drosophila 
genome (release dm3) using either local mapping parameters in the Bioscope software (Life 
Tecnologies). The total number of reads mapped for each library are shown in Table 4-1 (The 
2nd column). It is noteworthy that with the exception of Input DNA samples, mapping 
percentages were low (Table 4-1, the 3rd column shaded yellow), suggesting that ChIP-DNA 
libraries may have been contaminated by adaptor-dimers, which are prevalent when small 
amounts of DNA are used for library preparation. Mapped reads were also filtered for high 
quality reads using Samtools (Li et al., 2009) which resulted in even greater loss of mapping 
reads as shown in Table 4-1 (The 4th and 5th column shaded green). 
 
Table 4-1. ChIP sequencing map reads 
Library Total reads Mapped reads % Mapped Filtered reads % Filtered 
NURF301-A/B 
Input (Female) 
36,543,183  9,488,788  25.97  3,272,750  8.96  
NURF301-A/B 
Male 
92,241,527  2,404,941  2.61  993,940  1.08  
NURF301-A/B 
Female 
77,317,411  1,921,861  2.49  760,217  0.98  
NURF301-C 
Input (Male) 
44,791,213  8,294,403  18.52  3,148,436  7.03  
NURF301-C 
Male 
76,033,813  4,297,962  5.65  3,148,436  4.14  
NURF301-C 
Female 
86,147,157  4,931,614  5.72  2,771,168  3.22  
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Even though mapped read numbers were low, especially for NURF301-A/B ChIP samples, we 
attempted to call genome-wide peaks of NURF301-A/B and NURF301-C. Peaks were 
identified using the MACS programme (Zhang et al., 2008). MACS ChIP wiggle tracks were 
then used to generate averaged genome profiles of the distribution of the NURF301-A/B and 
NURF301-C peaks using the CEAS (Cis-regulatory Element Annotation System) script of the 
Cistrome package (Liu et al., 2011). 
 
Due to the low number of mapped and filtered reads that were obtained, ChIP profiles did not 
allow NURF recruitment at individual genes to be analyzed in any detail due to the low 
sequence tag coverage. However, we did attempt to extrapolate information on NURF 
recruitment by generating gene-averaged profiles. Using CEAS we were able to average 
NURF301-A/B and NURF301-C signals over all genes with respect to either transcription 
start sites (TSSs), transcription termination sites (TTSs) or by performing meta-gene analysis 
were all genes are artificially expanded or compressed to fit a hypothetical gene structure 
consisting of 1 kb of upstream and downstream regulatory regions and 3 kb of coding 
sequence. The averaged profiles of NURF301-A/B suggested that it was enriched at the TSS 
and TTS in both male and female samples (Figure 4-21, A and B). A peak of high occupancy 
of NURF301-C was seen around the transcription termination site (TTS) and flanking the 
transcription start site (TSS) in both male and female (Figure 4-22, A and B). Meta-gene 
analysis appears to indicate that there is a trend of increased enrichment of both NURF301-
A/B and NURF301-C towards the 3' end (TTS), indicating that they might exhibit more 
remodelling functions at transcription termination regions (Figure 4-21 and Figure 4-22, 
average gene profiles). However, it is important to restate that sequence coverage is low and 
ChIP efficiency would need to be increased to generate more sequence reads to allow NURF 
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ChIP profiles to be determined with any confidence. The low sequence coverage obtained 
makes profiles generated susceptible to mapping artefacts. 
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Figure 4-21. Average ChIP-seq read density profiles of the NURF301-A/B isoform. 
NURF301-A/B distribution is plotted relative to transcription start sites (TSS) and 
transcription termination sites (TTS). Both (A) male and (B) female show similar patterns.  
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Figure 4-22. Average ChIP-seq read density profiles of NURF301-C isoform. NURF301-
C distribution is plotted relative to transcription start sites (TSS) and transcription terminate 
sites (TTS). Both (A) male and (B) female show similar patterns. 
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4.3 Conclusion 
Immunostaining data of different cell types is consistent with our in vitro data of interactions 
between the NURF and histone modifications. We first examined the distributions of 
NURF301, its primary recognition mark H3K4me3, and H3T3p, a postulated flanking 
inhibitory mark, by immunostaining of wild-type (w
1118
) embryos. We observed that 
H3K4me3 was present in both interphase and mitotic cells in embryos after cellularization. 
NURF301 colocalized with H3K4me3 during interphase, but NURF301 was ejected from 
chromatin during mitosis. This corresponded with an increase in the H3T3p modification, 
which was highly expressed during metaphase and anaphase when NURF was absent from 
chromatin. These data were validated by double immunostaining of NURF and 
H3T3p/K4me3 showing no colocalization of NURF with H3T3p/K4me in dividing cells of 
embryos and neuroblasts, suggesting NURF301 could be delocalized by phosphorylation of 
H3T3 during mitosis. 
 
Immunostaining of non-mitotic interphase chromosomes from wild-type (w
1118
) larvae were 
also performed to analyse in vivo localization of NURF301, and the H3K9ac and 
H3K9ac/S10p modifications, which are postulated to be flanking enhancers of NURF binding 
to H3K4me3. NURF was mainly detected at interbands or the interface between bands. 
H3K9ac and H3K9ac/S10p were observed at numerous loci not only interbands but also 
DAPI stained bands. By double immunostaining of polytene chromosome, we observed that 
the NURF301 and H3K9ac colocalized at some interband sites, but NURF301 localization 
was not completely affected by loss of the H3K9ac modification in dGcn5 mutants. However, 
we later showed that the NURF301-A/B isoform colocalized well with H3K9ac and 
H3K9ac/S10p. This suggested that localization of full-length NURF301-A/B isoform 
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containing PHD2 domain, as we found interacting with those markers in vitro, could be 
affected by the presence of H3K9ac or H3K9ac/S10p modifications. 
 
We also attempted to verify that NURF301 binds the histone H3K23me3 modification, which 
was found as a primary recognition mark of the PHD1 domain. In a first series of experiments, 
the in vivo distribution of H3K23me3 was analysed by immunostaining of embryos, testes and 
ovaries. However no staining was detected using the available anti-H3K23me3 antibody. 
However, characterization of the binding specificity of this antibody using histone peptides 
suggested that this antibody is only capable of recognizing the H3K23me3 modification in the 
context of N-terminally clipped histone H3. Without alternative antibodies, the absence of 
staining prevents us from concluding whether this modification is truly absent or not 
detectable.   . 
 
For more functional analysis of these domains, we tried to generate serial deletions of the C-
terminus of Nurf301 by transposon excision. This would generate a sequential deletion series 
of Nurf301 deletion mutants in which chromatin-targetting domains were progressively 
deleted. However, these experiments failed to generate a progressive series of mutants as 
transposon insertion hotspots near to the Nurf301 C-terminal region resulted in a stepped 
series of deletions. However, we have established the BAC recombineering system which will 
allow us to engineer Nurf301 deletions more precisely and efficiently. We have used this 
system to generate C-terminally CTAP epitope-tagged variants of the NURF301-A/B and 
NURF301-C isoforms. We have used transgenic flies that express these to further analyse in 
vivo function and localization of NURF301. We expect this optimized system will also allow 
us to generate BAC constructs in which the PHD, PHD1, PHD2 and bromodomain can be 
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selectively deleted to examine function and targeting requirements.  
 
By using the CTAP tagged NURF301-A/B and NURF301-C transgenic lines we could  
discriminate the function of the two NURF301 isoforms in different cell types. 
Immunostainings of polytene chromosome NURF301-A/B and NURF301-C revealed that 
each isoform had specific and independent binding sites on chromatin. Moreover, in testes 
immunostaining, NURF301-A/B was observed to be expressed only at late stages of 
spermatogenesis in contrast to NURF301-C which was broadly expressed in germline stem 
cells and primary spermatocytes. These data indicate that alternative splicing of Nurf301 can 
generate distinct chromatin remodelling complexes. We suggest that these complexes have 
unique functions as a result of differential chromatin targeting as well as differential tissue 
expression.  
 
To extend our understanding of genome wide localizations of NURF301-A/B and C 
accurately, ChIP sequencing was performed using CTAP tagged NURF301-A/B and 
NURF301-C hemocytes. Although it was possible to generate gene averaged NURF profiles, 
the low sequence coverage precluded detailed analysis of NURF301-A/B or NURF301-C 
isoforms and comparisons with histone modifications. 
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CHAPTER 5. DISCUSSION 
5.1 The recruitment and function of NURF is influenced by histone modifications 
In this study, we analysed the full histone modification-binding specificities of the NURF301 
PHD domains and bromodomain by using modified histone peptide library arrays and peptide 
pull down assays containing individual modifications and combinations of histone 
modifications.  
 
5.1.1 Modified histone binding specificity of the PHD2 domain 
In the case of PHD2 domain, we observed clear binding specificity for histone H3 tri-
methylated Lys 4 as previously identified (Li et al., 2006; Wysocka et al., 2006, Kwon et al., 
2009). No binding was observed to any other singly-modified histone tails on arrays. This is 
significant as it was previously speculated that the NURF301/BPTF PHD2 domain may also 
recognize other methylation states of the H3K4 residue, for example H3K4me2 (Sims and 
Reinberg, 2006). However, our binding studies using two different sets of peptide arrays are 
consistent with specific recognition of H3K4me3 over H3K4me2.   
 
In addition, we found that the binding of the PHD2 domain to H3K4me3 was able to be 
inhibited by phosphorylation of flanking Thr 3, and enhanced by acetylation of Lys 9 and 
phosphorylation of Ser 10. The enhancement of binding by the H3K9ac modification is 
consistent with recent MS (mass spectrometry) based proteomic analysis revealed that BPTF 
binding to H3K4me3 was increased by H3K9ac (Vermeulen et al., 2010). These studies did 
not discriminate the mechanism of this enhancement. It was possible that binding of the 
double marks was mediated by distinct domains such as the PHD2 and bromodomains. 
However, our data conclusively shows that this enhancement is mediated through the single 
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PHD2 domain and that H3K9ac modifies the binding of the PHD2 domain to H3K4me3. Our 
structural modelling indicates the existence of favourable charge interactions that stabilise 
binding of the PHD2 domain H3K4me3/K9ac/S10p peptides. It is important to note that 
binding to H3K9ac and H3S10p is not observed unless the H3K4me3 mark is present. 
H3K4me3 is the primary target of the PHD2 domain with other modifications acting as 
rheostats to increase or decrease binding. These data are consistent with studies of other 
remodelling complexes, such as the RSC complex, which identified that recruitment of RSC 
can be increased by specific acetylation at histone H3 Lys 14 (H3K14ac) (Ferreira et al., 
2007).  
 
In contrast, we have clearly established that phosphorylation of the Thr3 residues is able to 
inhibit the binding of the PHD2 domain to H3K4me3. Our structural modelling suggests that 
this is the result of unfavourable charge interactions between H3T3p and negatively charged 
residues in the H3K4me3 binding pocket. Phosphorylation of H3T3p provides a convenient 
mechanism by which binding of NURF to H3K4me3 could be masked in a regulated manner, 
without requiring the removal of H3K4me3. Our data suggest that this may be responsible for 
controlling chromatin targeting of NURF during mitosis. While we have not been able to test 
this model by removing the kinase the deposits H3T3p (Haspin), analysis of NURF and 
H3T3p distribution indicates an inverse relationship. During mitosis high levels of H3T3p and 
H3T3pK4me3 are detected. At these stages NURF is ejected from chromatin.  
 
The NURF301 PHD2 finger provides another example of an emerging theme in methylated 
histone tail recognition, namely the existence of so called “phospho-methyl switches” that can 
regulate methylated histone tail recognition, blocking tail binding without requiring the 
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removal of the methylated lysine residue. This crosstalk has been suggested in several studies 
including regulation of HP1 (heterochromatin protein 1) (Fischle et al., 2005; Hirota et al., 
2005), PRC2 (polycomb repressive complex 2) (Gehani et al., 2010; Lau and Cheung, 2011), 
the WDR5 subunit of MLL1 (Couture et al., 2006; Ruthenburg et al., 2006) and the TAF3 
subunit of TFIID (Varier et al. 2010).  
 
5.1.2 Modified histone binding specificity of the PHD1 domain 
The PHD1 domain, which shows high sequence similarity to PHD2 domain (Figure 1-8), had 
also clear binding specificity for tri-methylated Lys 23 residue of histone H3. Initial reports 
suggested that this domain was only present in Drosophila NURF301 and not in human BPTF 
(Wysocka et al., 2006), but here we have identified an exon in human BPTF that encodes 
PHD1. This raises the possibility that human BPTF may exist in multiple splice variants and 
that alternative splicing of the PHD1 domain may generate human NURF complexes that 
have distinct modified histone recognition profiles. Research in our laboratory has shown that 
Drosophila NURF301 is controlled by alternative splicing (Kwon et al., 2009) and multiple 
splice variants of C. elegans NURF301 have been shown to occur (Andersen et al., 2006). 
Although alternative splicing of human BPTF has not previously been reported, splice 
variants of the SNF2L catalytic subunit have been reported (Barak et al., 2004). This data 
contributes to an emerging concept in chromatin remodelling that suggest that functionally 
diverse tissue- or stage-specific variants of chromatin remodelling complexes exist. These can 
be generated either by alternative splicing of core subunits as we have shown for NURF, or by 
the flexible incorporation of subunits in the case of SWI/SNF complexes (Olave et al., 2007; 
Lessard et al., 2007; Ho et al., 2009; Vogel-Ciernia et al., 2013).  
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The biological function of H3K23me3 has not been fully characterized, although there are 
suggestions that H3K23me3 is present on heterochromatic H3 from Tetrahymena, and that 
levels are increased during meiosis in Tetrahymena micronuclei (Papazvan et al., 2013). We 
have used the only available anti-H3K23me3 antibody to determine the distribution of 
H3K23me3 in Drosophila but are unable to detect a response. It is possible that the 
modification is absent from Drosophila, however our peptide dot blot analysis suggests that 
the antibody is affected by the presence of residues N-terminal to position K18 and thus may 
not recognise unclipped histone tails. This histone H3 tail clipping has been found in several 
organisms such as yeast, chicken, and humans and is suggested to regulate gene expression 
and histone modifications by removing the histone H3 N-terminal region (Santos-Rosa et al., 
2009; Mandal et al., 2013). In Drosophila, however, it is possible that histone H3 tail clipping 
activity is not prevalent, so the anti-H3K23me3 antibody was not able to recognize the 
H3K23me3 modification. 
 
Inspection of the histone H3 tail sequence reveals interesting parallels between the H3K4 and 
H3K23 residues. As shown in figure 5-1A, the H3K23 residue is flanked by an identical set of 
residues that we have shown can influence binding of PHD2 to H3K4me3. We speculate that 
the PHD1 binding to H3K23me3 could be able to be inhibited by phosphorylation of flanking 
Thr 22, and enhanced by acetylation of Lys 27 and phosphorylation of Ser 28. The absence of 
reagents (antibodies) that would allow us to detect these residues precludes further in vivo 
analysis of these modifications, however, it would be tempting to speculate the binding of 
PHD1 to multiply modified H3K23me3 peptides would be regulated by flanking T22 
phosphorylation and phosphoacetylation of H3K27 and H3S28. Inspection of the amino acid 
sequence of the PHD1 domain compared with the PHD2 domain shows that core tri-
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methylated lysine binding pocket residues (Y10, Y17, Y23, W32) are conserved as expected. 
However, charged residues, that we previously speculated hinder or interact with negatively 
charged phosphate groups of H3T3p and H3S10p, are divergent (Figure 5-1 B). In the PHD1 
domain, some of the negatively charged residues (E44, E46, D49 and E50 in PHD2) which 
we showed could repulse negatively charged H3T3p and inhibit PHD2 binding to H3K4me3, 
are conserved, but two positively charged lysine residues (K46, K47 in PHD1) also exist that 
could favour binding with a phosphate group on H3T22 and thus enhance the binding of 
PHD1 to H3K23me3. Moreover, one of the positively charged residues (R36 in PHD2) which 
we speculated interacted with negatively charged H3S10p, was changed to a negatively 
charged residue in the PHD1 domain (D36 in NURF301 PHD1 and E36 in BPTF PHD1). 
This suggests that flanking phosphorylation at Ser 28 may not enhance the binding of the 
PHD1 domain to H3K23me3, but reduce binding. Thus it is possible that the PHD1 domain 
binding to H3K23me3 may be regulated by phospho-methyl and phospho-acetyl switches but 
in an opposite manner to PHD2 binding to H3K4me3. 
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Figure 5-1. Protein sequence alignment of histone H3 N-terminal sequence and 
PHD2/PHD1 domains. (A) N-terminal sequence alignment of H3 (1-19) and (20-37) shows 
conservation of modification target residues that flank H3K4 and H3K23. (B) PHD2 and 
PHD1 domain sequence alignment shows conserved trimethyl lysine-binding residues (green), 
while positively charged residues (blue) and negatively charged residues (red) which could 
interact with flanking phosphorylation vary. 
 
5.1.3 Modified histone binding specificity of the Bromodomain 
The C-terminal bromodomain showed more enhanced binding to multiply acetylated H4 (K5, 
K8, K12, K16) compared to the single H4 K16 acetylation. This property of bromodomains 
was also found in recent study showing high-affinity binding of the BRDT bromodomain to 
multiple acetylated histone tails (Morinière et al., 2009; Filippakopoulos et al., 2012). 
Analysis of the crystal structures of bromodomains in a complex with multiply acetylated 
histone tails suggests that the bromodomain is only able to bind to two acetylated residues at 
any one time (Morinière et al., 2009; Filippakopoulos et al., 2012). The bromodomain does 
not bind simultaneously to all the acetylated residues on tetra-acetylated histone tails, rather it 
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is more likely that the bromodomain is in rapid exchange between flanking di-acetylated 
residues. The apparent increase in binding to the tetra-acetylated histone tails can be 
explained as an effect on avidity rather than affinity. Effects on avidity are frequently used to 
describe antibody-antigen interactions in immunology. "Affinity" is the strength of binding of 
one molecule to a substrate, while "Avidity" is the sum of total strength of binding of more 
than one molecule to substrates. They are not separate concepts but correlated, as the strength 
of "Avidity" depends on the "Affinity" and the valency of interactions (Murphy et al., 2008). 
Therefore, binding preference of NURF301 bromodomain to multiply acetylated histone H4 
tails might be correlated to the high "Avidity" of the bromodomain binding pocket that has 
"Affinity" for two acetylated lysines on histone H4 tail. 
 
5.1.4 Modified histone binding specificity of the N-terminal PHD domain 
Our data suggests that the PHD domain does not have clear modified-histone binding 
specificity, but binds generally the free N-terminal tails of H4. This is consistent with BLAST 
comparison of the NURF301 PHD domain that indicated that the PHD domain is most similar 
to the PHD domains BHC80 (also known as PHF21A, a plant homeodomain (PHD) finger-
containing protein, Lan et al., 2007) and AIRE (Human autoimmune regulator, Koh et al., 
2010) both of which have been shown to bind to unmodified histone tails. However, the 
observed binding interactions of the PHD domain were weak and it is equally possible that 
the PHD domain may serve no strong role in nucleosome recognition. The PHD may act as a 
protein-protein interaction surface that serves a structural role in the organisation of the 
NURF complex. Alternatively, it is possible that the PHD domain acts as the reader of as yet 
unknown ligands. Early reports suggested that the PHD domain of ING2 could bind to 
nuclear phosphoinositides (Gozani et al., 2003), providing an attractive mechanism by which 
chromatin remodelling activity could be regulated by signal transduction pathways. 
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5.1.5 Multivalent histone recognition by NURF 
An important question is whether the modified histone binding specificities observed using 
the isolated PHD and bromodomains are the same as those of the full-length NURF301 or the 
assembled NURF complex. It has been shown that the modified histone recognition of the 
tandem PHD domains of the muscle regulator DPF3 is not shared by the individual PHD 
fingers (Lange et al., 2008). We have not exhaustively addressed this issue by expressing all 
combinations of PHD fingers and bromodomains, however, in the case of PHD1 and PHD2 
we have been able to show that a tandem PHD1+PHD2 GST fusion protein shows binding to 
modified histone peptide arrays that is a composite of the binding specificities of the 
individual domains (data not shown). New recognition specificities were not observed.  
We believe that the modified histone recognition of full-length NURF301 and the NURF 
complex will be a composite of the modified histone binding of the individual domains. In 
combination histone tail recognition by the PHD2 and PHD1 fingers and the bromodomain 
will allow the recognition of multiply-modified nucleosomes and stabililise binding through 
increased valency of interaction. As shown in figure 5-2, this allows the construction of 
detailed models of recruitment and interaction of NURF301 with nucleosomes via the PHD 
domains and bromodomain (Figure 5-2). Some support for this is provided by the analysis of 
interactions between H3K4me3 and H4K16ac where our laboratory has shown overlap 
between these marks and NURF in vivo (Kwon et al., 2009) and in vitro studies using 
multiply-modified nucleosomes shows enhanced recognition of H3K4me3, H4K16ac 
modified nucleosomes by BPTF (Ruthenburg et al., 2011). We speculate that the presence of 
multiple protein-interaction modules could generate high target selectivity and increased 
binding affinity with substrates due to avidity through simultaneous binding of several 
interaction domains (Wu et al., 2009; Muller et al., 2011).  
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Figure 5-2. Predicted binding model of Drosophila NURF and histone modifications 
based on our data (P. Badenhorst (unpublished data)). Modified histone binding 
specificities of domains (PHD, PHD1, PHD2 and Bromodomain) may lead the NURF 
recruitment to a nucleosome as indicated.  
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5.2 NURF may interact with other epigenetic regulators: Haspin and Gcn5 
The deposition and effect of histone post-translational modifications requires many proteins 
which can be classified in three simple groups: epigenetic writers, erasers and readers (Figure 
5-3). The epigenetic "writers" attach modifications to DNA or histones (acetyl-transferases, 
methyl-transferases, kinases), "erasers" remove these marks (deacetylases, demethylases, 
phosphatases), while "readers" are proteins that are able to bind to the modifications through 
binding domains such as the PHD domain, bromodomain and chromodomain. The “readers” 
recognize specifically modified sites producing changes in gene expression (Gardner et al., 
2011). We have found that there is a close relationship between the “reader” NURF and two 
histone modification "writers" – the H3T3-specific kinase Haspin, and the H3K9 and K14 
specific acetyltransferase Gcn5. 
 
 
Figure 5-3. Schematic illustrating the concept "writer", "eraser" and "reader". The 
"writer" places PTMs on histone proteins (left), an "eraser" removes such modifications from 
histone proteins (middle), and a "reader" interacts with these covalent modifications (right) to 
mediate diverse downstream processes. Figure was adapted from Gardner et al. (2011). 
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Here we have shown that H3T3 phosphorylation blocks binding of the PHD2 domain to 
H3K4me3 by immunostaining assay in vivo. Double immunostaining of H3T3 
phosphorylation and NURF301 showed no overlap during any stage of the cell cycle 
indicating that H3T3p can act as a mark to eject NURF from chromatin. Haspin is known to 
be required to phosphorylate histone H3T3 and this modification is critical for chromosome 
condensation during metaphase (Dai et al., 2005). In previous studies, it was shown that 
Drosophila Nurf301 mutants cause aberrant structure of interphase chromosomes (Badenhorst 
et al. 2002). Surprisingly, however, metaphase chromosome structure is unaffected in Nurf301 
mutants (Badenhorst and Kwon unpublished data). As the Haspin kinase mainly affects 
metaphase chromosome structure by phosphorylation of H3T3 (Dai et al., 2005; Higgins, 
2009), it is possible that H3T3 phosphorylation by Haspin allows a switch that removes 
NURF from chromosomes by masking H3K4me3 sites that might normally recruit NURF. 
This ejection of NURF may be important in moving the cell cycle from interphase into 
metaphase.  
 
However, we have not been able to conclusively show that H3T3p is required to eject NURF 
from chromatin by either ectopically providing or removing this mark. To functionally dissect 
the interaction between NURF and Haspin we tried a number of genetic approaches to ablate 
Haspin by generating Haspin mutant flies. But neither approach including transposon excision 
mutation or X-ray mutagenesis were successful. We attempted to use RNAi-knockdown to 
ablate Haspin but existing Haspin siRNA strains were unable to reduce H3T3p levels 
indicating that Haspin levels were not affected by Haspin siRNAs when expressed in blood 
cells. One approach that may be attempted is to use inhibitors of Haspin. Recent studies have 
identified small-molecule inhibitors of Haspin that could be used for this study (De Antoni et 
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al., 2012; Wang et al., 2012). One potential concern with inhibitors is the possibility of off-
target effects when using an inhibitor. Moreover, the use of Haspin inhibitors require that cells 
are synchronized at the G2/M boundary prior to use of the inhibitor as effects are also 
observed of these inhibitors on interphase cells (De Antoni et al., 2012; Wang et al., 2012). It 
is challenging to synchronize Drosophila cultured cells which would require that these 
experiments be performed using mammalian cultured cells. Using synchronized HeLa cells 
and Haspin inhibitors the interplay of NURF and Haspin in chromosomal condensation and 
mitosis would be able to be determined.  
 
Unlike the mark/writer pair of H3T3p/Haspin, which inhibit NURF binding, we speculate that 
writers Gcn5 (the acetylase for H3K9) and Jil-1 (the H3S10 kinase, Wang et al., 2001) 
enhance binding of the PHD2 domain to H3K4me3. Our immunostaining of polytene 
chromosomes is consistent with Gcn5 and Jil-1 stabilizing NURF binding to chromatin as we 
see overlap between NURF and H3K9ac/S10p modifications. The availability of mutants 
Gcn5 has allowed use to functionally dissect whether the phospho-acetyl H3K9ac/S10p mark 
is required for NURF recruitment. We observe in our study that loss of Gcn5 influences 
localization of the NURF301 in vivo by double immunostaining of polytene chromosomes. 
This data is consistent with previously published interactions of NURF301 with the Gcn5 
containing complexes ATAC (known to acetylate K5/K12 of histone H4, Ciurciu et al., 2006) 
and SAGA (known to acetylate K9/K14 of histone H3, Carre et al., 2005) that were reported 
by Carre and co-workers (Carré et al., 2008). These authors suggested that NURF301 
interacts with the ATAC complex, which may impact on H4 tail recognition by the 
bromodomain. ATAC is also required for H4K16 acetylation, which has been shown to 
influence nucleosome sliding by ISWI which is the catalytic subunit of the NURF, ACF and 
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CHRAC complexes in Drosophila (Carre et al., 2005; Suganuma et al., 2008). However, it is 
also possible that the SAGA Gcn5-containing complexes is responsible for the affect on 
NURF301 recruitment and nucleosome remodelling. SAGA is required for H3K9ac and has 
been shown to synergise with NURF nucleosome remodelling to facilitate in vitro 
transcription of chromatin templates (Mizuguchi et al., 2001).  
 
This suggests that both Gcn5 complexes regulate the level of histone acetylation which might 
affect NURF301 binding to chromatin and remodelling activity. Altough our data suggests a 
positive correlation between histone acetylation and the recruitment and function of NURF, 
some other reports have suggested an antagonistic relationship. For example, acetylation at 
lysine 12 and 16 of the histone H4 tail have been reported to inhibit substrate recognition by 
ISWI and reduce its ATPase activity (Clapier et al., 2002; Corona et al., 2002). Although some 
workers have shown that acetylation enhances sliding by ISWI-containing remodelling 
complexes (Suganuma et al., 2008), other reports have suggested that modified 
mononucleosomes containing histone H4K16ac inhibit sliding activity by ACF (Shogren-
Knaak et al., 2006). This indicates that relationship between acetylation and chromatin 
remodelling activity is still controversial. Thus, the mechanism of how these modifications 
affect NURF remodelling activity and chromatin structural changes remains to be determined. 
For this reason, it will be of interesting to define the recruitment as well as remodelling 
activity of NURF for nucleosomes with/without these modifications. 
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5.3 Generation of epitope tagged NURF301-A/B and -C isoforms would extend our 
understanding of NURF 
Previous research in our laboratory has shown that NURF301 expresses three distinct 
isoforms: the full-length NURF301 A and B isoforms, and the C-terminally truncated 
NURF301 C isoform (Kwon et al., 2009). The existence of similar multiple splice variants of 
mammalian BPTF remains to be conclusively established but our data here indicates the 
existence of transcript variants that contain or lack reader domains such as the PHD1 domain. 
This has the potential to encode variant NURF complexes that have distinct targeting 
specificity and activity. Epitope-tagged variants of these isoforms provide important reagents 
for determining these distinct functions. Previously in our laboratory, we attempted to 
generate epitope tagged variants of the NURF301-A and NURF301-C isoforms using Nurf301 
cDNAs cloned into plasmid vectors in bacteria. However, the large size of the resultant 
plasmids and toxicity of the cDNAs meant that the bacteria grew poorly and inactivated the 
cDNA during culture (Badenhorst and Kwon unpublished data). To circumvent this, here we 
have used a more controllable expression system and genomic constructs containing introns. 
Using BAC plasmids harbouring Nurf301 genomic DNA and the GalK recombineering 
system, we successfully generated CTAP tagged NURF301-A and NURF301-C constructs. 
Those constructs have been injected to flies containing φ C31 integrase system (Venken et al., 
2006; Bischof et al., 2007) and we generated flies that express CTAP tagged full-length 
NURF301-A/B isoform and C-terminally truncated NURF301-C isoform transgenic flies. 
 
Polytene chromosome immunostaining data using these epitope tagged transgenic lines, 
showed that NURF301-A/B and NURF301-C colocalize at some regions, but genes where 
NURF301-A/B or NURF301-C did not overlap were also detected. It is possible that lack of 
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overlap at these regions may be due to technical reasons – a difference in the relative intensity 
of isoforms rather than absence of localization – but it is most likely that this reflects the, loss 
of important histone modification binding modules (C-terminal PHD1, PHD2 and 
bromodomain) in the NURF301-C isoform that restricts localization and function. This 
provides a clear example how alternative splicing could regulate chromatin modifying and 
remodelling factors by generating functionally distinct variants in which domains critical for 
function are substituted (Lois et al., 2007). These results are consistent with reports that the 
function and localization of the human NURF can be regulated by differential splicing of 
SNF2L, the catalytic subunit of human NURF (Barak et al., 2004; Lazzaro et al., 2008), and 
studies showing that mutation or loss of histone binding modules change target gene 
expression by altering histone binding specificity or interactions with other transcription 
factors (Matangkasombut and Buratowski, 2003; Chen et al., 2008).  
 
Alternative splicing of NURF301 can affect the diversity of chromatin remodelling complexes 
in two ways: either generating functional diversity within the same cell, or generating 
functional diversity between distinct cell types. If two splice variants are expressed in the 
same cells, as we have shown occurs in salivary glands (polytene chromosomes), alternative 
splicing can generate chromatin remodelling complexes that are possess different functions 
due to the chromatin territories to which they are targeted. Thus the NURF301-A containing 
complexes would be expected to be targeted to regions that contain the combinations of 
histone modifications we have identified here. NURF301-C complexes, in contrast, which do 
not contain the histone-modification binding PHD1, PHD2 and bromodomains would not be 
anticipated to be enriched in these regions. The resolution of polytene chromosome bands 
precludes us from mapping the extent of overlap between NURF301-A, NURF301-C and 
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histone modifications and we have made a major effort to map these two isoforms on 
chromatin by chromatin immunoprecipitation coupled sequencing (ChIP-Seq). However, as 
shown in results section 4.2.9 (Table 4-1), whether due to the nature of the NURF-chromatin 
interaction or the low efficiency of NURF ChIP and the low cell numbers that are used in our 
hemocyte ChIP procedures, we have not been able to generate ChIP-Seq profiles of 
NURF301-A/B or NURF301-C isoforms.  
 
Alternative splicing of NURF301 could also be used to generate tissue and/or stage specific 
NURF variants. Previously, the whole genome expression profiling of NURF null mutant and 
Nurf301ΔC mutant revealed that a subset of genes require full-length NURF301-A/B. Loss of 
the full-length NURF A/B isoform appeared to selectively affect genes involved in primary 
spermatocyte development, for example the fuzzy onions (fzo) gene (Hales and Fuller, 1997; 
Kwon et al., 2009). Our male testes immunostaining data was also consistent with these 
findings as we showed that NURF301-A/B was only expressed in the later stage of 
spermatogenesis, while NURF301-C was observed in all stages. This suggest the NURF301-
A/B and NURF301-C isoforms can also have unique functions as a result of differential 
chromatin targeting as well as differential tissue expression. This latter result is consistent 
with an emerging body of data where functional diversity of SWI/SNF complexes is 
generated by alternative incorporation of subunits at different stages and in different tissues. 
During neural development switching occurs in SWI/SNF complexes (Olave et al., 2002; 
Lessard et al., 2007; Yoo et al., 2009; Vogel-Ciernia et al., 2012) with the exchange of 
BAF53a and BAF45a (PHF10) for the related BAF53b and BAF45b subunits. Equally a stem 
cell-specific SWI/SNF complex with a distinct subunit composition has been identified (Ho et 
al., 2009). 
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5.4 Final conclusion and future work 
In summary, each chromatin targeting module, the PHD, PHD1 and PHD2 domains and 
bromodomain in NURF301 exhibits different binding specificity. The PHD2 domain binds 
specifically to H3K4me3, but binding is inhibited by phosphorylation of flanking Thr 3, and 
enhanced by acetylation of Lys 9 and phosphorylation of Ser 10. The PHD1 specifically 
interacts with H3K23me3, while PHD does not have binding specificity but generally binds to 
the free N-terminal tails of H4. The Bromodomain binds preferentially to a multiply 
acetylated H4 tail. These results allow us to draw models of recruitment and interaction of 
NURF301 with nucleosomes via the PHD domains and bromodomain. These data also 
suggest interactions between NURF301 with histone modifying enzymes, the H3T3-specific 
kinase Haspin, and the H3K9 and K14 specific acetyltransferase Gcn5. Finally, we have 
successfully generated CTAP tagged Nurf301-A/B and C BAC constructs and transgenic flies 
that provide important reagents for determining distinct functions of the NURF301-A/B and C 
isoforms by looking at immunostaining of different cell types and ChIP sequencing. 
 
In future work it will be important to demonstrate functional requirements of the PHD 
domains and bromodomain for recruitment of NURF in vivo. One way in which this can be 
achieved is by using our established recombineering method to generate CTAP- or NTAP-
tagged NURF301-A/B constructs containing deletions of the PHD, PHD1 and PHD2 domains 
and bromodomain respectively. Using these constructs, we would be able to generate 
transgenic flies expressing specific domain deleted forms of NURF301-A/B and analyze 
biological functions of the each domain precisely by comparing with wild type and NURF-
A/B and C full deletion mutant. 
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To extend our finding that the PHD1 domain is present in human BPTF and that alternative 
splice variants of BPTF may exist in which the PHD fingers and Bromodomains are 
alternatively incorporated, we will determine the tissue- and disease-specific splicing patterns 
of BPTF. The Birmingham Human Tissue Biorepository collects and stores human tissue for 
use in biomedical research. We will obtain tissue samples from the biorepository, isolate 
mRNA, generated cDNA and profile BPTF isoform variants using real time PCR. A particular 
focus will be to determine whether PHD1 is alternatively incorporated in ovary and testes 
samples. 
 
Lastly, to generate ChIP-Seq profiles of NURF, we will use Drosophila S2 cells for our next 
ChIP experiment using anti-NURF301 antibody (recognizes all NURF301-A.B and C 
isoforms). We can generate large numbers of S2 cells which will allow enough ChIP DNA to 
be prepared even if ChIP efficiency is low. Although we will not able to discriminate 
NURF301-A/B or NURF301-C isoforms directly it will provide a first NURF profile. By 
comparing S2 cells and Kc cells, we may also be able to explore sex dependent NURF 
distributions.  
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CHAPTER 6. APPENDIX 
 
Appendix 1. Layout of the histone array on the slide. 
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Appendix 2. Histone H3 peptide library array. 
195 
 
Appendix 3. Histone H3, H4 N-terminal peptide library array. 
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Appendix 4. Layout of the Active Motif MODified histone peptide array 
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                                    Active Motif 
                          MODified™ Histone Peptide Array* 
                              Catalog Nos. 13001 & 13005 
         
Modification 
number 
Peptide 
location Peptide sequence Name Mod1 Mod2 Mod 3 Mod 4 N-terminus 
1 A 1 A R T K Q T A R K S T G G K A P R K Q H3 1-19 unmod    Free 
2 A 2 A Rme2s T K Q T A R K S T G G K A P R K Q H3 1-19 R2me2s    Free 
3 A 3 A Rme2a T K Q T A R K S T G G K A P R K Q H3 1-19 R2me2a    Free 
4 A 4 A Cit T K Q T A R K S T G G K A P R K Q H3 1-19 R2Citr    Free 
5 A 5 A R pT K Q T A R K S T G G K A P R K Q H3 1-19 T3P    Free 
6 A 6 A R T Kme1 Q T A R K S T G G K A P R K Q H3 1-19 K4me1    Free 
7 A 7 A R T Kme2 Q T A R K S T G G K A P R K Q H3 1-19 K4me2    Free 
8 A 8 A R T Kme3 Q T A R K S T G G K A P R K Q H3 1-19 K4me3    Free 
9 A 9 A R T Kac Q T A R K S T G G K A P R K Q H3 1-19 K4ac    Free 
10 A10 A R T K Q T A Rme2s K S T G G K A P R K Q H3 1-19 R8me2s    Free 
11 A11 A R T K Q T A Rme2a K S T G G K A P R K Q H3 1-19 R8me2a    Free 
12 A12 A R T K Q T A Cit K S T G G K A P R K Q H3 1-19 R8Citr    Free 
13 A13 A R T K Q T A R Kme1 S T G G K A P R K Q H3 1-19 K9me1    Free 
14 A14 A R T K Q T A R Kme2 S T G G K A P R K Q H3 1-19 K9me2    Free 
15 A15 A R T K Q T A R Kme3 S T G G K A P R K Q H3 1-19 K9me3    Free 
16 A16 A R T K Q T A R Kac S T G G K A P R K Q H3 1-19 K9ac    Free 
17 A17 A R T K Q T A R K pS T G G K A P R K Q H3 1-19 S10P    Free 
18 A18 A R T K Q T A R K S pT G G K A P R K Q H3 1-19 T11P    Free 
19 A19 A R T K Q T A R K S T G G Kac A P R K Q H3 1-19 K14ac    Free 
20 A20 A Rme2s pT K Q T A R K S T G G K A P R K Q H3 1-19 R2me2s T3P   Free 
21 A21 A Rme2s T Kme1 Q T A R K S T G G K A P R K Q H3 1-19 R2me2s K4me1   Free 
22 A22 A Rme2s T Kme2 Q T A R K S T G G K A P R K Q H3 1-19 R2me2s K4me2   Free 
23 A23 A Rme2s T Kme3 Q T A R K S T G G K A P R K Q H3 1-19 R2me2s K4me3   Free 
24 A24 A Rme2s T Kac Q T A R K S T G G K A P R K Q H3 1-19 R2me2s K4ac   Free 
25 B 1 A Rme2a pT K Q T A R K S T G G K A P R K Q H3 1-19 R2me2a T3P   Free 
26 B 2 A Rme2a T Kme1 Q T A R K S T G G K A P R K Q H3 1-19 R2me2a K4me1   Free 
27 B 3 A Rme2a T Kme2 Q T A R K S T G G K A P R K Q H3 1-19 R2me2a K4me2   Free 
28 B 4 A Rme2a T Kme3 Q T A R K S T G G K A P R K Q H3 1-19 R2me2a K4me3   Free 
29 B 5 A Rme2a T Kac Q T A R K S T G G K A P R K Q H3 1-19 R2me2a K4ac   Free 
30 B 6 A Cit pT K Q T A R K S T G G K A P R K Q H3 1-19 R2Citr T3P   Free 
31 B 7 A Cit T Kme1 Q T A R K S T G G K A P R K Q H3 1-19 R2Citr K4me1   Free 
32 B 8 A Cit T Kme2 Q T A R K S T G G K A P R K Q H3 1-19 R2Citr K4me2   Free 
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33 B 9 A Cit T Kme3 Q T A R K S T G G K A P R K Q H3 1-19 R2Citr K4me3   Free 
34 B10 A Cit T Kac Q T A R K S T G G K A P R K Q H3 1-19 R2Citr K4ac   Free 
35 B11 A R pT Kme1 Q T A R K S T G G K A P R K Q H3 1-19 T3P K4me1   Free 
36 B12 A R pT Kme2 Q T A R K S T G G K A P R K Q H3 1-19 T3P K4me2   Free 
37 B13 A R pT Kme3 Q T A R K S T G G K A P R K Q H3 1-19 T3P K4me3   Free 
38 B14 A R pT Kac Q T A R K S T G G K A P R K Q H3 1-19 T3P K4ac   Free 
39 B15 A Rme2s pT Kme1 Q T A R K S T G G K A P R K Q H3 1-19 R2me2s T3P K4me1  Free 
40 B16 A Rme2s pT Kme2 Q T A R K S T G G K A P R K Q H3 1-19 R2me2s T3P K4me2  Free 
41 B17 A Rme2s pT Kme3 Q T A R K S T G G K A P R K Q H3 1-19 R2me2s T3P K4me3  Free 
42 B18 A Rme2s pT Kac Q T A R K S T G G K A P R K Q H3 1-19 R2me2s T3P K4ac  Free 
43 B19 A Rme2a pT Kme1 Q T A R K S T G G K A P R K Q H3 1-19 R2me2a T3P K4me1  Free 
44 B20 A Rme2a pT Kme2 Q T A R K S T G G K A P R K Q H3 1-19 R2me2a T3P K4me2  Free 
45 B21 A Rme2a pT Kme3 Q T A R K S T G G K A P R K Q H3 1-19 R2me2a T3P K4me3  Free 
46 B22 A Rme2a pT Kac Q T A R K S T G G K A P R K Q H3 1-19 R2me2a T3P K4ac  Free 
47 B23 A R T K Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 R8me2s K9me1   Free 
48 B24 A R T K Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 R8me2s K9me2   Free 
49 C 1 A R T K Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 R8me2s K9me3   Free 
50 C 2 A R T K Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 R8me2s K9ac   Free 
51 C 3 A R T K Q T A Rme2a K pS T G G K A P R K Q H3 1-19 R8me2s S10P   Free 
52 C 4 A R T K Q T A Rme2a K S pT G G K A P R K Q H3 1-19 R8me2s T11P   Free 
53 C 5 A R T K Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 R8me2a K9me1   Free 
54 C 6 A R T K Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 R8me2a K9me2   Free 
55 C 7 A R T K Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 R8me2a K9me3   Free 
56 C 8 A R T K Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 R8me2a K9ac   Free 
57 C 9 A R T K Q T A Rme2a K pS T G G K A P R K Q H3 1-19 R8me2a S10P   Free 
58 C10 A R T K Q T A Rme2a K S pT G G K A P R K Q H3 1-19 R8me2a T11P   Free 
59 C11 A R T K Q T A Cit Kme1 S T G G K A P R K Q H3 1-19 R8Citr K9me1   Free 
60 C12 A R T K Q T A Cit Kme2 S T G G K A P R K Q H3 1-19 R8Citr K9me2   Free 
61 C13 A R T K Q T A Cit Kme3 S T G G K A P R K Q H3 1-19 R8Citr K9me3   Free 
62 C14 A R T K Q T A Cit Kac S T G G K A P R K Q H3 1-19 R8Citr K9ac   Free 
63 C15 A R T K Q T A Cit K pS T G G K A P R K Q H3 1-19 R8Citr S10P   Free 
64 C16 A R T K Q T A Cit K S pT G G K A P R K Q H3 1-19 R8Citr T11P   Free 
65 C17 A R T K Q T A R Kme1 pS T G G K A P R K Q H3 1-19 K9me1 S10P   Free 
66 C18 A R T K Q T A R Kme1 S pT G G K A P R K Q H3 1-19 K9me1 T11P   Free 
67 C19 A R T K Q T A R Kme1 S T G G Kac A P R K Q H3 1-19 K9me1 K14ac   Free 
68 C20 A R T K Q T A R Kme2 pS T G G K A P R K Q H3 1-19 K9me2 S10P   Free 
69 C21 A R T K Q T A R Kme2 S pT G G K A P R K Q H3 1-19 K9me2 T11P   Free 
70 C22 A R T K Q T A R Kme2 S T G G Kac A P R K Q H3 1-19 K9me2 K14ac   Free 
71 C23 A R T K Q T A R Kme3 pS T G G K A P R K Q H3 1-19 K9me3 S10P   Free 
72 C24 A R T K Q T A R Kme3 S pT G G K A P R K Q H3 1-19 K9me3 T11P   Free 
73 D 1 A R T K Q T A R Kme3 S T G G Kac A P R K Q H3 1-19 K9me3 K14ac   Free 
74 D 2 A R T K Q T A R Kac pS T G G K A P R K Q H3 1-19 K9ac S10P   Free 
75 D 3 A R T K Q T A R Kac S pT G G K A P R K Q H3 1-19 K9ac T11P   Free 
76 D 4 A R T K Q T A R Kac S T G G Kac A P R K Q H3 1-19 K9ac K14ac   Free 
77 D 5 A R T K Q T A R K pS pT G G K A P R K Q H3 1-19 S10P T11P   Free 
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78 D 6 A R T K Q T A R K pS T G G Kac A P R K Q H3 1-19 S10P K14ac   Free 
79 D 7 A R T K Q T A R K S pT G G Kac A P R K Q H3 1-19 T11P K14ac   Free 
80 D 8 A R T K Q T A Rme2s Kme1 pS T G G K A P R K Q H3 1-19 R8me2s K9me1 S10P  Free 
81 D 9 A R T K Q T A Rme2s Kme2 pS T G G K A P R K Q H3 1-19 R8me2s K9me2 S10P  Free 
82 D10 A R T K Q T A Rme2s Kme3 pS T G G K A P R K Q H3 1-19 R8me2s K9me3 S10P  Free 
83 D11 A R T K Q T A Rme2s Kac pS T G G K A P R K Q H3 1-19 R8me2s K9ac S10P  Free 
84 D12 A R T K Q T A Rme2s Kme1 S pT G G K A P R K Q H3 1-19 R8me2s K9me1 T11P  Free 
85 D13 A R T K Q T A Rme2s Kme2 S pT G G K A P R K Q H3 1-19 R8me2s K9me2 T11P  Free 
86 D14 A R T K Q T A Rme2s Kme3 S pT G G K A P R K Q H3 1-19 R8me2s K9me3 T11P  Free 
87 D15 A R T K Q T A Rme2s Kac S pT G G K A P R K Q H3 1-19 R8me2s K9ac T11P  Free 
88 D16 A R T K Q T A Rme2a Kme1 pS T G G K A P R K Q H3 1-19 R8me2a K9me1 S10P  Free 
89 D17 A R T K Q T A Rme2a Kme2 pS T G G K A P R K Q H3 1-19 R8me2a K9me2 S10P  Free 
90 D18 A R T K Q T A Rme2a Kme3 pS T G G K A P R K Q H3 1-19 R8me2a K9me3 S10P  Free 
91 D19 A R T K Q T A Rme2a Kac pS T G G K A P R K Q H3 1-19 R8me2a K9ac S10P  Free 
92 D20 A R T K Q T A Rme2a Kme1 S pT G G K A P R K Q H3 1-19 R8me2a K9me1 T11P  Free 
93 D21 A R T K Q T A Rme2a Kme2 S pT G G K A P R K Q H3 1-19 R8me2a K9me2 T11P  Free 
94 D22 A R T K Q T A Rme2a Kme3 S pT G G K A P R K Q H3 1-19 R8me2a K9me3 T11P  Free 
95 D23 A R T K Q T A Rme2a Kac S pT G G K A P R K Q H3 1-19 R8me2a K9ac T11P  Free 
96 D24 A R T K Q T A Rme2a Kme1 pS pT G G K A P R K Q H3 1-19 R8me2a K9me1 S10P T11P Free 
97 E 1 A R T K Q T A Rme2a Kme2 pS pT G G K A P R K Q H3 1-19 R8me2a K9me2 S10P T11P Free 
98 E 2 A R T K Q T A Rme2a Kme3 pS pT G G K A P R K Q H3 1-19 R8me2a K9me3 S10P T11P Free 
99 E 3 A R T K Q T A Rme2a Kac pS pT G G K A P R K Q H3 1-19 R8me2a K9ac S10P T11P Free 
100 E 4 A Rme2s T Kme1 Q T A Rme2s K S T G G K A P R K Q H3 1-19 R2me2s K4me1 R8me2s  Free 
101 E 5 A Rme2s T Kme2 Q T A Rme2s K S T G G K A P R K Q H3 1-19 R2me2s K4me2 R8me2s  Free 
102 E 6 A Rme2s T Kme3 Q T A Rme2s K S T G G K A P R K Q H3 1-19 R2me2s K4me3 R8me2s  Free 
103 E 7 A Rme2s T Kac Q T A Rme2s K S T G G K A P R K Q H3 1-19 R2me2s K4ac R8me2s  Free 
104 E 8 A Rme2a T Kme1 Q T A Rme2a K S T G G K A P R K Q H3 1-19 R2me2a K4me1 R8me2a  Free 
105 E 9 A Rme2a T Kme2 Q T A Rme2a K S T G G K A P R K Q H3 1-19 R2me2a K4me2 R8me2a  Free 
106 E10 A Rme2a T Kme3 Q T A Rme2a K S T G G K A P R K Q H3 1-19 R2me2a K4me3 R8me2a  Free 
107 E11 A Rme2a T Kac Q T A Rme2a K S T G G K A P R K Q H3 1-19 R2me2a K4ac R8me2a  Free 
108 E12 A Rme2s T Kme1 Q T A R Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4me1 K9me1  Free 
109 E13 A Rme2s T Kme2 Q T A R Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4me2 K9me1  Free 
110 E14 A Rme2s T Kme3 Q T A R Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4me3 K9me1  Free 
111 E15 A Rme2s T Kac Q T A R Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4ac K9me1  Free 
112 E16 A Rme2a T Kme1 Q T A R Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4me1 K9me2  Free 
113 E17 A Rme2a T Kme2 Q T A R Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4me2 K9me2  Free 
114 E18 A Rme2a T Kme3 Q T A R Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4me3 K9me2  Free 
115 E19 A Rme2a T Kac Q T A R Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4ac K9me2  Free 
116 E20 A Rme2s T Kme1 Q T A R Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4me1 K9me3  Free 
117 E21 A Rme2s T Kme2 Q T A R Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4me2 K9me3  Free 
118 E22 A Rme2s T Kme3 Q T A R Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4me3 K9me3  Free 
119 E23 A Rme2s T Kac Q T A R Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4ac K9me3  Free 
120 E24 A Rme2a T Kme1 Q T A R Kac S T G G K A P R K Q H3 1-19 R2me2a K4me1 K9ac  Free 
121 F 1 A Rme2a T Kme2 Q T A R Kac S T G G K A P R K Q H3 1-19 R2me2a K4me2 K9ac  Free 
122 F 2 A Rme2a T Kme3 Q T A R Kac S T G G K A P R K Q H3 1-19 R2me2a K4me3 K9ac  Free 
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123 F 3 A Rme2a T Kac Q T A R Kac S T G G K A P R K Q H3 1-19 R2me2a K4ac K9ac  Free 
124 F 4 A R T Kme1 Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 K4me1 R8me2s K9me1  Free 
125 F 5 A R T Kme2 Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 K4me2 R8me2s K9me1  Free 
126 F 6 A R T Kme3 Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 K4me3 R8me2s K9me1  Free 
127 F 7 A R T Kac Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 K4ac R8me2s K9me1  Free 
128 F 8 A R T Kme1 Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 K4me1 R8me2a K9me1  Free 
129 F 9 A R T Kme2 Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 K4me2 R8me2a K9me1  Free 
130 F10 A R T Kme3 Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 K4me3 R8me2a K9me1  Free 
131 F11 A R T Kac Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 K4ac R8me2a K9me1  Free 
132 F12 A R T Kme1 Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 K4me1 R8me2s K9me2  Free 
133 F13 A R T Kme2 Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 K4me2 R8me2s K9me2  Free 
134 F14 A R T Kme3 Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 K4me3 R8me2s K9me2  Free 
135 F15 A R T Kac Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 K4ac R8me2s K9me2  Free 
136 F16 A R T Kme1 Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 K4me1 R8me2a K9me2  Free 
137 F17 A R T Kme2 Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 K4me2 R8me2a K9me2  Free 
138 F18 A R T Kme3 Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 K4me3 R8me2a K9me2  Free 
139 F19 A R T Kac Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 K4ac R8me2a K9me2  Free 
140 F20 A R T Kme1 Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 K4me1 R8me2s K9me3  Free 
141 F21 A R T Kme2 Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 K4me2 R8me2s K9me3  Free 
142 F22 A R T Kme3 Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 K4me3 R8me2s K9me3  Free 
143 F23 A R T Kac Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 K4ac R8me2s K9me3  Free 
144 F24 A R T Kme1 Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 K4me1 R8me2a K9me3  Free 
145 G 1 A R T Kme2 Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 K4me2 R8me2a K9me3  Free 
146 G 2 A R T Kme3 Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 K4me3 R8me2a K9me3  Free 
147 G 3 A R T Kac Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 K4ac R8me2a K9me3  Free 
148 G 4 A R T Kme1 Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 K4me1 R8me2s K9ac  Free 
149 G 5 A R T Kme2 Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 K4me2 R8me2s K9ac  Free 
150 G 6 A R T Kme3 Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 K4me3 R8me2s K9ac  Free 
151 G 7 A R T Kac Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 K4ac R8me2s K9ac  Free 
152 G 8 A R T Kme1 Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 K4me1 R8me2a K9ac  Free 
153 G 9 A R T Kme2 Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 K4me2 R8me2a K9ac  Free 
154 G10 A R T Kme3 Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 K4me3 R8me2a K9ac  Free 
155 G11 A R T Kac Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 K4ac R8me2a K9ac  Free 
156 G12 A Rme2s T Kme1 Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4me1 R8me2s K9me1 Free 
157 G13 A Rme2s T Kme2 Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4me2 R8me2s K9me1 Free 
158 G14 A Rme2s T Kme3 Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4me3 R8me2s K9me1 Free 
159 G15 A Rme2s T Kac Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4ac R8me2s K9me1 Free 
160 G16 A Rme2a T Kme1 Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 R2me2a K4me1 R8me2s K9me1 Free 
161 G17 A Rme2a T Kme2 Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 R2me2a K4me2 R8me2s K9me1 Free 
162 G18 A Rme2a T Kme3 Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 R2me2a K4me3 R8me2s K9me1 Free 
163 G19 A Rme2a T Kac Q T A Rme2s Kme1 S T G G K A P R K Q H3 1-19 R2me2a K4ac R8me2s K9me1 Free 
164 G20 A Rme2s T Kme1 Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 R2me2s K4me1 R8me2s K9me2 Free 
165 G21 A Rme2s T Kme2 Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 R2me2s K4me2 R8me2s K9me2 Free 
166 G22 A Rme2s T Kme3 Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 R2me2s K4me3 R8me2s K9me2 Free 
167 G23 A Rme2s T Kac Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 R2me2s K4ac R8me2s K9me2 Free 
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168 G24 A Rme2a T Kme1 Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4me1 R8me2s K9me2 Free 
169 H 1 A Rme2a T Kme2 Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4me2 R8me2s K9me2 Free 
170 H 2 A Rme2a T Kme3 Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4me3 R8me2s K9me2 Free 
171 H 3 A Rme2a T Kac Q T A Rme2s Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4ac R8me2s K9me2 Free 
172 H 4 A Rme2s T Kme1 Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4me1 R8me2s K9me3 Free 
173 H 5 A Rme2s T Kme2 Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4me2 R8me2s K9me3 Free 
174 H 6 A Rme2s T Kme3 Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4me3 R8me2s K9me3 Free 
175 H 7 A Rme2s T Kac Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4ac R8me2s K9me3 Free 
176 H 8 A Rme2a T Kme1 Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 R2me2a K4me1 R8me2s K9me3 Free 
177 H 9 A Rme2a T Kme2 Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 R2me2a K4me2 R8me2s K9me3 Free 
178 H10 A Rme2a T Kme3 Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 R2me2a K4me3 R8me2s K9me3 Free 
179 H11 A Rme2a T Kac Q T A Rme2s Kme3 S T G G K A P R K Q H3 1-19 R2me2a K4ac R8me2s K9me3 Free 
180 H12 A Rme2s T Kme1 Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 R2me2s K4me1 R8me2s K9ac Free 
181 H13 A Rme2s T Kme2 Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 R2me2s K4me2 R8me2s K9ac Free 
182 H14 A Rme2s T Kme3 Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 R2me2s K4me3 R8me2s K9ac Free 
183 H15 A Rme2s T Kac Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 R2me2s K4ac R8me2s K9ac Free 
184 H16 A Rme2a T Kme1 Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 R2me2a K4me1 R8me2s K9ac Free 
185 H17 A Rme2a T Kme2 Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 R2me2a K4me2 R8me2s K9ac Free 
186 H18 A Rme2a T Kme3 Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 R2me2a K4me3 R8me2s K9ac Free 
187 H19 A Rme2a T Kac Q T A Rme2s Kac S T G G K A P R K Q H3 1-19 R2me2a K4ac R8me2s K9ac Free 
188 H20 A Rme2s T Kme1 Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4me1 R8me2a K9me1 Free 
189 H21 A Rme2s T Kme2 Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4me2 R8me2a K9me1 Free 
190 H22 A Rme2s T Kme3 Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4me3 R8me2a K9me1 Free 
191 H23 A Rme2s T Kac Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 R2me2s K4ac R8me2a K9me1 Free 
192 H24 A Rme2a T Kme1 Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 R2me2a K4me1 R8me2a K9me1 Free 
193 I 1 A Rme2a T Kme2 Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 R2me2a K4me2 R8me2a K9me1 Free 
194 I 2 A Rme2a T Kme3 Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 R2me2a K4me3 R8me2a K9me1 Free 
195 I 3 A Rme2a T Kac Q T A Rme2a Kme1 S T G G K A P R K Q H3 1-19 R2me2a K4ac R8me2a K9me1 Free 
196 I 4 A Rme2s T Kme1 Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 R2me2s K4me1 R8me2a K9me2 Free 
197 I 5 A Rme2s T Kme2 Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 R2me2s K4me2 R8me2a K9me2 Free 
198 I 6 A Rme2s T Kme3 Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 R2me2s K4me3 R8me2a K9me2 Free 
199 I 7 A Rme2s T Kac Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 R2me2s K4ac R8me2a K9me2 Free 
200 I 8 A Rme2a T Kme1 Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4me1 R8me2a K9me2 Free 
201 I 9 A Rme2a T Kme2 Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4me2 R8me2a K9me2 Free 
202 I10 A Rme2a T Kme3 Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4me3 R8me2a K9me2 Free 
203 I11 A Rme2a T Kac Q T A Rme2a Kme2 S T G G K A P R K Q H3 1-19 R2me2a K4ac R8me2a K9me2 Free 
204 I12 A Rme2s T Kme1 Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4me1 R8me2a K9me3 Free 
205 I13 A Rme2s T Kme2 Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4me2 R8me2a K9me3 Free 
206 I14 A Rme2s T Kme3 Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4me3 R8me2a K9me3 Free 
207 I15 A Rme2s T Kac Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 R2me2s K4ac R8me2a K9me3 Free 
208 I16 A Rme2a T Kme1 Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 R2me2a K4me1 R8me2a K9me3 Free 
209 I17 A Rme2a T Kme2 Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 R2me2a K4me2 R8me2a K9me3 Free 
210 I18 A Rme2a T Kme3 Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 R2me2a K4me3 R8me2a K9me3 Free 
211 I19 A Rme2a T Kac Q T A Rme2a Kme3 S T G G K A P R K Q H3 1-19 R2me2a K4ac R8me2a K9me3 Free 
212 I20 A Rme2s T Kme1 Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 R2me2s K4me1 R8me2a K9ac Free 
202 
213 I21 A Rme2s T Kme2 Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 R2me2s K4me2 R8me2a K9ac Free 
214 I22 A Rme2s T Kme3 Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 R2me2s K4me3 R8me2a K9ac Free 
215 I23 A Rme2s T Kac Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 R2me2s K4ac R8me2a K9ac Free 
216 I24 A Rme2a T Kme1 Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 R2me2a K4me1 R8me2a K9ac Free 
217 J 1 A Rme2a T Kme2 Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 R2me2a K4me2 R8me2a K9ac Free 
218 J 2 A Rme2a T Kme3 Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 R2me2a K4me3 R8me2a K9ac Free 
219 J 3 A Rme2a T Kac Q T A Rme2a Kac S T G G K A P R K Q H3 1-19 R2me2a K4ac R8me2a K9ac Free 
220 J 4 A R K S T G G K A P R K Q L A T K A A R H3 7-26 unmod    Acetylated 
221 J 5 A R K S T G G Kac A P R K Q L A T K A A R H3 7-26 K14ac    Acetylated 
222 J 6 A R K pS T G G Kac A P R K Q L A T K A A R H3 7-26 K14ac S10P   Acetylated 
223 J 7 A R K S pT G G Kac A P R K Q L A T K A A R H3 7-26 K14ac T11P   Acetylated 
224 J 8 A R K S T G G K A P Rme2s K Q L A T K A A R H3 7-26 R17me2s    Acetylated 
225 J 9 A R K S T G G K A P Rme2a K Q L A T K A A R H3 7-26 R17me2a    Acetylated 
226 J10 A R K S T G G K A P Cit K Q L A T K A A R H3 7-26 R17Citr    Acetylated 
227 J11 A R K S T G G K A P R Kac Q L A T K A A R H3 7-26 K18ac    Acetylated 
228 J12 A R K S T G G Kac A P Rme2s K Q L A T K A A R H3 7-26 K14ac R17me2s   Acetylated 
229 J13 A R K S T G G Kac A P Rme2a K Q L A T K A A R H3 7-26 K14ac R17me2a   Acetylated 
230 J14 A R K S T G G Kac A P R Kac Q L A T K A A R H3 7-26 K14ac K18ac   Acetylated 
231 J15 A R K S T G G K A P Rme2s Kac Q L A T K A A R H3 7-26 R17me2s K18ac   Acetylated 
232 J16 A R K S T G G K A P Rme2a Kac Q L A T K A A R H3 7-26 R17me2a K18ac   Acetylated 
233 J17 A R K S T G G K A P Cit Kac Q L A T K A A R H3 7-26 R17Citr K18ac   Acetylated 
234 J18 A R K S T G G Kac A P Rme2s Kac Q L A T K A A R H3 7-26 K14ac R17me2s K18ac  Acetylated 
235 J19 A R K S T G G Kac A P Rme2a Kac Q L A T K A A R H3 7-26 K14ac R17me2a K18ac  Acetylated 
236 J20 P R K Q L A T K A A R K S A P A T G G H3 16-35 unmod    Acetylated 
237 J21 P R K Q L A T K A A Rme2s K S A P A T G G H3 16-35 R26me2s    Acetylated 
238 J22 P R K Q L A T K A A Rme2a K S A P A T G G H3 16-35 R26me2a    Acetylated 
239 J23 P R K Q L A T K A A Cit K S A P A T G G H3 16-35 R26Citr    Acetylated 
240 J24 P R K Q L A T K A A R Kme1 S A P A T G G H3 16-35 K27me1    Acetylated 
241 K 1 P R K Q L A T K A A R Kme2 S A P A T G G H3 16-35 K27me2    Acetylated 
242 K 2 P R K Q L A T K A A R Kme3 S A P A T G G H3 16-35 K27me3    Acetylated 
243 K 3 P R K Q L A T K A A R Kac S A P A T G G H3 16-35 K27ac    Acetylated 
244 K 4 P R K Q L A T K A A R K pS A P A T G G H3 16-35 S28P    Acetylated 
245 K 5 P R K Q L A T K A A Rme2s Kme1 S A P A T G G H3 16-35 R26me2s K27me1   Acetylated 
246 K 6 P R K Q L A T K A A Rme2s Kme2 S A P A T G G H3 16-35 R26me2s K27me2   Acetylated 
247 K 7 P R K Q L A T K A A Rme2s Kme3 S A P A T G G H3 16-35 R26me2s K27me3   Acetylated 
248 K 8 P R K Q L A T K A A Rme2s Kac S A P A T G G H3 16-35 R26me2s K27ac   Acetylated 
249 K 9 P R K Q L A T K A A Rme2s K pS A P A T G G H3 16-35 R26me2s S28P   Acetylated 
250 K10 P R K Q L A T K A A Rme2a Kme1 S A P A T G G H3 16-35 R26me2a K27me1   Acetylated 
251 K11 P R K Q L A T K A A Rme2a Kme2 S A P A T G G H3 16-35 R26me2a K27me2   Acetylated 
252 K12 P R K Q L A T K A A Rme2a Kme3 S A P A T G G H3 16-35 R26me2a K27me3   Acetylated 
253 K13 P R K Q L A T K A A Rme2a Kac S A P A T G G H3 16-35 R26me2a K27ac   Acetylated 
254 K14 P R K Q L A T K A A Rme2a K pS A P A T G G H3 16-35 R26me2a S28P   Acetylated 
255 K15 P R K Q L A T K A A Cit Kme1 S A P A T G G H3 16-35 R26Citr K27me1   Acetylated 
256 K16 P R K Q L A T K A A Cit Kme2 S A P A T G G H3 16-35 R26Citr K27me2   Acetylated 
257 K17 P R K Q L A T K A A Cit Kme3 S A P A T G G H3 16-35 R26Citr K27me3   Acetylated 
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258 K18 P R K Q L A T K A A Cit K pS A P A T G G H3 16-35 R26Citr S28P   Acetylated 
259 K19 P R K Q L A T K A A R Kme1 pS A P A T G G H3 16-35 K27me1 S28P   Acetylated 
260 K20 P R K Q L A T K A A R Kme2 pS A P A T G G H3 16-35 K27me2 S28P   Acetylated 
261 K21 P R K Q L A T K A A R Kme3 pS A P A T G G H3 16-35 K27me3 S28P   Acetylated 
262 K22 P R K Q L A T K A A R Kac pS A P A T G G H3 16-35 K27ac S28P   Acetylated 
263 K23 P R K Q L A T K A A Rme2s Kme1 pS A P A T G G H3 16-35 R26me2s K27me1 S28P  Acetylated 
264 K24 P R K Q L A T K A A Rme2s Kme2 pS A P A T G G H3 16-35 R26me2s K27me2 S28P  Acetylated 
265 L 1 P R K Q L A T K A A Rme2s Kme3 pS A P A T G G H3 16-35 R26me2s K27me3 S28P  Acetylated 
266 L 2 P R K Q L A T K A A Rme2s Kac pS A P A T G G H3 16-35 R26me2s K27ac S28P  Acetylated 
267 L 3 P R K Q L A T K A A Rme2a Kme1 pS A P A T G G H3 16-35 R26me2a K27me1 S28P  Acetylated 
268 L 4 P R K Q L A T K A A Rme2a Kme2 pS A P A T G G H3 16-35 R26me2a K27me2 S28P  Acetylated 
269 L 5 P R K Q L A T K A A Rme2a Kme3 pS A P A T G G H3 16-35 R26me2a K27me3 S28P  Acetylated 
270 L 6 P R K Q L A T K A A Rme2a Kac pS A P A T G G H3 16-35 R26me2a K27ac S28P  Acetylated 
271 L 7 R K S A P A T G G V K K P H R Y R P G H3 26-45 unmod    Acetylated 
272 L 8 R K S A P A T G G V Kme1 K P H R Y R P G H3 26-45 K36me1    Acetylated 
273 L 9 R K S A P A T G G V Kme2 K P H R Y R P G H3 26-45 K36me2    Acetylated 
274 L10 R K S A P A T G G V Kme3 K P H R Y R P G H3 26-45 K36me3    Acetylated 
275 L11 R K S A P A T G G V Kac K P H R Y R P G H3 26-45 K36ac    Acetylated 
276 L12 S G R G K G G K G L G K G G A K R H R H4 1-19 unmod    Free 
277 L13 pS G R G K G G K G L G K G G A K R H R H4 1-19 S1P    Free 
278 L14 S G Rme2s G K G G K G L G K G G A K R H R H4 1-19 R3me2s    Free 
279 L15 S G Rme2a G K G G K G L G K G G A K R H R H4 1-19 R3me2a    Free 
280 L16 S G R G Kac G G K G L G K G G A K R H R H4 1-19 K5ac    Free 
281 L17 S G R G K G G Kac G L G K G G A K R H R H4 1-19 K8ac    Free 
282 L18 S G R G K G G K G L G Kac G G A K R H R H4 1-19 K12ac    Free 
283 L19 S G R G K G G K G L G K G G A Kac R H R H4 1-19 K16ac    Free 
284 L20 pS G Rme2s G K G G K G L G K G G A K R H R H4 1-19 S1P R3me2s   Free 
285 L21 pS G Rme2a G K G G K G L G K G G A K R H R H4 1-19 S1P R3me2a   Free 
286 L22 pS G R G Kac G G K G L G K G G A K R H R H4 1-19 S1P K5ac   Free 
287 L23 S G Rme2s G Kac G G K G L G K G G A K R H R H4 1-19 R3me2s K5ac   Free 
288 L24 S G Rme2s G K G G Kac G L G K G G A K R H R H4 1-19 R3me2s K8ac   Free 
289 M 1 S G Rme2a G Kac G G K G L G K G G A K R H R H4 1-19 R3me2a K5ac   Free 
290 M 2 S G Rme2a G K G G Kac G L G K G G A K R H R H4 1-19 R3me2a K8ac   Free 
291 M 3 S G R G Kac G G Kac G L G K G G A K R H R H4 1-19 K5ac K8ac   Free 
292 M 4 S G R G K G G Kac G L G Kac G G A K R H R H4 1-19 K8ac K12ac   Free 
293 M 5 S G R G K G G Kac G L G K G G A Kac R H R H4 1-19 K8ac K16ac   Free 
294 M 6 S G R G K G G K G L G Kac G G A Kac R H R H4 1-19 K12ac K16ac   Free 
295 M 7 pS G Rme2s G Kac G G K G L G K G G A K R H R H4 1-19 S1P R3me2s K5ac  Free 
296 M 8 pS G Rme2a G Kac G G K G L G K G G A K R H R H4 1-19 S1P R3me2a K5ac  Free 
297 M 9 S G Rme2s G Kac G G Kac G L G K G G A K R H R H4 1-19 R3me2s K5ac K8ac  Free 
298 M10 S G Rme2a G Kac G G Kac G L G K G G A K R H R H4 1-19 R3me2a K5ac K8ac  Free 
299 M11 S G R G Kac G G Kac G L G Kac G G A K R H R H4 1-19 K5ac K8ac K12ac  Free 
300 M12 S G R G K G G Kac G L G Kac G G A Kac R H R H4 1-19 K8ac K12ac K16ac  Free 
301 M13 pS G Rme2s G Kac G G Kac G L G K G G A K R H R H4 1-19 S1P R3me2s K5ac K8ac Free 
302 M14 pS G Rme2a G Kac G G Kac G L G K G G A K R H R H4 1-19 S1P R3me2a K5ac K8ac Free 
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303 M15 S G Rme2s G Kac G G Kac G L G Kac G G A K R H R H4 1-19 R3me2s K5ac K8ac K12ac Free 
304 M16 S G Rme2a G Kac G G Kac G L G Kac G G A K R H R H4 1-19 R3me2a K5ac K8ac K12ac Free 
305 M17 S G R G Kac G G Kac G L G Kac G G A Kac R H R H4 1-19 K5ac K8ac K12ac K16ac Free 
306 M18 G K G G A K R H R K V L R D N I Q G I T H4 11-30 unmod    Acetylated 
307 M19 G Kac G G A K R H R K V L R D N I Q G I T H4 11-30 K12ac    Acetylated 
308 M20 G K G G A Kac R H R K V L R D N I Q G I T H4 11-30 K16ac    Acetylated 
309 M21 G K G G A K Rme2s H R K V L R D N I Q G I T H4 11-30 R17me2s    Acetylated 
310 M22 G K G G A K Rme2a H R K V L R D N I Q G I T H4 11-30 R17me2a    Acetylated 
311 M23 G K G G A K R H Rme2s K V L R D N I Q G I T H4 11-30 R19me2s    Acetylated 
312 M24 G K G G A K R H Rme2a K V L R D N I Q G I T H4 11-30 R19me2a    Acetylated 
313 N 1 G K G G A K R H R Kme1 V L R D N I Q G I T H4 11-30 K20me1    Acetylated 
314 N 2 G K G G A K R H R Kme2 V L R D N I Q G I T H4 11-30 K20me2    Acetylated 
315 N 3 G K G G A K R H R Kme3 V L R D N I Q G I T H4 11-30 K20me3    Acetylated 
316 N 4 G K G G A K R H R Kac V L R D N I Q G I T H4 11-30 K20ac    Acetylated 
317 N 5 G K G G A K R H R K V L Rme2a D N I Q G I T H4 11-30 R24me2a    Acetylated 
318 N 6 G K G G A K R H R K V L Rme2s D N I Q G I T H4 11-30 R24me2s    Acetylated 
319 N 7 G Kac G G A Kac R H R K V L R D N I Q G I T H4 11-30 K12ac K16ac   Acetylated 
320 N 8 G K G G A Kac Rme2s H R K V L R D N I Q G I T H4 11-30 K16ac R17me2s   Acetylated 
321 N 9 G K G G A Kac Rme2a H R K V L R D N I Q G I T H4 11-30 K16ac R17me2a   Acetylated 
322 N10 G K G G A Kac R H Rme2s K V L R D N I Q G I T H4 11-30 K16ac R19me2s   Acetylated 
323 N11 G K G G A Kac R H Rme2a K V L R D N I Q G I T H4 11-30 K16ac R19me2a   Acetylated 
324 N12 G K G G A Kac R H R Kme1 V L R D N I Q G I T H4 11-30 K16ac K20me1   Acetylated 
325 N13 G K G G A Kac R H R Kme2 V L R D N I Q G I T H4 11-30 K16ac K20me2   Acetylated 
326 N14 G K G G A Kac R H R Kme3 V L R D N I Q G I T H4 11-30 K16ac K20me3   Acetylated 
327 N15 G K G G A Kac R H R Kac V L R D N I Q G I T H4 11-30 K16ac K20ac   Acetylated 
328 N16 G Kac G G A Kac R H R Kme1 V L R D N I Q G I T H4 11-30 K12ac K16ac K20me1  Acetylated 
329 N17 G Kac G G A Kac R H R Kme2 V L R D N I Q G I T H4 11-30 K12ac K16ac K20me2  Acetylated 
330 N18 G Kac G G A Kac R H R Kme3 V L R D N I Q G I T H4 11-30 K12ac K16ac K20me3  Acetylated 
331 N19 G Kac G G A Kac R H R Kac V L R D N I Q G I T H4 11-30 K12ac K16ac K20ac  Acetylated 
332 N20 G K G G A K R H Rme2a Kme1 V L R D N I Q G I T H4 11-30 R19me2a K20me1   Acetylated 
333 N21 G K G G A K R H Rme2a Kme2 V L R D N I Q G I T H4 11-30 R19me2a K20me2   Acetylated 
334 N22 G K G G A K R H Rme2a Kme3 V L R D N I Q G I T H4 11-30 R19me2a K20me3   Acetylated 
335 N23 G K G G A K R H Rme2a Kac V L R D N I Q G I T H4 11-30 R19me2a K20ac   Acetylated 
336 N24 G K G G A K R H Rme2s Kme1 V L R D N I Q G I T H4 11-30 R19me2s K20me1   Acetylated 
337 O 1 G K G G A K R H Rme2s Kme2 V L R D N I Q G I T H4 11-30 R19me2s K20me2   Acetylated 
338 O 2 G K G G A K R H Rme2s Kme3 V L R D N I Q G I T H4 11-30 R19me2s K20me3   Acetylated 
339 O 3 G K G G A K R H Rme2s Kac V L R D N I Q G I T H4 11-30 R19me2s K20ac   Acetylated 
340 O 4 G K G G A K R H R Kme1 V L Rme2a D N I Q G I T H4 11-30 R24me2a K20me1   Acetylated 
341 O 5 G K G G A K R H R Kme2 V L Rme2a D N I Q G I T H4 11-30 R24me2a K20me2   Acetylated 
342 O 6 G K G G A K R H R Kme3 V L Rme2a D N I Q G I T H4 11-30 R24me2a K20me3   Acetylated 
343 O 7 G K G G A K R H R Kac V L Rme2a D N I Q G I T H4 11-30 R24me2a K20ac   Acetylated 
344 O 8 G K G G A K R H R Kme1 V L Rme2s D N I Q G I T H4 11-30 R24me2s K20me1   Acetylated 
345 O 9 G K G G A K R H R Kme2 V L Rme2s D N I Q G I T H4 11-30 R24me2s K20me2   Acetylated 
346 O10 G K G G A K R H R Kme3 V L Rme2s D N I Q G I T H4 11-30 R24me2s K20me3   Acetylated 
347 O11 G K G G A K R H R Kac V L Rme2s D N I Q G I T H4 11-30 R24me2s K20ac   Acetylated 
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348 O12 S G R G K Q G G K A R A K A K S R S S H2a 1-19 unmod    Free 
349 O13 pS G R G K Q G G K A R A K A K S R S S H2a 1-19 S1P    Free 
350 O14 S G R G Kac Q G G K A R A K A K S R S S H2a 1-19 K5ac    Free 
351 O15 S G R G K Q G G Kac A R A K A K S R S S H2a 1-19 K9ac    Free 
352 O16 S G R G K Q G G K A R A Kac A K S R S S H2a 1-19 K13ac    Free 
353 O17 pS G R G Kac Q G G K A R A K A K S R S S H2a 1-19 S1P K5ac   Free 
354 O18 pS G R G K Q G G Kac A R A K A K S R S S H2a 1-19 S1P K9ac   Free 
355 O19 pS G R G K Q G G K A R A Kac A K S R S S H2a 1-19 S1P K13ac   Free 
356 O20 S G R G Kac Q G G Kac A R A K A K S R S S H2a 1-19 K5ac K9ac   Free 
357 O21 S G R G Kac Q G G K A R A Kac A K S R S S H2a 1-19 K5ac K13ac   Free 
358 O22 S G R G K Q G G Kac A R A Kac A K S R S S H2a 1-19 K9ac K13ac   Free 
359 O23 pS G R G Kac Q G G Kac A R A K A K S R S S H2a 1-19 S1P K5ac K9ac  Free 
360 O24 pS G R G Kac Q G G K A R A Kac A K S R S S H2a 1-19 S1P K5ac K13ac  Free 
361 P 1 pS G R G K Q G G Kac A R A Kac A K S R S S H2a 1-19 S1P K9ac K13ac  Free 
362 P 2 S G R G Kac Q G G Kac A R A Kac A K S R S S H2a 1-19 K5ac K9ac K13ac  Free 
363 P 3 pS G R G Kac Q G G Kac A R A Kac A K S R S S H2a 1-19 S1P K5ac K9ac K13ac Free 
364 P 4 P D P A K S A P A P K K G S K K A V T H2B 1-19 unmod    Free 
365 P 5 P D P A Kac S A P A P K K G S K K A V T H2B 1-19 K5ac    Free 
366 P 6 P D P A K S A P A P K Kac G S K K A V T H2B 1-19 K12ac    Free 
367 P 7 P D P A K S A P A P K K G pS K K A V T H2B 1-19 S14P    Free 
368 P 8 P D P A K S A P A P K K G S Kac K A V T H2B 1-19 K15ac    Free 
369 P 9 P D P A Kac S A P A P K Kac G S K K A V T H2B 1-19 K5ac K12ac   Free 
370 P10 P D P A Kac S A P A P K K G pS K K A V T H2B 1-19 K5ac S14P   Free 
371 P11 P D P A Kac S A P A P K K G S Kac K A V T H2B 1-19 K5ac K15ac   Free 
372 P12 P D P A K S A P A P K Kac G pS K K A V T H2B 1-19 K12ac S14P   Free 
373 P13 P D P A K S A P A P K Kac G S Kac K A V T H2B 1-19 K12ac K15ac   Free 
374 P14 P D P A K S A P A P K K G pS Kac K A V T H2B 1-19 S14P K15ac   Free 
375 P15 P D P A Kac S A P A P K Kac G pS K K A V T H2B 1-19 K5ac K12ac S14P  Free 
376 P16 P D P A Kac S A P A P K Kac G S Kac K A V T H2B 1-19 K5ac K12ac K15ac  Free 
377 P17 P D P A Kac S A P A P K K G pS Kac K A V T H2B 1-19 K5ac S14P K15ac  Free 
378 P18 P D P A K S A P A P K Kac G pS Kac K A V T H2B 1-19 K12ac S14P K15ac  Free 
379 P19 P D P A Kac S A P A P K Kac G pS Kac K A V T H2B 1-19 K5ac K12ac S14P K15ac Free 
380 P20 Bio A A N W S H P Q F E K A A 
Biotin, 
control peptide 
    Biotinylated 
381 P21 E Q K L I S E E D L A c-myc tag     Free 
382 P22 HAc neg. contol     Acetylated 
383 P23 
K Kme1 Kme2 Kme3 Kac R Rme2s R Rme2a R Cit K Kme1 
Kac Kme3 R K 
background 01     Acetylated 
384 P24 
R Rme2s K Kme1 Kac R Rme2a Kme2 K Kme3 R Kme1 
Rme2s K Kac R K 
background 02     Acetylated 
         
Appendix 5. Active Motif Histone H3/H4/H2A/H2B N-terminal peptide library 
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